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Abstract  
 
Thrombopoietin (TPO) is the primary regulator of megakaryocyte development, 
regulating proliferation and differentiation in addition to the number of circulating 
platelets through binding to and stimulation of the cell surface receptor MPL. 
Activating mutations in MPL constitutively stimulate downstream signalling 
pathways, leading to aberrant haematopoiesis and contribute to development of 
myeloproliferative neoplasms (MPNs). Several studies have mapped the tyrosine 
residues within the cytoplasmic domain of MPL that mediate these cellular signals; 
however, secondary signalling pathways are incompletely understood. Additionally, 
the identification of the JAK2
V617F
 mutation has profoundly increased our 
understanding of MPNs and although a role has been implicated in vitro, the in vivo 
role of MPL in JAK2
V617F
-positive MPNs has yet to be determined.  
 
In this thesis, a novel signalling pathway for the negative regulation of TPO 
signalling was identified whereby MPL
Y591
 is phosphorylated resulting in association 
of SYK which negatively regulates TPO-mediated ERK1/2 signalling. Additionally, 
genetic manipulation of an in vivo JAK2
V617F
-positive MPN mouse model led to the 
identification of MPL as an essential molecular component for development of 
JAK2
V617F
-postive MPNs. In the absence or reduction of MPL, the disease fails to 
develop. However, removal of the cytokine, TPO, was unable to prevent the disease 
from developing.   
 
These findings provide novel insights not only into regulation of TPO-signalling but 
also the role of TPO and MPL in JAK2
V617F
-positive MPN disease pathogenesis. 
Identification of the role of MPL in MPN pathogenesis, as well as insights into 
additional regulatory pathways, contributes to our understanding of normal and 
pathological TPO signalling. These new insights also provide a basis for 
development of novel therapeutics for the treatment of MPNs and other diseases 
resulting from aberrant of TPO signalling.  
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CHAPTER 1 INTRODUCTION 
1.1  
1.1 Haematopoiesis: An Overview 
Haematopoiesis is a dynamic process by which all of the mature blood cells of the 
body are generated through successive differentiation of a haematopoietic stem cell 
(HSC)(Figure 1.1). HSCs are a rare population of cells found in the bone marrow of 
adult mammals and are responsible for production of all mature blood cells 
throughout a person’s lifetime. HSCs are defined by their dual capacity to undergo 
self-renewal and differentiate into mature hematopoietic cells including lymphoid 
and myeloid cells.  
1.1.1 Embryonic Haematopoiesis: Emergence and expansion of HSCs 
Mammalian haematopoiesis initiates at embryonic day 7.5 (E7.5) in the yolk sac 
blood islands and subsequently occurs in the aorta-gonad-mesonephros (AGM) 
region and the foetal liver until the bone marrow (BM) develops and takes over as 
the primary site of haematopoiesis throughout adulthood(5-7)(Figure 1.2). 
Developmental haematopoiesis is separated into two sequential waves: primitive 
haematopoiesis and definitive haematopoiesis(8). Primitive haematopoiesis occurs in 
the mammalian yolk sac giving rise to a unique population of primitive erythroid 
progenitors(9) to facilitate transport of oxygen to the developing embryo(10). 
Additionally, macrophages are produced(11) to aid in tissue remodelling(12). 
Definitive haematopoiesis is marked by the emergence of functional HSCs(12), 
which initially arise in the AGM region at murine E10-11(13,14); this region is 
analogous to the ventral endothelium of the dorsal aorta in the 5-week human 
embryo(15). Runx1, also known as acute myeloid leukaemia 1 protein (AML1) or 
core-binding factor subunit alpha-2 (CBFA2), is a transcription factor essential for 
AGM-derived HSC formation(16). All embryonic HSCs were shown to express 
Runx1(17). Mice lacking functional Runx1 exhibit normal primitive or yolk-sac 
derived haematopoiesis but failed to establish normal foetal liver haematopoiesis 
resulting in death at E12.5(16). Additionally, HSCs have also been detected in the 
mouse placenta paralleling the timing of appearance in the AGM region(18,19).  
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Figure 1.2 Embryonic Haematopoiesis 
(A) Diagram of a mouse embryo at E11.5 with haematopoietic tissues labelled. (B) Diagram of cells 
generated within haematopoietic tissues within an embryo. (C) A timeline illustrating the primary 
regions of haematopoiesis during embryogenesis to birth in both mice and humans. Abbreviations: 
AGM – aorta-gonad-mesonephros; ECs – endothelial cells; RBCs – red blood cells; HSCs – 
haematopoietic stem cells; LT-HSC – long term haematopoietic stem cell; ST-HSC – short term 
haematopoietic stem cell; CMP – common myeloid progenitor; CLP – common lymphoid progenitor; 
MEP – megakaryocyte/erythroid progenitor; GMP – granulocyte/monocyte progenitor; B – B-cell; T 
– T cell.  
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Subsequent haematopoiesis occurs when HSCs migrate through the circulation 
where they colonize and expand within the foetal liver(12). HSCs ultimately 
colonize the thymus, spleen and bone marrow(5). It is believed that these sites 
provide niches to support HSC expansion rather than de novo generation(5). In adult 
mammals, the bone marrow is the primary site of haematopoiesis.  
1.1.2 The Haemangioblast  
In addition to initiation of primitive haematopoiesis, endothelial cells also 
differentiate from the mesoderm at E7.5. This concurrent development resulted in 
the hypothesis of a common precursor for blood and vascular cells called the 
haemangioblast (Figure 1.3). A number of cell surface markers are common between 
haematopoietic precursors and endothelial cells including the haematopoietic 
progenitor cell antigen CD34 (CD34), Foetal Liver Kinase 1 (Flk-1/CD135/fms-like 
tyrosine kinase 3 (FLT-3)) and the angiopoietin-1 receptor (Tie2)(20-22), further 
suggesting presence of a common progenitor. Both Flk
-/-
 and Tie2
-/-
 embryos are 
deficient in both haematopoietic and vascular development and die in utero between 
E8.5-9.5 or at E10.5, respectively(21,22). In vitro culture of individual blast colony 
forming cells derived from embryonic stem (ES) cells was able to generate both 
multi-lineage haematopoietic and endothelial cells, providing evidence for the 
existence of the elusive haemangioblast(23,24). 
1.1.3 Haematopoietic Stem Cell 
HSCs are a small subset of cells in the bone marrow responsible for production of all 
mature blood cells throughout a person’s lifetime. HSCs are defined by their dual 
capacity to undergo self-renewal and differentiate into mature haematopoietic 
cells(25). 
 
In 1961, Till and McCulloch observed in irradiated mice distinct nodules in the 
spleen of recipient mice which contained colonies of proliferating cells of multiple 
haematopoietic lineages(26), these colonies were later determined to be clones from 
single cells(27) capable of self-renewal(28). Due to this capacity for self-renewal in 
addition to their ability to expansively proliferate and differentiate, these cells were 
thought to be HSCs(29) and importantly, spleen colony formation provided an in 
vivo method to quantify these cells(26).  
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Figure 1.3 The Haemangioblast 
A schematic depicting the differentiation of a haemangioblast into both HSCs and endothelial cells. 
Above the cells are cell associated cell surface markers. Transcription factors promoting lineage 
differentiation are indicated by arrows. Adapted from Medvinsky et al. Development, 2011(30). 
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The study of HSC biology is reliant on the ability to distinguish HSCs from other 
progenitor cells. To this end, there have been many studies aiming to identify 
markers capable of definitive identification of HSCs. The characterization of HSCs 
was vastly improved with the introduction of flow cytometry. As HSCs are capable 
of differentiation into multiple hematopoietic lineages, it was postulated that cells 
expressing lineage specific markers could be excluded as HSCs(31). In order to 
isolate a more pure population of HSCs from mouse bone marrow, monoclonal 
antibodies against B cells (B220), granulocytes (Gr-1), myelomonocytic cells (Mac-
1) and T cells (CD4, CD8) were used to isolate lineage negative (Lin
-
) cells(32). This 
isolated population was found to express low levels of thymocyte differentiation 
antigen 1 (Thy-1, CD90), consistent with previous reports characterizing rat(33) 
HSCs. This population is further divided based on stem cell antigen-1 (Sca-1) 
expression, to enrich for thymic repopulation ability(34), and it was reported that 
Thy-1
lo
Lin
-
Sca-1
+
 cells (0.05% of whole bone marrow) comprised of a 50% pure 
long term HSC (LT-HSC) population(32). The Thy-1
lo
Lin
-
Sca1
-
 population is 
enriched for short term HSCs (ST-HSC)(32). Later reports, however, found this 
fraction of cells to be heterogeneous with only 25% of the cells being capable to long 
term repopulation ability, the remainder providing only transient multilineage 
repopulation(35). In the search for a pure HSC population a number of additional 
cell surface markers were analysed for their potential to better distinguish the HSC. 
Morrison et al. found stem cell growth factor receptor (c-kit, CD117) expression to 
further enrich the Thy-1
lo
Lin
-
Sca-1
+
 HSC population for LT-HSCs(35). Osawa et al. 
then utilized the human HSC marker, CD34, to further enrich the c-kit
+
Thy-1
lo
Lin
-
Sca-1
+
 HSC population. Unexpectedly, the CD34
lo/-
 population was better at 
distinguishing LT-HSCs than the CD34
+
 population(36).  Christiansen et al. used a 
different tyrosine kinase, Flk-2 and found isolated that c-kit
+
Thy-1.1
lo
lin
-/lo
Sca-
1
+
Flk-2
-
 cells were functionally superior at long term multilineage reconstitution, 
reconstituting all irradiated recipients whereas c-kit
+
Thy-1.1
lo
lin
-/lo
Sca-1
+
Flk-2
+
 cells 
provided only short term reconstitution(37). Thus, the Thy-1
lo/-
Lin
-
Sca-1
+
c-
kit
+
CD34
lo/-
Flk-2
-
 mouse bone marrow population is highly enriched for LT-HSCs 
whereas the Thy-1
lo/-
Lin
-
Sca-1
+
c-kit
+
CD34
+
Flk-2
+
 is enriched for ST-HSCs. 
Although these markers are very good for distinguishing between LT-HSCs and ST-
HSCs from the bone marrow, the number of antibodies necessary to isolate these 
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cells makes studying these cells in vivo within their microenvironment extremely 
difficult. To this end, the SLAM family of cell surface receptors was identified as 
markers of HSCs(38).  
 
The SLAM family includes signalling lymphocytic activation molecule 1 
(SLAMF1/CD150), natural killer cell receptor 2B4 (CD244) and signalling 
lymphocytic activation molecule 2 (SLAMF2/CD48) are differentially expressed on 
HSCs, multipotent progenitors (MPPs) and lineage restricted progenitors. Using only 
the SLAM family of markers, the CD150
+
CD244
-
CD48
-
 population 
(0.0084%±0.0028% of whole bone marrow) contains 20% LT-HSCs while the 
CD150
-
CD244
+
CD48
-
 population is indicative of MPPs and the CD150
-
CD244
+
CD48
+
 population of lineage restricted progenitors(38). However, the HSC 
purity in this fraction of cells is further improved upon selection from the Sca-
1
+
Lin-c-kit
+
 subset of HSCs, with 50% of the Sca-1
+
Lin-c-kit
+
CD150
+
CD244
-
CD48
- 
population
 
being LT-HSCs(38). Although this fraction is highly enriched for LT-
HSCs, it still requires a lot of markers for identification and isolation. Kent et al. 
defined a modified set of markers, termed E-SLAM(39) which differs from SLAM 
HSCs (CD150
+
CD48
-
) in that it includes the murine endothelial protein C receptor 
(EPCR/CD201) which was found highly expressed in HSCs(40). Selection for the 
four E-SLAM
+
 markers, C150
+
CD45
+
CD201
+
CD48
-
, yields 43% LT-HSCs(39).  
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1.2 Thrombopoietin Signalling  
1.2.1 Discovery of MPL 
The myeloproliferative leukemia virus (MPLV) was first described in 1986 by 
Wendling and colleages(41). They showed that mice infected with MPLV developed 
an acute and generalised myeloproliferative disorder, characterised by 
hepatosplenomegaly, granulocytosis, thrombocytosis and polycythemia(41). MPLV 
infection was sufficient to induce myeloid progenitor cell transformation resulting in 
the ability of these cells to grow and differentiate in the absence of exogenous 
growth factors in vitro(42,43). To conclusively demonstrate that MPLV was the 
molecular entity responsible for the disease, the full-length provirus was cloned and 
tested for transforming ability(44). Intravenous injection of viral supernatant into 
mice resulted in splenomegaly, leucocytosis and polycythaemia(44). Further analysis 
of haematopoietic progenitor cells from these mice revealed cells capable of 
proliferation and differentiation in the absence of exogenous colony-stimulating 
factors(44), demonstrating that MPLV was indeed the molecular entity necessary for 
the observed myeloproliferation. Sequence analysis of MPLV in 1990 revealed it 
was derived from Friend murine leukemia virus (F-MuLV) with 1.5kb of the F-
MuLV envelope replaced by a novel 0.7kb non-viral sequence(44). The novel 
sequence, termed viral mpl (v-mpl), was found to be conserved among mammals, 
including humans and specific to cells within major hematopoietic compartments of 
mice(44). The predicted amino acid (aa) sequence of the MPLV env-mpl gene 
suggested that the v-mpl protein coded for a membrane spanning receptor with no 
predicted kinase activity and a conserved Trp-Ser-X-Trp-Ser (WSXWS) NH2-
terminal ligand binding motif characteristic of the hematopoietic cytokine receptor 
superfamily(44,45). The human homolog, cellular MPL (c-MPL), was successfully 
cloned in 1992(46). In this body of work, MPL refers to c-MPL.  
1.2.2 MPL structure  
MPL belongs to the homodimeric type I cytokine receptor family. This family of 
receptors is characterised by the presence of four conserved cysteine residues 
forming a cytokine receptor homology module (CRM), the WSXWS motif, 
fibronectin type III domains and conserved Box1/Box2 motifs(47)(Figure 1.4).  
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Figure 1.4 Schematic representation of human MPL monomer 
Figure represents full length human MPLP isoform which is 635aa long. The location of important 
motifs is indicated. MPL contains an 18aa signal peptide, 2 CRMs, a single transmembrane spanning 
region, an amphipathic motif at the junction between the transmembrane and cytoplasmic regions, 
Box1/Box2 motifs for JAK2 binding and cytoplasmic residues that are phosphorylated in response to 
TPO.   
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The family can be further subdivided into groups based on sequence and structural 
homology of the cytokine and its receptor. MPL belongs to the group 1 receptors 
along with the erythropoietin receptor (EPOR), prolactin receptor (PRLR), growth 
hormone receptor (GHR) and orphan receptor CLF-3(48). Group 1 receptors and 
ligands are considered the prototypic type I cytokines. These receptors are comprised 
of a single chain, function as homodimers and are characterised by an extracellular 
domain consisting of only CRMs(48,49). Full length human MPL protein is 
comprised of 635aa with a large 485aa extracellular domain including a predicted 
18aa signal peptide and two CRMs, a 22aa transmembrane domain and a short 122aa 
intracellular domain(46)(Figure 1.4). Human MPL was mapped to chromosome 
1p34(50) and murine MPL to chromosome 4(51). MPL is highly conserved, the 
human and mouse proteins share 81% amino acid identity, conservation is highest 
for the cytoplasmic domain with 91% identity(52). Human MPL is encoded by 12 
exons over 17kb of DNA with a single exon coding for the signal peptide, four exons 
for each of the two CRMs, a single exon for the transmembrane domain and two 
exons for the cytoplasmic domain(53). There are four MPL mRNA isoforms found 
in humans. The first isoform, MPLP contains 12 exons and encodes the full length 
functional receptor(46,53). Translation initiation is thought to occur at the 
methionoine codon at position 8(46). The second isoform, MPLK, encodes a 
truncated 572aa receptor resulting from premature transcript termination within 
intron 10(46,53). The resulting receptor contains an extracellular and transmembrane 
domain identical to MPLP but has a cytoplasmic domain of only 66aa which differs 
from MPLP after 9aa(46). The extracellular domains of both MPLP and MPLK 
contain four N-linked glycosylation sites(46). A third isoform, MplS, is the result of 
transcripts lacking exons 9 and 10, resulting in loss of CRM-2 and the 
transmembrane domain thus coding for a soluble form of MPL(53). A fourth 
isoform, termed MPL-del, lacks 24 amino acids within the extracellular domain 
resulting from alternative splicing between exons 8 and 9 and encodes a protein that 
is not expressed on the cell surface(54). Upon western blot detection of human MPL 
from Ba/F3-MPL cell lines, there are 2 glycoforms present, an 85kDa and 80kDa 
form representing the mature fully glycosylated and immature forms of the receptor, 
respectively(55,56).  
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1.2.3 MPL Biology 
It was recognised early on that the cellular role of MPL was in 
haematopoiesis(41,44). The ability of the v-mpl to induce generalised 
myeloproliferation was the first line of evidence(41). Moreover, MPL expression is 
restricted to haematopoietic tissues including adult spleen, foetal liver and bone 
marrow(44). The ability of MPLV to induce growth factor independence within a 
broad range of hematopoietic lineages suggested its role in early HSCs(44). 
Antisense oligodeoxynucleotide targeting of Mpl prevented maturation of MK 
progenitors, revealing its role as a regulator of megakaryopoiesis(57). The proposed 
role of MPL in HSCs and megakaryopoeisis was supported by its expression on 
primitive hematopoietic progenitor cells and enriched expression on megakaryocytes 
and platelets(57). Although MPL was identified in 1990, it remained an orphan 
receptor until the cloning of its ligand thrombopoietin (TPO) in 1994, making it 
difficult to study its exact biological role. The biological roles of TPO and MPL are 
discussed together in detail in the subsequent sections.   
1.2.4 Cloning of Thrombopoietin  
Platelets were first described by Bizzozero in 1882 and in the 1900s, Wright reported 
that these cells, which arose from bone marrow megakaryocytes, were essential in 
coagulation (Reviewed in(58)). A number of studies following these seminal 
observations, led to the idea that platelet production was a regulated process 
(Reviewed in (58)), eventually leading Kelemen to the coin the term 
‘thrombopoietin’(59). The cytokine was finally cloned almost simultaneously in 
1994 by five independent groups and was shown to stimulate platelet production in 
vivo through expansion of megakaryocyte progenitors and promotion of 
megakaryocyte maturation as measured by increased cell size and polyploidy(60-64) 
and (Reviewed in (58)). Based off of the N-terminal sequence of purified porcine 
TPO, de Sauvage and colleagues were able to clone human TPO(62). Whereas, 
genetic removal of previously cloned cytokines capable of moderately increasing 
platelet counts did not result in thrombocytopenia (Reviewed in (58)), animals 
genetically deficient in the gene for TPO (thpo), were severely 
thrombocytopenic(65), validating TPO as the regulator of platelet production.    
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1.2.5 Thrombopoietin structure  
Human TPO cDNA is 1,774 nucleotides in length with a poly(A)
+
 tail with an open 
reading frame of 1,059 nucleotides(62). It is synthesized as a 353 amino acid long 
polypeptide which is cleaved to form a mature 332 amino acid long secreted 
protein(66). The human TPO gene was mapped to chromosome 3q27 and is 6.2kb in 
length comprised of six exons and five introns(67), although an additional exon was 
subsequently detected upstream of exon 1(68). The protein is encoded by exons 3-
7(68). Only a single copy of the TPO gene was detected in the genome(67) but a 
number of splice variants have been reported. The first has a 4aa deletion of residues 
112-115 at the junction of exon 6 and 7 but maintained the same reading frame 
whereas the second variant has an extra splice site within exon 7 and resulted in a 
frameshift. Studies in which cells were transfected with full-length TPO cDNA 
resulted in expression and secretion of biologically active TPO(68,69); however, 
both splice variants were expressed but not secreted(68) and was therefore unable to 
induce proliferation of MPL expressing Ba/F3 cells(69). 
 
The protein consists of two distinct domains. The amino(N)-terminal domain of 
human TPO, which consists of 153-residues, is responsible for receptor binding(64). 
This region is also highly hydrophobic and is predicted to function as a secretory 
signal(69). The carboxyl(C)-terminal domain is less conserved; however, conserved 
glycosylation sites within this domain(69) undergo both N- and O-linked 
glycosylation(70,71), which promotes protein stability(70). Although independent 
studies found the C-terminal domain to be necessary for protein secretion, the role of 
glycosylation remains uncertain. One study found glycosylation at Asn213 and 
Asn234 to be necessary for proper secretion of the protein(72) whereas another study 
reported that N-linked glycosylation only played a minor role(71).  
 
The receptor-binding domain or N-terminal region of TPO shares structural 
similarities and high sequence homology with EPO, maintaining 22% identity and 
25% conserved substitutions; however, both bind to their cognate receptor with high 
fidelity(65,73,74). Sequence alignment of TPO against interleukin-4 (IL-4) resulted 
in prediction of 40 surface exposed residues that were subsequently tested for 
functional activity using alanine-scanning mutagenesis, monoclonal epitope mapping 
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and phage display binding assays(75). Mutation of two residues, Asp8 and Lys138, 
had the largest effect on receptor binding increasing the half-maximal effective 
concentration (EC50) values approximately 20-fold. Additional residues affecting 
binding include Lys14, Lys52, Arg136 and Arg140 with an increased EC50 between 
5- and 15-fold and Arg17, Ser24, Lys59, Arg98, Ser106, Leu129, Gln132, His133 
and Leu144 which increased EC50 between 2- to 5-fold. The majority of these resides 
map to helix-1 and helix-4 and map to one side of the predicted protein(75). 
Recently, a clinical mutation of TPO, Arg17Cys, which maps to helix-1, was 
recently described in a family with congenital thrombocytopenia and aplastic 
anaemia(76) validating the importance of helix-1 for receptor association. The 
crystal structure of the receptor-binding domain of TPO revealed a four helix bundle 
with up-up-down-down topology, also known as an antiparallel four-helix bundle 
fold(73). 
1.2.6 Thrombopoietin biology 
1.2.6.1 Thrombopoietin regulation  
It was discovered well before the cloning of human TPO that plasma, serum and 
urine from thrombocytopenic patients and animals contained the factor capable of 
promoting megakaryopoiesis (reviewed in(77)). In fact, this served as the basis for 
some of the strategies utilized to clone TPO(62-64).  The cloning of TPO allowed for 
investigation into its regulation. Insight into transcriptional regulation came when a 
Tpo
-/-
 mouse was generated by de Sauvage et al.(65). Unlike the Mpl
+/-
 mouse(78), 
the heterozygous Tpo mouse displayed an intermediate platelet count between wild-
type (WT) and Tpo
-/-
, indicative of a gene dosage effect which was supported by 
reduced TPO mRNA in these mice(65). Therefore, TPO is constitutively expressed 
with regulation occurring predominantly at the post-transcriptional level. TPO is 
primarily synthesized in the liver and to a lesser extent the kidneys and subsequently 
released into the circulation (Figure 1.5)(79). Analysis of TPO levels relative to 
platelet mass revealed an inverse relationship between the two(80,81). The 
stimulatory effect of TPO rich serum from thrombocytopenic animals on 
megakaryopoiesis was eliminated after addition of platelets or soluble MPL(80), 
suggesting that MPL expressed on platelets was a likely candidate for sequestering  
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Figure 1.5 Regulation of thrombopoietin  
Thrombopoietin (TPO) synthesis (green arrows) is both constitutive and inducible. Constitutive 
synthesis occurs primarily by the liver and to a lesser degree by the kidneys. Under physiological 
stress, such as thrombocytopenia or inflammation, TPO synthesis is induced in the liver and bone 
marrow stroma. Additionally, binding of desialylated platelets to hepatic Ashwell-Morell receptors is 
also thought to induce TPO synthesis in the liver. TPO acts primarily in the bone marrow (blue 
arrow), where receptor(MPL)-bearing cells bind and utilise the cytokine. Uptake of TPO by platelets 
and megakaryocytes regulates levels of circulating TPO (red arrows).Abbreviations: BM – bone 
marrow; HSC – haematopoietic stem cell; BV – blood vessel; EC – endothelial cell; MK – 
megakaryocyte.   
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circulating TPO. This mechanism for TPO clearance is known as the “sponge 
theory” and was further supported by the observation that Mpl-/- mice have elevated 
TPO levels despite normal levels of TPO mRNA(78). Similarly, in patients with 
congenital amegakaryocytic thrombocytopenia (CAMT) resulting from non-
functional MPL, there are increased concentrations of circulating TPO(82). 
Additionally, transfusion of WT platelets into Mpl
-/-
 mice was able to reduce plasma 
TPO levels through binding, internalization and degradation of the cytokine(83). 
Although some studies found no change in TPO mRNA levels in kidneys and livers 
of thrombocytopenic mice(65,83), McCarty and colleagues detected increased TPO 
mRNA in marrow and spleens of thrombocytopenic mice by semi-quantitative RT-
PCR(84), suggesting that TPO can be regulated transcriptionally in response to 
platelet demand within these tissues. Additionally, expression can be regulated by 
the inflammatory mediator interleukin-6 (IL-6). Increases in IL-6 induce 
upregulation of hepatic TPO mRNA both in vitro and in vivo(85).   
 
Conversely, numerous studies suggest megakaryocyte mass rather than platelet mass 
is responsible for TPO clearance. It is difficult to distinguish the role of platelets 
versus megakaryocytes in TPO clearance as megakaryocyte mass directly correlates 
with platelet mass. However, this theory is predominantly based on two disorders, 
immune thrombocytopenic pupura (ITP) and myelodyplastic syndrome (MDS), 
whereby megakaryopoiesis is maintained but platelets are prematurely cleared by the 
immune system or production of platelets is dysfunctional, respectively. Despite 
normal numbers of megakaryocytes in the marrow, patients with ITP had relatively 
normal TPO levels(86-88). Similarly, in patients with MDS, plasma TPO levels were 
similar to healthy control patients(88). Since TPO levels in these patients are not as 
high as those observed with aplastic anemia (AA) despite similar platelet levels, this 
supports the role of megakaryocytes in the clearance of plasma TPO.  
 
A recent study suggests binding of desialyated platelets to the Ashwell-Morell 
receptor (AMR) as the key regulator of TPO production(89). Platelets become 
desialylated over time and are subsequently removed by the AMR. In mice lacking 
functional AMR (Asgr2
-/-
), they reported increased platelet count, volume and half-
life with a larger proportion of mature platelets consistent with lack of clearance by 
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the AMR(89). Additionally, hepatic TPO mRNA was decreased by approximately 
45% in Asgr2
-/-
 mice suggesting that the AMR is not only necessary for clearance of 
desialylated platelets but also plays a role in upregulating TPO expression(89). 
Specifically, platelet uptake by the AMR results in increased Janus kinase 2 (JAK2) 
and Signal Transducer and Activator of Transcription 3 (STAT3) activation in 
hepatocytes in vivo and results in increased TPO mRNA expression in vitro(89). 
However, induced immune thrombocytopenia was able to increase plasma TPO 
levels but not increase TPO mRNA levels in WT and Asgr2
-/-
 mice(89), thereby 
suggesting that although the AMR may play a role in TPO production, there are 
additional mechanisms regulating levels of circulating TPO.  
1.2.6.2 Thrombopoietin and megakaryopoiesis 
Several lines of evidence suggested a role for MPL in megakaryopoiesis, firstly, 
reduction in MPL expression in CD34
+
 cells through use of antisense 
oligonucleotides to MPL resulted in decreased in vitro megakaryocytic colony 
formation (CFU-MK) without affecting other haematopoietic lineages(57). 
Additionally, expression of MPL is highly enriched in platelets and 
megakaryocytes(57,90). The cloning of TPO provided a crucial element in the study 
of megakaryopoiesis. When TPO was cloned it was shown that TPO was able to 
drive megakaryocyte expansion and maturation both in vitro and in vivo(61).  
Injection of recombinant TPO in vivo induces a significant increase in 
platelets(60,91) resulting from stimulation of megakaryopoiesis(61,91). 
Additionally, TPO works synergistically with interleukin-3 (IL-3) and stem cell 
factor (SCF) to support CFU-MK formation(61). Importantly, lack of TPO 
completely prevents CFU-MK maturation, demonstrating that TPO is the primary 
regulator of megakaryocyte development and expansion(92). However, its role in 
thrombopoiesis is less defined. Culture of megakaryocytes in TPO promotes 
demarcation of the membrane, indicative of platelet formation(92).  However, 
CD34
+
 progenitor cells are able to produce platelets in the absence of TPO when 
cultured in IL-3, IL-6 and SCF(93). Additionally, mice deficient in TPO or MPL 
(Tpo
-/-
 or Mpl
-/-
) are still capable of producing a low level of platelets(65,78) which 
suggests additional pathways exist to compensate in the absence of TPO signalling.   
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1.2.6.3 Thrombopoietin and haematopoietic stem cells  
The ability of MPLV to induce proliferation of multiple haematopoietic lineages(41) 
alluded to a possible role for MPL in HSCs. Furthermore, in addition to expression 
on megakaryocytes, MPL is expressed on CD34
+
 progenitor cells(57). Culture of 
LT-HSCs in TPO, IL-3, IL-6 and SCF increased proliferation significantly compared 
to culture in IL-3, IL-6 and SCF(94). However, culture in TPO alone was unable to 
recapitulate this proliferative effect, although it was able to support survival of these 
cells(94). In ST-HSCs, culture in TPO was sufficient to induce CFU-MK(94). These 
data suggest that TPO is capable of promoting HSC survival and promoting 
megakaryopoiesis. As mentioned previously, additional insights into the role of TPO 
and MPL in haematopoiesis came from generation of Mpl
-/-
 and Tpo
-/-
 mice. In Mpl
-/-
 
mice, the number of haematopoietic progenitor cells is greatly reduced(95). In BM 
transplantation studies, the repopulation capacity of HSCs lacking MPL was reduced 
seven-fold(96). In another study, WT  HSCs were transplanted into Tpo
-/-
 or WT 
mice; HSC expansion was reduced 15-20-fold when transplanted into Tpo
-/-
 mice 
compared to WT(97). The importance of MPL in HSC maintenance is highlighted in 
patients that harbour mutations in MPL resulting in CAMT; although patients 
initially present with thrombocytopenia, the disease progresses to complete bone 
marrow failure, presumably due to exhaustion of the stem cell pool, necessitating a 
bone marrow transplant(82,98). These data support a significant role for TPO and 
MPL in HSC biology.  
1.3 Thrombopoietin Signalling  
Cytokines binding to their cognate receptors induce phosphorylation of the receptors 
themselves in addition to downstream signalling targets(99). Receptor tyrosine 
phosphorylation is a critical step in growth factor-induced signal transduction(100) 
as evidenced by experiments demonstrating that tyrosine kinase inhibition reduces 
cytokine-induced growth(101) whereas inhibition of phosphatases sustains 
proliferation of cells in the absence of cytokine(102). Regulation of signal 
transduction is necessary for normal cellular function while unregulated activation 
can lead to disease. Consequently, it is important to develop a clear understanding of 
cytokine induced signalling cascades and the regulators in place for dissolution of 
these signals.  
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1.3.1 TPO-mediated signal transduction 
Like other members of the type I cytokine receptor family, the cytoplasmic domain 
of MPL lacks intrinsic kinase activity but transduces a signal through recruitment of 
JAK2 to the conserved box1 and box2 domains of the receptor(103). Upon TPO 
binding, MPL monomers at the cell surface homodimerize and undergo a 
conformational change allowing the closer juxtaposition of bound JAK2 proteins, 
resulting in trans-auto-phosphorylation of the JAK2s(104-108). Phosphorylated 
JAK2 can then, in turn, phosphorylate tyrosine residues within the cytoplasmic 
domain of MPL in addition to signal transduction proteins including those of the 
JAK-STAT pathway, the mitogen-activated protein kinase (MAPK) pathway, 
photidylinositol-3-kinase (PI3K) and protein kinase C (PKC)(Figure 1.6)(3,109-
112).  
1.3.1.1 MPL cytoplasmic domain  
There are 5 tyrosine residues located within the cytoplasmic domain of MPL (Figure 
1.4) of which, 2 (Y625 and Y630 also termed Y112 and Y117, respectively when 
labeled based on intracellular residues) have been shown to undergo phosphorylation 
in response to TPO(3). Tyrosine 625 is essential for TPO mediated proliferation and 
is phosphorylated in response to TPO stimulation(3). Phosphorylation of Y625 is 
necessary for activation of downstream signal transduction proteins, including 
Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP1), SHC-
transforming protein 1 (Shc), STAT3, GRB2-associated-binding protein 1 and 2 
(Gab1/2) and Tyrosine-protein phosphatase non-receptor type 11 (SHP-2, PTPN11) 
resulting in downstream activation of the PI3K and MAPK pathways(3,110,113). 
Using receptor truncations, Drachman et al.(3) demonstrated that MPL, SHIP, Shc, 
STAT3, STAT5 and JAK2 were all phosphorylated in response to TPO stimulation. 
Phosphorylation state of these proteins was unaltered upon truncation just upstream 
of Y630; however, further truncation removing Y625 resulted in abolished MPL, 
SHIP, Shc and STAT3 phosphorylation suggesting a major role of Y625 in TPO 
dependent phosphorylation of these proteins. This study also showed that removal of 
the site via a tyrosine to phenylalanine point mutation (Y625F), severely impairs 
signalling and growth in response to TPO(3). Multiple studies also showed that 
Gab1/2 is phosphorylated in response to TPO followed by subsequent activation of  
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Figure 1.6 Thrombopoietin signalling 
TPO binding to MPL results in activation of associated JAK2 molecules. Activated JAK2 
phosphorylates distal MPL tyrosine residues; when these tyrosines are phosphorylated (P), they serve 
as docking sites for downstream signalling molecules and result in activation of the PI3K and MAPK 
pathways. Additionally, activated JAK2s phosphorylate STAT3 and STAT5 resulting in dimersation 
and translocation of these molecules into the nucleus where gene transcription is initiated. 
Subsequently, negative regulators such as SOCS proteins, LYN, LNK and CBL are activated which 
turn of TPO signalling.        
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the PI3K pathway, this activation was also dependent on Y625 of MPL(113) and 
regulated by SHP-2 as shown by overexpression of a dominant negative form of 
SHP-2(111). Additionally, Rojnukarin et al.(110) demonstrated that TPO-induced 
extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation was also 
dependent on the 10 carboxyl terminal residues of MPL, this was later shown in a 
different cell type to be Y625 dependent(114). Additionally, Y630 is also 
phosphorylated in response to TPO and like Y625, is involved in MPL 
phosphorylation and STAT3 activation(3). There are 3 additional tyrosine residues 
found in the cytoplasmic domain of MPL: Y521, Y542 and Y591 (also termed Y8, 
Y29 and Y78, respectively based on the intracellular numbering of residues). These 
residues were not found to be phosphorylated in response to TPO in early studies(3). 
Mutation of Y521 and Y542 to phenylalanine in a receptor missing the distal 3 
tyrosine residues was unable to alter proliferation in response to TPO(3); however, it 
was possible these residues play a role in TPO signalling independent of sustaining 
proliferation. This was found to be the case with Y521, which is involved in 
targeting of MPL for lysosomal degradation(1). Conversely, cells expressing mutant 
MPL with a deletion encompassing Y591(115) or a Y591F mutation(3) exhibited an 
increased proliferative effect compared to cells expressing receptors with intact 
Y591, suggesting the location of a negative regulatory region within the cytoplasmic 
tail of MPL. It was also determined that the region encompassing Y591 is 
dispensable for proliferation yet necessary for differentiation(115). In Y591F mutant 
expressing cells, stimulation with TPO increased Protein kinase B (Akt, PKB) and 
ERK1/2 signalling relative to WT(1) further supporting Y591 as a negative regulator 
of TPO signalling. The role of Y591 extends even further as it also mediates MPL 
internalization(1). More recently, Pecquet et al.(116) reported Y591 phosphorylation 
in a constitutively active MPL W515L receptor, meriting re-analysis of the 
phosphorylation state of Y591 in a WT receptor utilizing more sensitive detection 
methods.             
1.3.2 Negative regulation of TPO signalling 
Negative regulation of TPO-mediated signalling is controlled by a number of 
proteins, including protein phosphatases, suppressors of cytokine signalling (SOCS) 
proteins, src family kinases (SH2B adapter protein 3 (LNK), Tyrosine-protein kinase 
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Lyn (LYN)) and Focal Adhesion Kinase (FAK)(Figure 1.6)(117-119). SOCS3 is 
upregulated in response to TPO(117) and provides a negative feedback mechanism 
in the control of TPO signalling(120). Interferon-alpha (IFN-α) is able to inhibit 
megakaryopoiesis in primary cells and reduce proliferation of MPL-expressing cells 
cultured in TPO, an effect postulated to result from IFN-α induction of SOCS1 
which in turn inhibits TPO signalling(117). In megakaryocytes isolated from lnk null 
mice, Akt, STAT3, STAT5 and ERK1/2 phosphorylation in response to TPO was 
increased compared to WT cells(118). Similarly, megakaryocytes isolated from lyn 
null mice exhibited increased Akt and MAPK activation but reduced SHIP1 
phosphorylation following TPO stimulation(119). Furthermore, in FAK-null 
megakaryocytes, Lyn kinase activity was reduced and similar to lyn null 
megakaryocytes, ERK1/2 and Akt phosphorylation was increased suggesting FAK as 
an upstream regulator of Lyn in the regulation of TPO signalling(121). Additionally, 
in lnk and lyn null mice and in mice with Fak null megakaryocytes, there was a 
marked increase in the number of megakaryocytes, demonstrating that these proteins 
function to suppress TPO mediated signalling necessary for megakaryopoiesis. 
However, the region of MPL necessary for each of these proteins to inhibit TPO 
signalling has yet to be determined. Additional negative regulatory control occurs 
through receptor internalization via clathrin-dependent endocytosis dependent and 
E3 ubiquitin protein ligase casitas B-lineage lymphoma(Cbl)-mediated 
ubiquitination and degradation through the proteasome in addition to degradation by 
lysosomal pathways(1,122), which have been attributed to Y591 and Y521, 
respectively. We and others have reported an increased proliferative capacity in 
response to TPO stimulation in cells lacking Y591, supporting the role of Y591 as a 
negative regulator of TPO-mediated proliferation(1,3). Aberrant positive signalling 
results in cellular hyperproliferation leading to development of haematological 
malignancies(123-125). Therefore, a thorough understanding of the regulation of 
TPO-mediated signalling is important for protection against uncontrolled cellular 
proliferation. 
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1.4 Myeloid Malignancies  
Myeloid malignancies (MM) are a group of clonal diseases of HSC origin. MMs 
include acute myeloid leukaemia (AML), myeloproliferative neoplasms (MPN) and 
myelodysplastic syndromes (MDS) (Figure 1.7). AML is characterised by excessive 
proliferation of myeloid blast cells within the BM resulting in disruption of normal 
haematopoiesis (Reviewed in (126)) and is the second most prevalent leukaemia in 
the United Kingdom (UK)(Haematological malignancy research network (HMRN), 
www.hmrn.org). MDS are characterised by ineffective haematopoiesis due to 
improper maturation of myeloid progenitor resulting in cytopaenias (Reviewed in 
(127)). Whereas AML and MDS are characterised by overproduction of immature 
cells, MPNs are characterised by overproduction of mature myeloid cells(128). Of 
the three, prevalence of MPNs is highest in the UK (HMRN) and both MDS and 
MPNs can both progress to AML. Despite increased molecular insight into these 
diseases, overlapping clinical features makes exact classification difficult resulting in 
overlapping classifications such as MDS/MPN (Figure 1.7) (Reviewed in (129)). 
Further studies are necessary to better understand and characterise these disorders.    
 
1.5 Myeloproliferative Neoplasms  
In 1951, William Dameshek coined the term ‘myeloproliferative disorders 
(MPDs)’(128). Dameshek recognized that hyperproliferation of bone marrow cells, 
specifically erythroblasts, granulocytes and megakaryocytes were often a concurrent 
event. Due to the similarities and overlapping clinical features of some 
myeloproliferative syndromes, he grouped together chronic myelogenous leukemia 
(CML), polycythemia vera (PV), primary myelofibrosis (PMF) and essential 
thrombocythemia (ET), speculating that they shared a common cellular origin that 
was being overstimulated by a ‘myelostimulatory factor’. The clonal nature of these 
disorders was confirmed in female PV patients using X-linked chromosomal 
inactivation patterns (XCIP)(130). The nomenclature of MPDs was changed to 
myeloproliferative neoplasms (MPNs) in the 2008 World Health Orgainzation 
(WHO) re-classification of haematological malignancies(129)(Figure 1.7). However, 
the classification of MPNs still largely resembles that which Dameshek described in 
1951.  
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Figure 1.7 2008 WHO Classification of Myeloid Malignancies  
Myeloid malignancies are grouped into five major categories shown in blue: Acute myeloid 
leukaemia (AML), myeloproliferative neoplasms-eos (MPN-eos), myeloproliferative neoplasms 
(MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and myelodysplastic syndrome 
(MDS). Subcategories are listed in pink and common mutations associated with each disease are 
listed in yellow.  
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 In 1960, Nowell and Hungerford described a chromosomal abnormality in several 
cases of CML(131), which was later termed the Philadelphia (Ph) chromosome. The 
observed cytogenetic abnormality was determined to have resulted from a 
translocation between the long arm of chromosomes 22 and 9 
(t(9;22)(q34;q11))(132) resulting in a breakpoint cluster region and Abelson murine 
leukaemia viral oncogene homolog 1 (BCR-ABL1) fusion gene(133). The BCR-ABL1 
gene encodes an active tyrosine kinase(134) and its expression is sufficient for 
induction of CML in vivo(135). The Ph chromosome was the first cytogenetic factor 
identified in haematological malignancies. This discovery led to further classification 
of the classical MPNs into two distinct classes: Ph-positive MPNs which consists of 
CML and Ph-negative MPNs which is comprised of PV, ET and PMF. 
1.5.1 Ph-positive MPNs 
1.5.1.1 Chronic Myelogenous Leukaemia (CML) 
CML accounts for approximately 1.5% of all haematological malignancies in the UK 
with a median diagnosis occurring at approximately 59 years of age and a 5-year 
survival rate of 87.1% (HMRN). The disease is typically characterised by increased 
cells of the granulocytic lineage including blasts in both the PB and BM (Reviewed 
in (136) and (137)). Symptoms associated with CML include fatigue, weight loss, 
night sweats and abdominal discomfort resulting from splenomegaly(138); however, 
between 20% to 40% of patients are diagnosed without presentation of any 
symptoms(138). CML can undergo acute transformation resulting in AML(139,140), 
the transformation rate has been reported at approximately 28%(141). Presence of 
the Ph chromosome is a hallmark of CML(129) and it is present in 99% of all CML 
patients(142). 
1.5.2 Ph-negative MPNs 
Ph-negative MPNs include PV, ET and PMF. Together, Ph-negative MPNs account 
for approximately 8.7% of total haematological malignancies in the UK. Around 
3,200 new cases are diagnosed each year in the UK (HMRN). Similar to CML, these 
MPNs predominantly affect the elderly population with the median age at diagnosis 
being approximately 72 years (HMRN). Symptoms associated with Ph-negative 
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MPNs include fatigue, concentration problems, early satiety, inactivity, night sweats, 
itching, abdominal discomfort, bone pain, weight loss and fever(143). 
1.5.2.1 Polycythaemia Vera (PV)  
PV is characterised by an increase in red cell volume, haemoglobin, haematocrit and 
blood viscosity resulting from hyperproliferation of the erythroid lineage(128). Its 
annual incidence is 2.8 cases per 100,000 people per year(144). The 5-year survival 
rate is high at approximately 93% (HMRN). The most common clinical 
complications associated with PV are increased risk of arterial and venous 
thrombosis(145), with thrombosis at clinical presentation reported in 13-60% of 
patients(146). Although less common, PV patients are also at risk for haemorrhagic 
events. Risk of transformation to myelofibrosis or AML occurs at a rate of 6% and 
7%, respectively at 15 years(147).  Thrombosis is the major cause of mortality in PV 
patients(147,148).  
1.5.2.2 Essential Thrombocythaemia (ET)  
ET is characterised by a sustained increase in platelet count resulting from 
proliferation of cells within the megakaryocytic lineage. The annual incidence of ET 
has been reported at 1.5 cases per 100,000 people per year(144) with the 5-year 
survival rate at approximately 93% (HMRN). Similar to patients with PV, ET 
patients are also at risk of both thrombotic and haemorrhagic events and thrombosis 
at clinical presentation was reported in 11-51% of patients whereas bleeding 
accounts for 0.3% of events per year(146). Despite the low percentage, haemorrhagic 
events account for approximately 4% of deaths of ET patients(146).  The incidence 
of haemorrhagic events is associated with extremely high platelet counts(146), which  
is typically attributed to platelet sequestration of von Willebrand factor (vWF); 
although, recent evidence suggests that endothelial cells may also play a role in these 
haemorrhagic complications(149). The risk of progression to myelofibrosis or AML 
is 4% and 2%, respectively at 15 years(147,150).  
1.5.2.3 Primary Myelofibrosis (PMF) 
PMF is characterised by multilineage expansion of the myeloid lineage which is 
accompanied by BM fibrosis(151). The annual incidence of PMF has been reported  
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at 0.4 cases per 100,000 people per year(144). The 5-year survival rate is 43% 
(HMRN). Symptoms include pancytopenia, bleeding and infection resulting from 
progressive bone marrow failure and pain, weight loss and sweating due to marked 
splenomegaly resulting from extramedullary haematopoiesis(137). PMF is difficult 
to diagnose due to broad symptoms and varying levels of multilineage expansion; 
additionally, depending on the stage of the disease, peripheral blood counts 
change(137). Although all MPNs are capable to transformation to AML, the risk is 
highest in PMF with approximately 25% of patients developing AML(137). PMF 
has the worst outcome with morality due to infections or haemorrhage resulting from 
bone marrow failure(137).  
1.6 JAK2 in MPN pathogenesis  
Identification of the Ph chromosome in CML prompted a search a similar 
cytogenetic cause for other haematological malignancies. In early studies of PV, ET 
and PMF patients, mutations in EPOR and MPL could not be identified, suggesting 
that the cause of cytokine hypersensitivity in these diseases was due to an effector 
downstream of these receptors(152). In 2005 several groups identified the JAK2
V617F
 
mutation in most patients with PV and approximately half of patients with ET and 
PMF. Subsequently, additional mutations in exon 12 of JAK2 were identified in 
patients with PV and idiopathic erythrocytosis(153). These discoveries identified 
mutations in JAK2 as the main genetic lesions of Ph-negative MPNs providing 
significant insight into the molecular pathogenesis of these diseases.  
1.6.1 JAK-STAT signalling  
Hematopoietic cytokine receptor signalling is largely dependent on the JAK-STAT 
signalling axis (Reviewed in (154)). Cytokine receptors lack intrinsic kinase activity 
and often rely on JAKs for signal transduction (Reviewed in (154)). There are four 
members of the JAK family: JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). The 
JAK family of proteins is composed of four functional domains (Figure 1.8), the 4-
point, ezrin, radixin, moesin (FERM) domain, a SRC homology 2 (SH2)-like domain 
and two JAK homology (JH) domains.  
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Both JH domains, JH1 and JH2, share high homology with tyrosine kinase domains; 
however, only JH1 has was initially believed to harbour catalytic kinase activity. 
JAK2 catalytic activity is stimulated upon phosphorylation of Tyr1007 within the 
activation loop(155). Regulation of kinase activity is an intrinsic property whereby 
the JH2 domain, also termed the pseudokinase domain, regulates the kinase activity. 
It was thought that this was occurring through interaction of the pseudokinase 
domain with the kinase domain(156,157). Additional JAK2 regulation involves 
phosphorylation at Tyr570 which inhibits JAK2-dependent signalling(158). Recent 
evidence suggests that the pseudokinase domain does, in fact, possess kinase activity 
and negatively regulates catalytic activity of JAK2 through phosphorylation of 
negative regulatory sites, Tyr570 and Ser523(159). The crystal structure of the JH2 
domain revealed that JH2 domain phosphorylates Ser523 in cis whereas Tyr570 is 
phosphorylated in trans(160). Phosphorylation at these sites is JAK2 specific and 
possibly acts as an additional inhibitory regulator(160). Disruption of the 
pseudokinase domain results in increased basal JAK2 activity(159) and cytokine 
independent activation of STATs(156). The Src Homology 2(SH2)-like domain of 
JAKs was predicted through computational modelling(161,162) and functional 
assays with JAK3 show that this domain is capable of association with 
phosphorylated tyrosine residues(162). However, functional studies with JAK1 
utilizing a common loss of function mutation within the SH2 domain did not affect 
cell surface localization at the plasma membrane or signalling(163). The N-terminal 
FERM domain is necessary for receptor association. Experiments utilizing shortened 
fragments of JAK FERM domains consisting of only the JH6 and JH7 regions 
showed that these fragments are sufficient for receptor association(164,165). 
Additionally, it was shown that the JAK2 FERM domain acts as a chaperone 
promoting EPOR cell surface expression, which is accomplished in the absence of an 
active kinase domain(166). Moreover, the JAK FERM domains are responsible for 
receptor specificity(167). Mutation of conserved hydrophobic resides within the 
FERM domain, Y107 of JAK1(168), L98, I102 and clinically relevant mutation of 
Y100 of JAK3(169) disrupt association with cytokine receptors utilizing gp130 and 
IL-2Rγ, respectively. These data demonstrate the biological function of the N-
terminal domain of JAK which is independent of kinase activity.  
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Figure 1.8 Functional domains of JAK2 protein  
Diagram depicting the seven Janus homology (JH) domains of JAK2. JH1 is the C-terminal kinase 
domain and possess catalytic tyrosine kinase activity. JH2 is the pseudokinase domain which is 
responsible for regulating catalytic activity. JH3 and JH4 comprise the SRC homology 2(SH2)-like 
domain; its function is not fully understood. JH6 and JH7 comprise the 4-point, ezrin, radixin, moesin 
(FERM) domain which facilitates association with cytokine receptors.  
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Different JAKs preferentially activate different cytokine receptor complexes (Figure 
1.9), the specificity arising from differences in JAK FERM domains(167). 
Homodimeric receptors such as EPOR, GHR, MPL, PRLR or granulocyte-
macrophage colony-stimulating factor receptor (GMCSFR) preferentially activate 
JAK2. Whereas heterodimeric and heterotrimeric receptors can activate different 
JAKs depending on the receptor subunits (Reviewed in (170)).    
 
Cytokine binding to their respective receptors results in receptor aggregation or in 
the case of pre-formed dimers, a conformational change that results in JAK tyrosine 
phosphorylation and subsequent activation. The activated kinase can then in turn 
phosphorylate tyrosine residues within the cytoplasmic tail of the receptor in 
addition to downstream STATs. Phosphorylated STATs are able to dimerize and 
translocate to the nuclease where they activate gene transcription (Figure 1.6) 
(Reviewed in (154,170,171)).   
1.6.2 Negative regulation of JAK2 signalling  
As with any signalling cascade, tight regulation is necessary to prevent aberrant 
signalling and deregulated proliferation which could result in development of 
disease. JAK2 signalling is controlled by a number of regulatory mechanisms 
including kinase inactivation, ubiquitination and inhibition of downstream signal 
transducers.  
 
Inactivation of JAK2 kinase activity is accomplished through interactions of the 
kinase domain with the pseudokinase domain. The inhibition is thought to occur 
through phosphorylation of specific inhibitory residues, Ser523 and Try570, within 
the pseudokinase domain. Phosphorylation at these sites is accomplished through 
both cis (Ser523) and trans (Tyr570) phosphorylation. Importantly, JAK2 is the only 
JAK that utilizes homodimeric cytokine receptors, which assures presence of a 
second JAK2 molecule to facilitate the trans phosphorylation(160). Phosphorylation 
at these sites prevents activation of the kinase; however, once the kinase is activated 
there are a number of proteins involved in suppressing the signalling cascade 
including phosphotryosine phosphatases (PTP), SOCS and LNK.  
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Figure 1.9 Cytokine receptor differential JAK activation  
The JAK family of kinases differentially associate with cytokine receptors and are activated upon 
cytokine binding to receptors. This schematic shows the different families and subgroups of cytokine 
receptors and their associated JAKs. IL – interleukin; GMCSFR – granulocyte-macrophage colony 
stimulating factor receptor; EPOR – erythropoietin receptor; MPL – thrombopoietin receptor; GCSFR 
– granulocyte colony stimulating factor; GHR growth hormone receptor; PRLR – prolactin receptor; 
IFN – interferon.  
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A PTP involved in regulation is Src homology region 2 domain-containing 
phosphatase-1 (SHP-1). SHP-1 associates with either the receptor or to JAK2 itself 
and dephosphorylates the activated proteins(172) thereby disrupting signalling. 
SOCS proteins are part of a negative feedback loop that inhibits JAK-STAT 
signalling. SOCS proteins are transcriptionally regulated by STATs and function by 
binding to either activated receptors or JAK2 proteins to turn off the pathway(172). 
Specifically, SOCS3 binds directly to JAK2 and the receptor and occludes the 
substrate-binding groove of JAK2 effectively inhibiting the kinase(173). The adaptor 
protein, LNK, is a negative regulator of cytokine signalling regulating signal 
transduction downstream of IL-3, SCF, TPO, EPO, platelet-derived growth factor 
(PDGF) and tumour necrosis factor (TNF)(174). Specifically, LNK attenuates 
signalling downstream of TPO and EPO through interaction and attenuation of JAK2 
activity resulting in decreased STAT3, STAT5, Akt and MAPK 
signalling(118,174,175).  
 
Removal of JAK2 associated receptors from the cell surface and targeting of them 
for recycling or degradation is another mechanism of control. This is accomplished 
through ubiquitination of receptors. Specifically, for MPL, ubiquitination of the 
receptor occurs after cytokine-induced activation at two intracellular lysine residues, 
MPL
K553
 and MPL
K573
(122). Ubiquitination results in receptor internalization and 
degradation through both the lysosomal and proteosomal pathways(122), effectively 
preventing additional signal transduction.   
 
Immediately downstream of JAK2 in the canonical signalling cascade is the 
activation of STAT proteins. Inactivation of these signal transducers will also inhibit 
JAK2 signal transduction. A family of proteins known as protein inhibitor of 
activated STAT protein (PIAS) inhibit STAT signalling by binding to activated 
STAT dimers and inhibiting their association with DNA for induction of 
transcription(172) thereby terminating additional downstream activation. 
PIAS1(176) and PIASy(177) both inhibit STAT1 whereas PIAS3 inhibits STAT3 
signalling(178).  
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1.6.3 The JAK2V617F mutation  
Given its role in signal transduction of multiple haematopoietic cytokine receptors, 
JAK2 was a promising candidate as a molecular driver for MPNs. Indeed, 
sequencing of JAK2 from granulocytes of MPN patients in three independent studies 
identified a single G to T nucleotide transition in exon 14 of JAK2, resulting in a Val 
to Phe substitution at amino acid residue 617 located in the pseudokinase 
domain(179-181). The mutation was absent in control patients and in T-cells from 
patients with JAK2
V617F
-positive peripheral-blood granulocytes revealed that the 
mutation was MPN specific and that it was an acquired mutation(179). The 
JAK2
V617F
 mutation was detected in 98% of patients with PV and approximately 
50% of patients with ET and PMF(179-181). Although the JAK2
V617F
 mutation 
predominates in classic Ph-negative MPNs, it can also be detected in approximately 
5% of patients with CML, MDS or denovo AML(152). In agreement with its 
characterisation as a clonal stem cell disorder, the JAK2
V617F
 mutation was detected 
in haematopoietic progenitors(179) in addition to the CD34
+
CD38
-
CD90
+
Lin
+
 subset 
of HSCs(182).  
 
Presence of the JAK2
V617F
 mutation in only half of patients with ET and PMF attest 
to the heterogeneity of these diseases. Although identification of this mutation has 
profoundly increased the precise categorisation of these diseases based on molecular 
pathogenesis, questions still remain regarding how a single point mutation can result 
in three different clinical pathologies in addition to the molecular basis of disease in 
JAK2
V617F
-negative MPN patients.    
1.6.3.1 One mutation, three phenotypes  
Although identification of the JAK2
V617F
 mutation significantly increased our 
understanding of the molecular pathogenesis of Ph-negative MPNs, it is still not 
completely understood. One central question that remains unanswered is how a 
single mutation yields three distinct clinical phenotypes. There are a number of 
hypotheses that have been explored to try and answer this outstanding question. 
They include differences in JAK2
V617F
 dosage, presence of additional somatic 
mutations, differences in the cell type where the mutation is acquired and differential 
STAT signalling, all of which are discussed in this section (  Figure 1.10). 
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1.6.3.1.1  Gene dosage  
In this model, it is thought that the phenotypic variation observed between PV, ET 
and PMF patients is a continuum that depends on level of mutant kinase present 
within the cell. JAK2
V617F
 was detected in patients with PV, ET and PMF; however, 
the mutation was found either in a homozygous or heterozygous state in these 
patients(179). Homozygosity for JAK2
V617F
 is a consequence of a mitotic 
recombination event(179-181), the rate of which was highest in granulocyte DNA 
from PV patients at 25% compared to 3% and 9% in ET and PMF, respectively(179). 
Studies of individual myeloid progenitor colonies from PV and ET patients found 
homozygous JAK2
V617F
 clones in almost all progenitors from PV patients but rarely 
in ET patients(183). Additionally, not only is homozygosity more characteristic of 
PV, even within PV, higher levels of JAK2
V617F
 burden correlates with significantly 
higher haemoglobin levels and progression to myelofibrosis(184,185). These clinical 
data support the idea of a phenotypic continuum dependent upon level of JAK2
V617F
 
expression and is further supported by JAK2
V617F
 mouse models. In models 
generated through transplantation of retrovirally tranduced BM cells, JAK2
V617F
 
expression was superphysiological resulting in development of PV-like 
phenotypes(186-189). In later models where human JAK2
V617F
 was expressed under 
the control of the mouse Jak2 locus, the ratio of mutant JAK2 to WT Jak2 was 
similar and this yielded an ET-like phenotype(190). Tiedt and colleagues developed 
a mouse model where copy number and consequently expression of human 
JAK2
V617F
 could be modulated through induction of recombination by different Cre 
recombinases. They showed that lower levels of JAK2
V617F 
expression correlated 
with an ET-like phenotype whereas high expression resulted in PV(191).Taken 
together, these data strongly support that JAK2
V617F 
expression levels play a role in 
determining MPN phenotype.  
1.6.3.1.2  Host genetic variations  
Another theory in the explanation of varying phenotypes resulting from JAK2
V617F 
expression is the idea that genetic variations predispose patients to development of a 
particular MPN phenotype. In experiments utilizing JAK2
V617F
 mouse models, 
expression of JAK2
V617F
 in C57Bl/6 mice resulted in trilineage hyperplasia and 
splenomegaly characteristic of PV whereas Balb/C mice developed PV but also 
marked leukocytosis(186,189). These results suggest that the genetic variations 
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between C56Bl/6 and Balb/C mice caused the varying phenotypes. The influence of 
host genetic variations has been tested in patients. Single nucleotide polymorphisms 
(SNP) for four candidate genes associated with JAK-STAT signalling: EPOR, MPL, 
granulocyte colony-stimulating factor receptor (GCSFR) and JAK2 identified 
correlations between SNPs in JAK2 and EPOR and development of PV(192) 
suggestive of at a least a partial role of genetic background on MPN phenotype 
although no definitive link has been determined.  
1.6.3.1.3  Acquisition of JAK2V617F in different cell types  
Ph-negative MPNs are clonal disorders(193) and their phenotypes are characterised 
based on the specific haematopoietic lineages that are being overproduced. It is 
thought that MPN phenotype is dependent on the cell in which the JAK2
V617F
 
mutation is acquired. Different cells have varying capacities for lineage 
differentiation so it is possible acquisition of JAK2
V617F
 in cells capable of 
differentiation down only the megakaryocytic lineage leads to development of ET 
whereas acquisition in a cell capable of megakaryocytic, erythroid and granulocytic 
differentiation leads to PV or PMF. One study found JAK2
V617F
-positive cells in 
granulocytic, erythroblastic, megakaryocytic and lymphoid lineages from PV and 
PMF patients(194) suggestive of acquisition in an early haematopoietic progenitor. 
Additional considerations include differences even within the HSC compartment 
which have been reported between PV and PMF patients, where the frequency of 
JAK2
V617F
-positive HSCs is higher in PMF compared to PV(195). However, due to 
the difficulty in determining the specific cell where the JAK2
V617F
 was acquired, 
explicitly proving this model would be difficult. 
1.6.3.1.4  Differential STAT activation  
Another theory to explain how JAK2
V617F
 results in three distinct clinical phenotypes 
is based on the fact that JAK2 can activate a number of different STATs and 
proposes that differential activation of specific STATs drives a specific MPN 
phenotype. A study analysing the expression pattern of phosphorylated STAT3 and 
STAT5 found increased STAT3 and STAT5 phosphorylation in PV, an increase in 
STAT3 but decrease in STAT5 phosphorylation was observed in ET and both 
STAT3 and STAT5 phosphorylation was decreased in PMF(196). Additionally, 
another study analysing differences between clonally-derived JAK2
WT
 and JAK2
V617F
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CD34
+
 cells found increased phosphorylated STAT1 in JAK2
V617F
 cells compared to 
JAK2
WT
 cells from the same ET patient; however, this was not observed in cells 
from PV patients(197). Furthermore, modulation of STAT1 activation in 
heterozygous JAK2
V617F
 ET cells was able to induce a PV-like phenotype(197), 
providing strong evidence that STAT1 activation has a role in determining MPN 
phenotype.  
1.6.4 JAK2 exon 12 
Although 98% of PV patients harbour the JAK2
V617F
 mutation, there remains a subset 
of PV patients that are JAK2
V617F
-negative. In this subset of patients, JAK2 exon 12 
mutations were identified; additionally, these mutations were not detectable in ET 
patients(153). Four different mutations in JAK2 exon 12 were identified in the 
original study: F537-K539delinsL, H538QK539L, K539L and N542-E543del, all 
located within a conserved region predicted to lie within the linker region between 
the SH2 and pseudokinase domain of JAK2(153). The mutational frequency was low 
in granulocyte DNA but prevalent in erythropoietin (EPO)-independent erythroid 
colonies(153).  Similar to JAK2
V617F
, co-expression of each of the JAK2 exon 12 
mutations within EPOR in Ba/F3 cells was sufficient to induce cytokine-independent 
proliferation and activation of downstream signalling pathways(153,181). 
Expression of the most common exon 12 mutation, JAK2
K539L
, in vivo was able to 
recapitulate an MPN in mice(153). Identification of these mutations provides 
additional evidence that the molecular pathogenesis of PV is highly dependent on 
JAK2 as mutations are found in essentially all PV patients. This also provides an 
additional level for diagnostic stratification which may make it easier for 
implementation of specific targeted therapies.  
1.7 Additional Mutations Associated with MPNs 
Although JAK2 is the predominant mutation in Ph-negative MPNs, it is not present 
in all MPN patients, specifically those with ET and PMF. Additional mutations have 
been identified and described in MPN patients, some of which are discussed below.  
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1.7.1 MPL 
Activating mutations in exon 10 of MPL are found in the neoplastic cells of 5-10% 
of patients with ET or PMF(124,125,198). Although not common, MPL mutations 
are not mutually exclusive from JAK2
V617F
(199). The most common mutation are 
MPL
W515L
(124) and MPL
W515K
(125) but the MPL
S505N
(200) mutation has also been 
described. These mutations are sufficient to induce disease and are discussed in 
greater detail in Section 1.9.1. 
1.7.2 Calreticulin (CALR) 
Recent identification of somatic mutations of exon 9 of CALR in patients with ET 
and PMF(201,202) has not only provided important insight into the molecular 
pathogenesis of these diseases but also serves as an additional prognostic tool(201). 
Mutations in JAK2 and MPL account for approximately 50% and 10%, respectively 
of mutations found in ET and PMF; within the subset of patients negative for both of 
these genetic lesions, CALR mutations accounted for 67% of patients with ET and 
88% of patients with PMF(201). Additionally, CALR mutations are mutually 
exclusive with JAK2 and MPL mutations(201,202); however, it was also found 
mutated in other myeloid cancers(202). The mutation is present in HSCs and 
progenitor cells suggestive of an initiating mutation(202).There are 2 types of CALR 
mutations, both resulting in frameshift mutations causing loss of the endoplasmic 
reticulum-retention motif (Lys-Asp-Glu-Leu [KDEL] amino acid sequence). The 
type I CALR mutation is able to induce cytokine independent proliferation in vitro 
and utilises the JAK/STAT signalling axis(201). Both ET and PMF patients with 
CALR mutation presented with higher platelet counts but lowered white-cell counts 
compared to patients with mutant JAK2(201,202). The CALR mutation also provides 
an additional means for prognostic stratification, with the CALR mutation correlating 
with increased survival among PMF patients relative to JAK2 or MPL mutations and 
increased survival among ET patients relative to JAK2 mutations(201), although 
transformation to PMF was increased(202). Unfortunately, 8.8% of patients, 
predominantly with ET, are triple negative for JAK2, MPL and CALR 
mutations(201) suggesting the possibility of an additional yet unidentified 
cytogenetic lesion or other non-genetic factors.  
Chapter 1 
 
 
38 
 
1.7.3 TET2 
In 2009, mutations in tet methylcytosine dioxygenase 2 (TET2) were identified in a 
wide range myeloid malignancies including MPNs with 11% of JAK2
V617F+
 patients 
harboring a TET2 mutation(203,204). Analysis of progenitor cells from 5 JAK2
V167F 
and TET2 double mutant MPN patients found that all cells expressing JAK2
V617F
 also 
possessed a TET2 mutation, suggesting that TET2 mutations preceded the JAK2 
mutation(203); however, this was later challenged when subsequent studies showed 
acquisition of TET2 mutations following acquisition of JAK2
V617F
(205). Additional 
studies are needed to further elucidate the correlation between TET2 mutations and 
MPNs.  
1.8 Treatments for MPNs 
MPNs are a heterogeneous group of disorders with varying symptom profiles and 
clinical needs, making the choice of therapy difficult(143). A number of molecular 
insights have improved the understanding of the molecular pathogenesis allowing for 
more precise diagnosis and development of targeted therapies. There are currently a 
few categories of available treatments for MPNs including cytoreductive therapies, 
allogeneic stem cell transplantation and targeted therapies, namely imatinib and 
ruxolitinib, which are discussed below.   
1.8.1 Imatinib  
Imatinib (STI571 (4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate) is a small 
molecule tyrosine-kinase inhibitor marketed by Novartis as Glivec and Gleevec in 
the UK and United States (USA), respectively used specifically in for the treatment 
of CML(206). It is the most successful drug for targeted MPN therapy and the gold 
standard for treatment of CML; however, its efficacy is restricted to CML. Imatinib 
is able to inhibit the BCR-ABL1 tyrosine kinase through competitive inhibition at its 
ATP-binding site, preventing activation of the kinase and downstream signal 
transduction(207). Treatment results in cytogenetic remission in approximately 90% 
of all CML patients(208) with low levels of toxicity reported(209). Additionally, 
molecular remission is also achieved with low or undetectable levels of BCR-ABL1 
transcripts detected in imatinib treated patients in cytogenic remission(210). 
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However, despite the efficacy of the drug, acquired mutations within the kinase 
domain result in resistance to imatinib treatment (Reviewed in (211).  
1.8.2 Allogeneic stem cell transplant 
Allogenic stem cell transplants are currently the only curative option for PMF. 
However, the procedure is high-risk for patients with the possibility of graft failure, 
graft versus host disease and toxicity resulting from treatment. Additional factors 
such as the state of disease progression, availability of a suitable donor and age of 
the patient also complicate the decision to implement treatment especially as 3-year 
overall survival rate is approximately 50% with reports of life expectancy being 
lower with than without treatment. Allogenic stem cell transplants are therefore 
reserved for patients with a life expectancy of less than 5 years (Reviewed in (143)).  
1.8.3 Aspirin and cytoreductive therapy  
Thrombotic complications are leading cause of morbidity and mortality in untreated 
MPN patients(212); therefore many therapies aim to reduce these events. A study by 
Marchioli et al. reported a significantly lower rate of major thrombotic complications 
and associated mortality when haematocrits of less than 45% were maintained 
compared to those with a haematocrit target of 45-50%(213).Currently, the most 
common therapy for PV patients is a regimen of low-dose aspirin which reduces the 
risk of vascular events without significantly increasing the incidence of major 
bleeding; however its role in ET is less understood(143,212). Aspirin regimens in PV 
patients were initially reported to increase the incidence of gastrointestinal 
bleeding(214); however, it was later recognized that this was a result of improper 
dosage(212).  
 
The aim of cytoreductive therapy is to reduce cancer cell burden. Phlebotomy is a 
non-drug therapy aimed at reducing haematocrit in PV patients to levels that lower 
the risk of thrombotic events(148,213). Surprisingly, phlebotomy alone resulted in 
increased survival compared to combinatorial therapies although there were 
increased incidences of thrombotic complications resulting in mortality within the 
first 2-4 years(148). In PV and ET patients hydroxycarbamide (HC), formerly 
hyroxyurea, is the most common cytoreductive treatment followed by 
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anagrelide(215,216). HC functions by inhibiting the biosynthesis of 
deoxyribonucleotides from ribonucleotides(217) preventing production of new cells. 
The mechanism of action of anagrelide is not well described but it has been shown to 
inhibit megakaryocytic differentiation(218) and is a known phosphodiesterase 
inhibitor(219). However, there are conflicting results regarding the advantages of HC 
compared to anagrelide on decreasing thrombotic risk. One study reported 
significantly increased vascular risk including thrombosis, haemorrhage and 
transformation to MF on an anagrelide regime compared to HC(215) whereas 
another study reported no significant difference in risk between the two 
treatments(216).  HC is also used for treatment of PMF, although it has only resulted 
in modest clinical benefits(220). Interferon-α2 (IFN-α2) therapy is another 
successful regime in the treatment of MPNs, inducing an approximate 80% response 
in patients(221). However, its toxicity has led to discontinuation in approximately 
20% of patients(221). A modified version of the drug, pegylated interferon α-2a 
(PEG-IFN-α-2) is an emerging treatment for both PV and ET with 76% and 77% of 
PV and ET patients, respectively exhibiting a haematological response to 
treatment(222). Notably, PEG-IFN-α-2 has also been reported to induce molecular 
remission in 18% and 17% of PV and ET patients, respectively(222). However, 
similar to other treatments(211), acquired mutations reduce responsiveness to 
therapy(222).  Use of anti-cancer drugs, pipobroman and busulfan are reserved for 
PV and ET patients intolerant to hydroxycarbamide or anagrelide due to increased 
leukemogenic potential(143,220,223).  
1.8.4 Splenectomy  
Patients with PMF can develop marked splenomegaly, therefore therapeutic 
intervention includes splenectomy. It is typically reserved for patients with marked 
splenomegaly whose splenomegaly is not responsive to drug therapies(224) as 
perioperative mortality rates range from 7%-15%(225) and morbidity rates are 
approximately 25%(224). Additionally, splenectomy does not improve survival and 
serves a more palliative role(225). 
 
 
 
Chapter 1 
 
 
41 
 
1.8.5 Ruxolitinib 
Given the large role JAK2 mutations have in driving Ph-negative MPNs and the 
effectiveness of the kinase inhibitor imatinib in treatment of CML, it was thought 
that inhibition of JAK2 would effectively treat Ph-negative MPNs. However, the 
efficacy of therapeutic JAK2 inhibitors has been limited due to specificity issues and 
adverse side effects, since JAK2 function is critical for normal haematopoiesis. 
Ruxolitinib (INCB018424) is a small molecular JAK inhibitor that functions by 
binding to the ATP-binding pocket of kinase(226) thereby limiting the availability of  
nucleoside triphosphate molecule for transfer to a tyrosine residue which would 
result in tyrosine phosphorylation. Preclinical studies determined that it was a potent 
inhibitor of JAK1 and JAK2 although it was also able to inhibit JAK3 and 
TYK2(227). In vitro, it was able to inhibit JAK2
V617F
 –induced signalling and 
proliferation of EPOR and JAK2
V617F
 expressing Ba/F3 cells and was also able to 
inhibit proliferation of haematopoietic progenitor cells from MPN patients(227). 
Additionally, in a JAK2
V617F+ 
MPN
 
allotransplantation mouse model, ruxolitinib 
significantly reduced splenomegaly, decreased JAK2
V617F+
 cell burden and increased 
overall survival compared to control mice without affecting peripheral blood 
counts(227). Of note, the MPN model used in this study did not display any changes 
in peripheral blood counts upon introduction of JAK2
V617F
. These data strongly 
supported ruxolitinib for treatment of MPNs. In a phase 1-2 clinical trial, patients 
with myelofibrosis treated with ruxolitinib showed clinical improvement 
characterised by a prompt and significant reduction in spleen size, weight gain and 
observable functional improvements(228). Non-haematologic toxicity was reported 
in less than 10% of patients(228). The main haematologic side effect was 
thrombocytopenia which was decreased upon lowering dosage and reversed upon 
discontinuation of treatment(228). Additionally, the increase in circulating 
inflammatory cytokines, including IL-6, observed in myelofibrosis patients(229) was 
also reduced(228), possibly contributing to the observed decrease in splenomegaly. 
Similar results were obtained in 2 separate, randomised, phase 3 clinical trials of 
ruxolitinib(220,230). Median survival was increased in patients receiving ruxolitinib 
compared to placebo (8.4% vs 15.6%, respectively)(230); however median survival 
was similar for ruxolitinib treated patients compared to those receiving best available 
therapy (8% vs 5%, respectively)(220). However, in both studies, patients in the 
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ruxolitinib group reported decreased symptoms and increased quality-of-
life(220,230). Despite the marginal increase in overall survival compared to placebo, 
ruxolitinib provides significant palliative care making it a useful drug in the 
treatment of MPN symptoms. Results from these trials prompted the U.S. Food and 
Drug Administration to approve ruxolitinib for treatment of myelofibrosis at the end 
of 2014. 
 
Although not yet approved by the United States Food and Drug Administration 
(FDA) for treatment of PV, Ruxolitinib is currently undergoing clinical trials for 
treatment of PV(231). In general, it was well tolerated and was able to reduce 
haematocrit and splenomegaly in patients with advanced PV who were refractory or 
intolerant to HC and similarly to trials in myelofibrosis patients, thrombocythaemia 
and anaemia were the most adverse side effects(231). 
 
Additional JAK inhibitors are currently under development as therapeutic 
compounds. TG101348, like ruxolitinib, is a ATP-competitive inhibitor which 
exhibits high selectivity for JAK2 and JAK2
V617F
 although FLT3 and RET were also 
inhibited(232). In contrast to ruxolitinib, there were no reported changes in pro-
inflammatory cytokines(232), possibly due to more selective JAK2, rather than 
JAK1 inhibition. Additionally, JAK2
V617F
 allele burden was significantly reduced in 
patients with an initial allele burden higher than 20%(232). Another kinase inhibitor, 
Lestaurtinib (CEP-701) also exhibits selective inhibition of JAK2 and JAK2
V617F
 but 
similar to TG101348 it is also able to inhibit FLT3 and RET in addition to 
TRKA(233). However, JAK2
V617F
 allele burden was not reduced following 
treatment(234). Additional inhibitors under development include: XL019, SB518, 
CYT387, AZD1480, INCB028050, INCB16562, tascocitinib, NVP-BSK805; these 
compounds will not be discussed in this work but are reviewed in (235). In general 
these compounds are successful at inhibiting JAK activity both in vitro and in vivo; 
however, selectivity remains the largest obstacle. Although off target effects are 
undesired for the treatment of MPNs, JAK2 inhibitors that target additional JAKs, 
such as those involved in immunological or inflammatory responses, are being 
investigated for treatment of rheumatological disorders, autoimmune diseases, 
prevention of allograft rejection and inflammatory conditions(Reviewed in (235)).  
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1.9 MPL and TPO: their current and prospective roles in MPNs 
MPL and TPO are essential for proper regulation of platelet production, 
dysregulation of either result in disease. Insufficient production or function of MPL 
or TPO results in thrombocytopenias whereas overproduction or unsolicited 
activation results in thrombocythaemias. Mutations can result in disease; however, 
they also provide insight into normal regulation of these proteins. This section 
focuses on the role of MPL and TPO and their association with MPNs. 
1.9.1 Activating MPL mutations  
Activing mutations within MPL typically result in thrombocythaemia: the 
overproduction of platelets. A number of activating mutations in MPL have been 
described. The first report of unsolicited MPL activation was the translocation of the 
v-mpl envelope protein to a portion of the intracellular domain of MPL resulting in 
myeloproliferation, which eventually led to the cloning of the receptor. Since then, a 
number of additional mutations have been reported. A study analysing a family with 
familial ET found a heterozygous serine to asparagine mutation within the 
transmembrane domain at codon 505 of MPL (MPL
S505N
)(200). All members of the 
family harbouring the mutation had increased platelet counts whereas counts from 
the members without the mutation were unaffected(200). In another study, sequence 
analysis of cytokine receptors from granulocyte DNA of myelofibrosis patients 
revealed a tryptophan to leucine mutation at codon 515 (MPL
W515L
)(124). Four of 
forty-five (9%) patients harboured this mutation which was absent from buccal cell 
control DNA from the same patients, suggesting a somatic origin(124). Additionally, 
in a larger study, the MPL
W515K
 mutation was later identified, also from granulocyes 
of MPN patients(125). Both, the MPL
S505N
 and MPL
W515L
 mutations confer 
cytokine-independent signalling and proliferation when expressed in cell 
lines(124,200); although this has not been shown for MPL
W515K
, it is expected to 
exhibit a similar functional consequence. MPL
W515
 is located at the transmembrane-
cytoplasm interface and resides within an α-helical amphipathic domain (KWQFP in 
murine and RWQFP in humans) that prevents unsolicited dimerization and 
subsequent activation of MPL(236). The W515 mutations were only found in 
patients with myelofibrosis or ET(125).  
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1.9.2 MPL expression in MPNs 
Shortly after the cloning of MPL in 1992, its expression was assessed in a number of 
human haematological malignancies. The study reported low levels of MPL 
transcript levels detected by northern blot in bone marrow or peripheral blood from 
patients with myeloproliferative neoplasms, acute lymphoblastic leukaemia (ALL) 
and non-Hodgkin’s lymphoma (NHL)(237). Subsequent studies supported these 
findings. Horikawa et al. reported decreased MPL mRNA transcript and protein 
expression in platelets from ET patients (238). Duensing et al. reported decreased 
MPL mRNA expression in peripheral blood from PV and ET patients (239). 
Harrison et al. and Li et al. reported that MPL expression was significantly decreased 
in ET patients, as measured using immmuno-labeling of cell surface MPL on 
platelets (240,241). Conversely, Moliterno et al. reported decreased MPL expression 
on platelets from PV patients but normal expression on platelets from an ET 
patient(242). This discrepancy could be explained by heterogeneity within MPNs as 
later studies also found reduced MPL expression in MPNs; yet, many of these studies 
reported heterogeneity of MPL expression in cells between and even within patients. 
Le Blanc et al. reported mixed MPL expression on platelets from PV patients as 
determined by western blot (243).  Numerous groups reported mixed MPL staining 
intensity and pattern in bone marrow sections from ET(244,245) and PV(246) 
patients(247). A study by Moliterno and Spivak found 2 isoforms of MPL in PV 
patients that were differentially recognized by antiserum against the MPL 
extracellular domain and an antibody against the C-terminal domain, possibly an 
additional explanation for the heterogeneous staining previously reported(55). They 
found the isoform specific to PV platelets to be incompletely glycosylated and 
therefore more susceptible to endoglycosidase H (EndoH) digestion resulting in 
decreased expression, a defect  which was exaggerated as the disease progressed(55). 
The dependence of MPL expression on disease duration makes precise delineation of 
its role difficult. Consequently, despite these studies, the role of MPL expression in 
MPNs remains to be determined. Many of these studies examined MPL expression 
as a prognostic marker for MPNs. However, recent discoveries have provided a 
better understanding of the molecular pathogenesis of MPNs; therefore, analysis of 
MPL expression based on these distinct subsets could help answer outstanding 
questions regarding the role on MPL expression in MPNs.      
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1.9.3 TPO expression in MPNs 
Unlike MPL, mutations of the TPO protein have not been reported to cause MPNs. 
However, cytogenetic abnormalities in the region of chromosome 3q26, where the 
THPO gene is located, are associated with abnormal haematopoiesis, including 
thrombocytosis(248-250). Additionally, mutations within the THPO genes have been 
reported which result in more efficient translation of the protein(251,252). Affected 
individuals present with high circulating TPO levels resulting in hereditary 
ET(251,252). Taken together, these data suggests that TPO plays a role in MPN 
development, specifically, when plasma TPO levels are dysregulated, MPNs may 
develop.  
 
This association has led a number of groups to study the relationship between TPO 
levels and MPNs. Harrison et al. report no significant differences in TPO levels 
between patients with ET, reactive thrombocytosis (RT) and other MPNs compared 
to normal patients(240). Similarly, Li et al. also found no difference between plasma 
TPO levels in ET patients compared to normal patients(241). Normal TPO levels 
were attributed to reduced MPL expression on platelets which offset the increase in 
platelet count characteristic of ET(241). Conversely, Tomita et al. report an inverse 
relationship between serum TPO levels and platelet count in ET patients. Successful 
therapeutic reduction of platelet count resulted in increased TPO levels. However, 
this can be explained by reports of lowered MPL expression on ET platelets resulting 
in decreased ability to sequester and remove circulating TPO(253). Furthermore, 
Wang and Hashimi investigated the reported increase in plasma TPO levels in MPN 
patients and found no abnormalities associated with the regulation of TPO 
production by BM mononuclear and BM stromal cells(254). Therefore the changes 
observed in plasma TPO levels is likely due to differences in MPL expression and 
thus ability to sequester TPO(254). Whereas there are reports of heterogeneity of 
MPL expression within the MPN patients, the consensus with TPO is clearer cut with 
the defect being specific to MPL rather than TPO.   
1.9.4 Interplay between JAK2 and MPL 
JAKs are not only necessary for signal transduction of cytokine receptors but also 
necessary for their cell surface localization and stability(166,255,256). Analysis of 
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proteins involved in the IL-6 signalling pathway revealed similar half-lives for the 
receptor component, gp130, and  JAKs(257).  Additionally, fluorescence recovery 
after photobleaching (FRAP) studies showed that once JAKs associate with a 
receptor, they cannot be exchanged(258) and it is only when JAKs are associated 
with a receptor are they localised to the plasma membrane(259). These studies 
demonstrate that JAKs and their receptors are highly interdependent.  
 
JAK2 is essential for haematopoiesis; deficient mice are embryonic lethal resulting 
from failure to develop definitive haematopoiesis(260). Additionally, inducible 
knockout of Jak2 from the haematopoietic compartment of adult mice results in 
pancytopenia and death on average 36 days post treatment(261). Similarly, TPO and 
MPL are also important for haematopoiesis as clinical mutations of MPL results in 
pancytopenia(98). JAK2 is the predominant JAK activated in response to TPO 
stimulation(103,262,263); it binds to the Box1 and Box2 motifs of MPL via its 
FERM domain and in the absence of this association, TPO signalling is 
abrogated(104). Additionally, JAK2 enhances cell surface localisation and stability 
of MPL(255). Given the close relationship between JAKs and their receptors, in 
addition to the functional interdependencies of MPL and JAK2, MPL and JAK2 can 
be considered functionally coupled.  
1.9.5 JAK2 and MPL in MPNs 
Activation of the JAK-STAT signalling pathway has been shown to cause MPNs. 
The JAK2
V617F
 mutation predominates in the classical MPNs with approximately 
95% of PV patients and 50% of patients with ET and PMF harbouring the 
mutation(179-181). Moreover, activating mutations in MPL, MPL
W515L/K
 and 
MPL
S505N
, result in development of JAK2
V617F
-independent ET and 
PMF(124,125,200). These mutations independently result in uncontrolled activation 
of the same JAK-STAT pathway resulting in MPNs. Additionally, MPNs are a stem 
cell disorder thus acquisition of JAK2
V617F
 must occur in an early haematopoietic cell 
to result in disease. Importantly, MPL is expressed on HSCs and although a number 
of other receptors are also expressed, the IL-3 receptor (IL-3R) and MPL are the 
only two that are dependent on JAK2 for signal transaction(235). Additionally, just 
as JAK2 is necessary for TPO signalling, it has been shown in vitro that JAK2
V167F
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requires expression of a homodimeric type I cytokine receptor to induce cytokine 
independent proliferation(264). IL-3R signals as a heterotetramer whereas MPL is a 
homodimer, thus it is likely that MPL is important for JAK2
V617F
 pathogenesis.  
 
Given the role of TPO and MPL in HSCs, the requirement for JAK2
V617F
 acquisition 
in HSCs to cause MPNs, the reliance of JAK2
V617F
 on a homodimeric type I cytokine 
receptor and the ability of activating mutations of MPL to result in MPNs, it is likely 
that MPL is also involved in JAK2
V617F
-positive MPN development. Although this 
has been investigated in vitro, there has been a relative failure to study the role of 
MPL on MPNs in vivo. Additionally, current treatments of MPNs are predominantly 
aimed at treating the symptoms rather than the disease itself. Specific inhibition of 
JAK2 by a small molecule inhibitor, ruxolitinib, is successful at treating the disease 
in some patients; however, due to the broad function of JAK2, treatment is often 
associated with undesired side effects. Therefore, additional research is required to 
identify additional targets for therapeutic intervention of MPNs.   
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1.10 Primary Aims 
In order to develop therapeutics in the treatment of MPNs, a more thorough 
understanding of the components necessary for disease pathogenesis is required. 
Although identification of the JAK2
V617F
 mutation greatly improved our 
understanding of MPNs, JAK2 inhibitors have not been able to recapitulate the 
effects observed with the use of Gleevec. It is possible that development of a better 
JAK2 inhibitor may result in better patient outcomes; however, further identification 
of additional factors necessary for disease development provides an additional and 
potentially more relevant therapeutic target. The role of TPO and its receptor, MPL, 
in development of MPNs has yet to be determined. The following specific aims were 
designed to answer some of the outstanding questions surrounding this field of study.  
 
 Characterise the additional regulatory elements within MPL necessary in the 
regulation of TPO signalling  
 
 Determine the functional role of MPL tyrosine residues in JAK2V617F-mediated 
signalling in vitro 
 
 Generate an in vivo model to determine the role of TPO and MPL in JAK2V617F-
positive MPNs  
 
 Determine the role of TPO and MPL in development of JAK2V617F-positive MPNs in 
vivo 
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CHAPTER 2 GENERAL MATERIALS AND 
METHODS  
1.  
2.1 Cell Culture 
2.1.1 Cell culture plasticware and reagents  
Tissue culture plasticware was purchased from BD Biosciences. Tissue culture 
media: Roswell Park Memorial Institute (RPMI) 1640, Dulbecco modified Eagle 
medium (DMEM) and Dulbecco’s phosphate-buffered saline (DPBS) was purchased 
from Corning|cellgro, Penicillin-Streptomycin-Glutamine (PSG) (10,000 I.U./mL 
Pencillin, 10,000 µg/mL Streptomycin,  29.2 mg/mL L-glutamine in a 10mM citrate 
buffer) was purchased from Life Technologies and heat inactivated Fetal Bovine 
Serum (FBS) was purchased from Gemini Bio-products (West Sacramento, CA, 
USA). All cells were cultured at 37°C, 5% CO2.  
2.1.2 Isolation and culture of primary murine bone marrow cells  
Mice were asphyxiated using CO2 and cervical dislocation was performed as a 
secondary physical method of euthanasia. Femurs and tibias from mice were 
extracted and flushed with 7mL and 3mL DMEM +10% FBS, respectively using a 
25G
5
/8 needle into a 50mL Falcon Tube. A single cell suspension is obtained by 
expelling cells through a 22G1½ needle into a 100μm nylon cell strainer (BD 
Biosciences, 352360). Cells were then pelleted at 300g and lysed for RNA or protein 
isolation or cultured in the appropriate medium as stated.  
2.1.3 Cell Line Culture Conditions 
Ba/F3 is an IL-3 dependent murine pro-B-cell line. These cells were cultured in 
RPMI 1640 containing 1% PSG, 10% FBS and 2μL/mL recombinant mouse(rm)IL-3 
supernatant in 75cm
2
 tissue culture flasks. The ecotropic retroviral packaging cell 
line, Platinum-E cells (Plat-E), were cultured in DMEM containing 1% PSG and 
10% FBS in 10cm
2
 tissue culture plates. F-36P is a human leukemia cell line derived 
from a patient with myelodysplastic syndrome. These cells were obtained from the 
Chapter 2 
 
 
50 
 
European Collection of Cell Culture and cultured as previously described(265), in 
1% PSG, 5% FBS and 5ng/mL recombinant human(rh)IL-3 (PeproTech). The 
Phoenix-amphotropic retroviral packaging cell line (φNX) was cultured in DMEM 
containing 1% PSG and 10% FBS. 
2.2 Total RNA Isolation  
Total RNA was isolated from cells using an RNeasy Mini Kit (Qiagen). Cells were 
lysed in the suggested amount of RLT buffer supplemented with 10μL/mL 2-
mercaptoethanol (β-ME) and homogenized using a QIAshredder homogenizer 
(Qiagen). 1 volume of 70% ethanol was added to the homogenized cells and this was 
then loaded onto a supplied RNeasy spin column, washed with Buffer RWI followed 
by 2 washes with Buffer RPE. RNA was eluted off the column using RNase-free 
water.  
2.3 cDNA synthesis from total RNA 
cDNA was synthesized from total RNA using a SuperScript
™
 II Reverse 
Transcriptase kit (Life Technologies). RNA, 1μL 10mM deoxynucleotide (dNTP) 
mix and 0.5μg oligo(dT)12-18 and RNase-free H2O were combined in a sterile 0.2mL 
polymerase chain reaction (PCR) tube and incubated at 65°C for 5 minutes, followed 
by a 4°C incubation for 1 minute. A 2X reaction master mix was prepared by 
combining 10X RT buffer, 25mM MgCl2, 40U/μL RNaseOUT
™
 and was added to 
the RNA/primer mixture. The samples were then incubated for 42°C for 2 minutes, 
then 1μL of SuperScript™ II reverse transcriptase enzyme was added to each tube 
and cDNA synthesis reaction was performed by incubation at 42°C for 50 minutes. 
The reaction was terminated by increasing the incubation temperature to 70°C for 15 
minutes, samples were then cooled to 4°C, 1μL of RNase H was added and 
incubated at 37°C for 20 minutes to hydrolyze phosphodiester bonds in RNA:DNA 
hybrid strands thereby removing the RNA templates from the reverse transcriptase 
reaction. Samples were diluted 1:5 in RNase-free H2O and used for PCR or stored at 
-20°C. A minus RT control was run for each sample and was treated the same as the 
cDNA samples except RNase-free H2O was added in place of SuperScriptII
™
 RT.   
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2.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR) 
A reaction mixture comprising 1X PCR reaction buffer, 0.2mM of each dNTP, 2mM 
of forward and reverse primers, 1µL of diluted cDNA from Section 2.3 and 0.5U of 
PfuUltra HF DNA polymerase (Agilent Technologies) were brought up to a final 
volume of 50µL in a thin-wall PCR tube. The PCR reaction was performed using an 
MJ Research PTC-200 thermal cycler (Bio-Rad). Cycle parameters are listed in 
Table 2.1 and annealing temperatures were optimised for each gene target. 15µL of 
each reaction product was mixed with 3µL of 6X DNA loading dye (0.25% 
bromophenol blue(w/v), 0.25% xylene cyanol FF (w/v), 30% glycerol (v/v)) and 
analysed on a 1.5% agarose Tris/borate/EDTA (TBE: 89mM Tris base, 89mM boric 
acid, 2mM EDTA, pH 8.0) gel containing  0.2µg/mL ethidium bromide (EtBr). DNA 
products were visualized using an ultra-violet (UV) light box.  
2.5 Western Blot Analysis  
2.5.1 Protein extraction 
Cultured or treated cells were harvested at 300g or 5 min at 4°C, washed three times 
in cold DPBS to remove any cytokines and media components and lysed in 500μL 
1% NP-40 lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl,  1% NP-40) 
containing protease inhibitors (Protease inhibitor cocktail for mammalian cell and 
tissue extracts, containing 104nM AEBSF, 80μM aprotinin, 4mM bestatin, 1.4mM 
E-64, 2mM leupeptin, 1.5mM Pepstatin A; Sigma-Aldrich) and phosphatase 
inhibitors (1mM Na3VO4, 10mM NaF) at 4°C for 10 minutes. Cellular debris was 
removed by centrifugation of samples for 15 minutes at 20,500g at 4°C and the 
supernatants were collected and transferred into new microcentrifuge tubes.  
2.5.2 Protein quantitation  
Protein concentrations were determined using a DC™ protein assay (Bio-rad) 
according to manufacturer’s instructions in a 96-well flat bottom microplate. This 
particular colormetric protein assay was chosen as it is compatible with protein 
samples containing detergent. It is a modified version of the Lowry assay and relies  
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Table 2.1 RT-PCR Cycling Parameters 
 
Segment Cycles Step Temperature (°C) Time (mm:ss) 
1 1 Polymerase 
activation 
94 10:00 
2 32 (unless 
otherwise 
stated) 
Denature 
dsDNA 
94 00:30 
Primer 
annealing 
Varies, as listed  00:30 
Extension  72 01:00 
3 1  4 hold 
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on the oxidation of aromatic residues, primarily tyrosine and tryptophan, by copper 
ions under alkaline conditions. Addition of Folin reagent results in its reduction by 
the modified aromatic residues resulting in development of a blue color which is 
then measured at an absorbance of 655nm on an iMark microplate absorbance reader 
(Bio-rad). Bovine serum albumin (BSA) protein standard solutions were prepared in 
1% NP-40 lysis buffer, ranging from 0-4mg/mL. 5μL of each standard was added in 
triplicate and 5μL of each unknown sample was added in duplicate to wells of a 96-
well plate. 1mL of working reagent A’ was prepared (1mL of reagent A and 20μL of 
reagent S) and 25μL was added to each well followed by addition of 200μL of 
reagent B. The plate was mixed using the mixing function on the microplate reader 
and incubated at 25°C for 15 minutes. The plate was then read at an absorbance of 
655nm. Any background absorbance was removed by subtracting the absorbance of 
the lysis solution and protein assay reagents. A standard curve was generated from 
the absorbance of the BSA standard solutions. From this, the concentration of each 
sample was calculated.   
2.5.3 Sodium dodecyl sulfate (SDS)-Polyacrylamide gel electrophoresis 
(PAGE) and protein transfer 
Protein samples were prepared using 10μg protein, 4x NuPAGE® LDS Sample 
Buffer (106mM Tris-HCl, 141 mM Tris base, 2% lithium dodecyl sulface (LDS), 
10% glycerol, 0.51mM EDTA, 0.22mM SERVA blue G250, 0.175mM phenol red, 
pH 8.5)  (Invitrogen) and 10x NuPAGE Sample Reducing Agent (50mM 
dithiothreitol (DTT)) (Invitrogen) brought to 20μL at 1x using 1% NP-40 lysis 
buffer. Samples were heated to 100°C for 5 minutes to denature the proteins. The 
samples were then loaded into a NuPAGE
®
 Novex
®
 4-12% Bis-Tris pre-cast 
polyacrylamide gel and separated in 1x NuPAGE
®
 MOPS SDS runnning buffer (50 
mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA, pH 7.7) (Invitrogen) 
supplemented with 500μL of NuPAGE Antioxidant in the inner chamber of the 
XCell SureLock
®
 Mini-Cell running apparatus. NuPAGE
® 
gels are at neutral pH thus 
some reducing agents including DTT do not always co-migrate with the protein 
allowing for the potential of protein re-oxidization so NuPAGE Antioxidant is added 
to ensure proteins remain in a reduced state during electrophoresis. Additionally, 
3μL of Precision Plus Protein™ Kaleidoscope™ Standard (Bio-Rad) was loaded 
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onto the gel to monitor separation. Gels were run at 200V for 50 minutes. Gels were 
then transferred onto methanol activated polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad) in transfer buffer (24mM Tris-base, 150mM Glycine, 20% 
Methanol (v/v)) using a Mini Trans Blot Cell transfer apparatus (Bio-Rad) at 110V 
for 1 hour.  
2.5.4 Immunodetection of proteins  
After proteins were immobilized onto PVDF, the membrane was incubated in 
blocking buffer (4% dry non-fat milk or BSA in Tris-buffered saline containing 
0.1% Tween-20 (TBS-T)) at 60 rotations per minute on an orbital shaker for 1 hour 
at 25°C. The blocking solution was then discarded and the membrane washed for 1 
minute in TBS-T before primary antibody diluted in blocking buffer was added. The 
membrane was incubated in primary antibody overnight at 4°C or 1 hour at 25°C. 
The blocking buffer, antibody concentration and time of incubation were optimized 
for each individual antibody used. Following primary antibody incubation, 
membranes were washed 3 times with TBS-T. For unconjugated antibodies, the 
membrane was then incubated with a horseradish peroxidase (HRP)-conjugated 
secondary antibody diluted in blocking buffer for 1 hour at 25°C followed by 4 
washes in TBS-T. Membranes were then subjected to chemiluminescent detection 
with ECL-plus (GE Healthcare, Little Chalfont, UK) and imaged using radiography 
film or a FluorChem M imager (ProteinSimple, Santa Clara, CA, USA). Western 
blots were quantified by densitometry using ImageJ image processing and analysis 
software (http://rsbweb.nih.gov/ij/, National Institutes of Health, USA). 
2.5.5 Membrane Stripping 
Membranes were stripped of bound antibody to allow for detection of additional 
proteins and loading controls. Membranes were incubated in stripping buffer (SDS) 
with 6μL/mL 2-mercaptoethanol (β-ME) at 60°C for 10 minutes. Membranes were 
then rinsed 5X with dH2O and incubated with agitation in TBS-T for 5 minutes 
before being used for additional immunodetection of proteins as described in Section 
2.5.4.  
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2.6 Cloning  
2.6.1 Site-directed mutagenesis 
Site-directed mutagenesis was performed using a QuikChange II site-directed 
mutagenesis kit (Agilent Technologies, 200523-51) following the manufacturer’s 
instructions. Vectors were mutagenized at various concentrations (25ng, 50ng 
100ng) to ensure ideal reaction conditions. Each mutagenesis reaction contained 1X 
reaction buffer, dsDNA plasmid template, 125ng each of forward and reverse 
primers, 1µL of a proprietary dNTP mix, 2.5U of PfuUltra High-Fidelity DNA 
polymerase and ddH2O to 50µL. Cycling parameters are listed in Table 2.2 and 
mutagenesis primer sequences and reaction annealing temperatures are listed in 
Table 2.3. Mutagenesis reactions were then Dpn I digested (10U/reaction) at 37ºC 
for 1 hour to digest the original dsDNA plasmid template.  
2.6.2 Transformation 
Mutagenized plasmids were transformed into Subcloning Efficiency
™
 DH5α™ 
competent E.Coli (Life Technologies). 2µL of the of the mutagenesis reaction was 
added to 50µL of the Subcloning Efficiency
™
 DH5α™ competent cells in a 
microfuge tube, the reaction was incubated on ice for 5 minutes, heat shocked for 45 
seconds in a 42ºC water bath, placed back on ice for 2 minutes then 500µL of S.O.C. 
medium (#15544-034, Life Technologies) was added to each reaction and incubated 
at 37ºC for 1 hour at 225 rpm to allow the cells to recover. 100µL of the 
transformation reaction was then plated on pre-warmed Luria-Bertani (LB) plates 
containing 100µg/mL ampicillin and cultured overnight at 37ºC to allow for growth 
of colonies. A maximum of 5 individual colonies were selected from plates for 
validation.  
2.6.3 Plasmid preparation  
Individual colonies selected from LB ampicillin plates were individually cultured for 
16 hours in 4mL of LB medium containing 100µg/mL ampicillin. Plasmids were 
then isolated from 3mL of each culture using a QIAprep Spin Miniprep Kit  
 
 
Chapter 2 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Site-directed Mutagenesis Cycling Parameters 
 
Segment Cycles Step Temperature (°C) Time (mm:ss) 
1 1 Polymerase 
activation 
95 00:30 
2 12
*
  Denature 
dsDNA 
95 00:30 
Primer 
annealing 
Varies, see Table 
2.3 
01:00 
Extension  68 10:00
**
 
*
recommended number of cycles for point mutations  
**
1 minute/kb of plasmid length. pMX-MPL = 9kb 
 
Adapted from the Agilent Technologies QuikChange II Site-Directed Mutagenesis Kit 
user manual  
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following the microcentrifuge spin protocol (Qiagen). Plasmids were then checked 
for the desired mutations as described in Section 2.6.4. For larger scale plasmid 
preparations, cultures in 400mL of LB medium containing 100µg/mL ampicillin 
were used for plasmid isolation with a QIAprep Maxi Kit (Qiagen) following the 
manufacturers’ protocol. 
2.6.4 Mutagenized plasmid validation  
A diagnostic digest was performed on each plasmid to ensure isolation of the desired 
plasmid. Restriction enzymes used to clone in the gene of interest were used to 
digest the plasmid preparation product where each digestion reaction contained 1X 
NEB Buffer selected for maximal enzyme compatibility, 2µg BSA, 2U of each 
desired restriction enzyme, 1µg of the isolated plasmid DNA and ddH2O was added 
to achieve a final reaction volume of 20µL. The reaction was then incubated at 37ºC 
for 1 hour then resolved on a 0.8% agarose (TBE) gel containing 0.2µg/mL EtBr 
(Figure 2.2). Correctly digested plasmids were sent to the Stony Brook Genomics 
Core for sequencing using primers to full length human MPL. Sequencing primers 
are listed in Table 2.4 and binding regions are shown in Figure 2.1. Plasmids with 
inserts containing the desired sequence underwent an additional plasmid preparation 
at a larger by Maxiprep (Section 2.6.3) and stored as a stock for experimental use. 
2.7 Generation of stable cell lines  
2.7.1 Generation of retroviral Particles   
2.7.1.1 Ecotropic viral particles  
Platinum-E (Plat-E) cells are an ecotropic retroviral packaging cell line used to 
generate vector containing retroviral particles used to make stable cell lines(266). 
These cells produce ecotropic retrovirus capable of infecting mouse or rat cells and 
were used to infect Ba/F3 cells. Plat-E cells are plated at 3 x 10
6
 cells per 10cm 
tissue culture plate and cultured for 16 hours to allow for attachment and 
proliferation. Once cells reach approximately 50% confluency, they are transfected 
with a 2:1 mixture (μL:μg) of Lipofectamine 2000 (Life Technologies) and plasmid 
DNA. Generally, 2μg of plasmid DNA is used per transfection and each component  
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Table 2.4 MPL sequencing primers  
 
Primer  Sequence 
Reverse 1 5’-CACTTCCTCCTGGTCTGGAA-3’ 
Forward 1 5’-ATGCCCTCCTGGGCCCTCTTC-3 
Forward 2 5’-CACGGTCATACAGCTGATTG-3 
Forward 3 5’-CTGGATCCACCAGGCTGTGC-3’ 
Forward 4 5’-GCCACCGAGACCGCCTGGAT-3’ 
Forward 5 5’-ACCATGCCCCTGTCTGTGTGC-3’ 
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Figure 2.1 MPL sequencing primer binding sites  
Figure showing binding regions for MPL sequencing primers listed in Table 2.1. Arrows dictate 
direction of sequencings reaction.  
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Figure 2.2 Restriction enzyme diagnostic digest  
Mutagenized plasmids were initially tested for the presence of the gene of interested, MPL, by a 
restriction enzyme diagnostic digest. MPL was cloned into the multiple cloning site between EcoRI 
and XhoI sites; therefore, plasmids were treated with no restriction enzyme, EcoRI or a double digest 
with EcoRI and XhoI to test for the presence of the MPL insert. Digestion products were resolved on 
a 0.8% agarose TBE gel with ethidium bromide to visualise products.  L – 1 kb plus ladder 
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is prepared separately in 250μL Opti-MEM media and mixed just prior to addition 
onto cells; Plat-E culture media is changed just prior to addition of the DNA-lipid 
complex. Culture media was replaced 32hrs after transfection and cultured for an 
additional 16hrs to allow for accumulation of retroviral particles. Media from these 
cells was then collected using a 10mL syringe and filtered with a 0.45µM syringe 
filter to remove any cells. Fresh media was added back onto the cells to allow for 
production of additional retroviral particles. These particles were harvested, same as 
previously, 8 hours later.  
2.7.1.2 Amphotropic viral particles  
φNX-amphotropic cells are an amphotropic retroviral packaging cell line developed 
by the Nolan laboratory at Standford University for efficient production of retroviral 
particles capable of infecting most mammalian cells 
(http://web.stanford.edu/group/nolan/_OldWebsite/retroviral_systems/phx.html). 
Retroviral particles were generated and harvested as described in Section 2.7.1.1. 
These viral particles were used to infect F-36P cells.   
2.7.1.3 Retroviral transduction of cells  
16 hours prior to harvest of the first batch of retroviral particles, Ba/F3 or F-36P cells 
were passaged 1:5 to ensure active proliferation of cells. Just after harvest of the first 
round of retroviral particles, 1 x 10
6
 cells were counted and cultured in the harvested 
retroviral supernatnat with the addition of necessary culture cytokines as stated in 
Section 2.1.3 and 10µg/mL polybrene (Millipore). Following the second round of 
retroviral particle harvest, cells were pelleted and re-cultured in fresh retroviral 
supernatant, again with addition necessary cytokines and polybrene.  
2.7.1.4 Antibiotic selection for infected cells 
72 hours post transduction, cells were selected for plasmid uptake by culture with 
5µg/mL puromycin for the PMX-puro plasmid or 400µg/mL geneticin (G418) for 
pQCXIN plasmid. Untransduced cells were also cultured in the respective antibiotic 
as a control. Cells were cultured under selection for 7 days following death of all the 
untransduced cells to ensure for complete selection.  
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2.8 Thrombopoietin ELISA 
A Mouse thrombopoietin Quantikine
®
 ELISA (R&D Systems) was used to quantify 
serum thrombopietin levels. Whole blood was collected via cardiac puncture using 
citrate (ACD Solution A of trisodium citrate, 22.0g / L; citric acid, 8.0 g / L; and 
dextrose 24.5 g / L, BD Biosciences) as an anticoagulant, samples were centrifuged 
at 10,000g for 10 minutes, platelet poor plasma (PPP) was collected and stored at -
80°C. Samples were thawed on ice and diluted 5-fold in supplied Calibrator Diluent 
RD5-3 prior to being assayed. The assay was performed following the manufactures’ 
protocol and standards, Control and samples were all assayed in duplicate.  
 
2.9 Statistical Analysis  
Data was analysed for statistical significance using GraphPad Prism 6 Software. 
Analysis of differences between means of multiple groups was performed using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons 
test. Analysis of differences between means of multiple groups with greater than one 
independent variable was performed using two-way ANOVA followed by Dunnett’s 
multiple comparisons test. Asterisks on graphs indicate significance compared to 
WT, ***P ≤ 0.001, **P ≤ 0.01 and *P ≤ 0.05. A value of P ≤ 0.05 was considered 
statistically significant. 
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CHAPTER 3 PHOSPHORYLATED MPL TYROSINE 
591 REGULATES THROMBOPOIETIN-INDUCED 
SIGNALING  
 
3.1 Experimental Rationale  
In this chapter, we investigate the role of MPL
Y591
 in the negative regulation of TPO 
signalling. First, the phosphorylation state of Y591 will be determined using mass 
spectrometry. Then, utilizing an in vitro system where human MPL is ectopically 
expressed in Ba/F3 cells, we aim to determine the consequence of MPL
 Y591
 removal 
on receptor phosphorylation and signal transduction in addition to identification of 
potential binding partners to Y591.  
3.2 Materials and Methods 
3.2.1 pMX-puro-MPL  
pMX-puro is a retroviral vector generated to facilitate cDNA library generation. It is 
composed of a modified pBabe-puro vector, termed pBabeX, where the SV40 
promotor and the puromycin resistance genes were removed and a multiple cloning 
site (MCS) was inserted(267). To maximize viral titers, the 5’ long terminal repeat 
(LTR) of pBabeX was replaced with the 5’ LTR and extended packaging signal of 
the MGF vector(268). For the purposes of our studies the SV40 promotor and 
puromycin resistance gene were reintroduced to the vector to allow for selection of 
transduced cells. Human MPL cDNA was cloned into a pMX-puro vector (Figure 
3.1) using EcoRI and XhoI restriction sites in the multiple cloning site(Figure 3.2). 
pMX-puro-MPL
Y591F
 was generated by site-directed mutagenesis (Section 2.6.1 and 
Table 2.3) and the mutation was confirmed by sequencing (Figure 3.3).  
 
 
 
 
 
Chapter 3 
 
65 
 
 
 
 
 
 
 
 
Figure 3.1 pMX-puro backbone vector  
pMX-puro backbone contains a multiple cloning site (MCS) to allow for insertion of genes for 
expression. An ampicillin resistance gene allows for selection in E.coli and a puromycin resistance 
gene allows for selection in eukaryotic cells under the control of the SV40 immediate promoter (IEP).  
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Figure 3.2 pMX-puro-MPL vector  
MPL was cloned into the pMX-puro vector between EcoRI and XhoI restriction sites within the MCS. 
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Figure 3.3 pMX-puro-MPL
Y591F
 Sequencing Results  
Sequence analysis of WT and mutagenized MPL in the pMX-puro-MPL vector.  
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3.2.2 Immunoprecipitation  
Protein lysate was obtained as described in 2.5.1. 500µg of protein was prepared to 
1µg/µL and incubated with 20µL packed Protein A beads (Millipore) for 1 hour on 
an end-to-end rotator at 4°C to remove any proteins non-specifically binding to the 
beads. Samples were then incubated with 2µg of anti-MPL antibody (Millipore, #06-
944) for 16 hours on an end-to-end rotator at 4°C. 20µL packed Protein A agarose 
beads (Millipore, 16-125) were then added for 4 hours on an end-to-end rotator at  
4°C, MPL-antibody—bead complexes were washed 3 times with 1% NP-40 lysis 
buffer, protein was eluted using 2X NuPAGE® LDS sample buffer containing β-ME 
(Invitrogen) and boiled at 100°C for 5min. Eluted protein was then subjected to 
western blotting as described starting at Section 2.5.3.  
3.2.3 Detection of active, GTP-bound Ras 
Levels of activated Ras were detected using an Active Ras Pull-down and Detection 
Kit (Thermo Scientific, Rockford, IL, USA) following the manufacturers’ protocol. 
Ba/F3-MPL cells were treated with or without 10ng/mL rhTPO for 5 minutes and 
lysed in the kit-provided lysis buffer supplemented with 1% protease inhibitor 
cocktail (Sigma-Aldrich, P8340). Lysates were then subjected to pulldowns using the 
Ras binding domain of RAF proto-oncogene serine/threonine-protein kinase (RAF1) 
to isolate the active, guanosine-5'-triphosphate (GTP)-bound Ras, and analysed using 
western blot (Section 2.5) to detect levels of active Ras.  
3.2.4 Peptide binding assays 
Biotinylated peptides corresponding to MPL residues 582–601 including an 
aminohexanoic acid spacer (Biotin-Ahx-LCSSQAQMDY591RRLQPSCLGT-NH2 
and Biotin-Ahx-LCSSQAQMD(pY591) RRLQPSCLGT-NH2) were synthesized by 
RS Synthesis (Louisville, KY). Lyophilized peptides were reconstituted to 10mM in 
DPBS. Peptide concentration was measured using a NanoDrop 2000 (Thermo 
Scientific) at 205nm rather than the typical method of protein quantification (Section 
2.5.2.) due to lack of tryptophan residues and presence of only a single tyrosine 
residue within the peptides. 400µL of reconstituted peptide was conjugated to 400µL 
High capacity NeutrAvidin Agarose Resin (Thermo Scientific, 29200) for 4.5 hours 
at room temperature. F-36P-MPL
WT
 cells were treated with or without 1ng/mL 
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rhTPO for 5 minutes and lysed in NP-40 lysis buffer. Lysates were pre-cleared by 
incubation with 40µL High capacity NeutrAvidin agarose resin for 1 hour at 4°C. 
1mg of pre-cleared lysate was incubated with 20µL peptide conjugated beads 
overnight at 4°C. The samples were centrifuged and washed 5 times with 1% NP-40 
lysis buffer, resuspended in 2X NuPAGE® LDS sample buffer containing β-ME 
(Invitrogen) and subjected to western blotting as described starting at Section 2.5.3. 
3.2.5 RNA interference  
Syk siRNAs were purchased from Dharmacon RNAi Technologies as a 
SMARTpool, and Ptpn6 siRNA and control siRNA were purchased from Invitrogen. 
All siRNAs were reconstituted according to the manufacturers’ instructions. Cells 
were subjected to 1 pulse of 1700volts for 20ms using the Neon® Transfection 
System (Invitrogen). Ba/F3-MPL
WT
 and MPL
Y591F
 cells were washed in DPBS and 
resuspended in R buffer at 2.0x10
7
/mL; 2.0x10
6
 cells were transfected with siRNA at 
a final concentration of 1µM. Cells were cultured for 24 hours post-transfection in 
RPMI 1640 +10% FBS supplemented with murine IL-3, they were then cytokine 
starved in RPMI 1640 +2% FBS for 16 hours, then stimulated with or without 
10ng/mL rhTPO for 15min and lysed in NP-40 lysis buffer. Lysates were then 
subjected to western blotting (Section 2.5.3) or Ras pulldown (Section 3.2.3).  
3.3 Results 
3.3.1 MPL tyrosine residue 591 (MPLY591) is phosphorylated in response to 
TPO  
To develop a better understanding of MPL phosphorylation in response to TPO, 
tandem mass spectrometry was used to determine sites of TPO-mediated 
phosphorylation of MPL. MPL peptides were obtained by immunoprecipitating MPL 
from rhTPO stimulated Ba/F3-MPL cells followed by trypsin digest. Phosphorylated 
peptides were enriched using immobilized metal affinity chromatography (IMAC) 
and subjected to tandem mass spectrometry. Generated data was analysed using 
SEQUEST® and revealed the mass spectrum of the peptide TPLPLCSSQAQMDYR 
(Figure 3.4). The quantity computation with the help of the b- and y-ion series 
revealed that the mass of tyrosine (Y) 14 is 243Da, instead of the native 163Da. This 
is indicative of a phosphomodification (+80Da) of this tyrosine residue. Tyrosine 14 
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of the peptide is equivalent to MPL
Y591
 found in the intracellular domain of MPL, 
indicating that this residue is phosphorylated in response to TPO. This work was 
completed by Dr. Sebastian J Saur.  
 
To begin assessing the role of MPL
Y591
, we first studied receptor phosphorylation in 
the absence of MPL
Y591
 phosphorylation. Tyrosine residue 591was mutated using 
site-directed mutagenesis to phenylalanine to inhibit residue phosphorylation. This 
mutant form of MPL was ectopically expressed in Ba/F3 cells, which were then 
stimulated with 10ng/mL of rhTPO for 5 minutes, lysed and subjected to 
immunoprecipitation using an anti-MPL antibody. Immunoprecipitated protein was 
then analysed by western blot and probed for phospho-tyrosine, revealing the 
phosphorylation state of MPL.  
 
In the absence of TPO stimulation, there is no detectable receptor phosphorylation; 
however, TPO stimulation induced a marked increase in WT receptor 
phosphorylation (Figure 3.5)(103). Consistent with previous reports, 
phosphorylation was comparable to WT when MPL
Y630
 was mutated and 
significantly diminished when MPL
Y625
, a residue important for receptor activation, 
was mutated (Figure 3.5) (3). Mutation of MPL
Y591
 resulted in decreased total 
receptor phosphorylation to a level similar to MPL
Y625F
 (Figure 3.5). Additionally, to 
study changes in sensitivity to TPO and kinetics of receptor phosphorylation, Ba/F3-
MPL
WT
 and MPL
Y591F
 cells were stimulated with varying concentrations of rhTPO 
and stimulated for different periods of time, respectively. In the absence of MPL
Y591
, 
receptor phosphorylation was less sensitive to TPO stimulation (Figure 3.6).  
Additionally, the duration of MPL
Y591F
 receptor phosphorylation was decreased 
(Figure 3.7).  
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Figure 3.4 Phospho-tyrosine peptide from the intracellular domain of MPL 
identified by LC-MS/MS following tandem IP
1 
Tandem mass spectra of the phosphopeptide TPLPLCSSQAQMDpYR were identified. The y and b 
series of the ions is indicated. The sequence resulting from these spectra is indicated above the panel. 
The mass of tyrosine (Y) 14 is 243 Da, instead of the native 163 Da. This indicates a 
phosphomodification (+80 Da) of this tyrosine residue. Tyrosine 14 of the peptide equals tyrosine 591 
in the intracellular domain of MPL. 
1Ectopically expressed human MPL protein in Ba/F3 cells recovered by tandem IP (anti-
MPL→trypsin→IMAC). Peptide sequence is indicated along with the position of pY sites in MPL, 
the indicated peptide scores, charge state (z), and observed mass-to-charge ratios (m/z). 
This work was completed by Dr. Sebastian J Saur. 
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Figure 3.5 Mutant MPL receptor phosphorylation  
Ba/F3 cells stably expressing human WT or mutant MPL were stimulated with rhTPO, lysed and 
subjected to immunoprecipitation with an anti- MPL antibody. Immunoprecipitates were analysed 
via western blot using a phospho-tyrosine probe to compare total receptor phosphorylation of the 
mutants to the wild-type receptor in response to TPO stimulation, blots were stripped and re-
probed with an anti- MPL antibody to assess the level of immunoprecipitated protein.  Data are 
representative of 3 independent experiments. Ba/F3 cells expressing different tyrosine to 
phenylalanine mutants of MPL were stimulated with 10ng/mL rhTPO for 5min. This is 
representative of 3 individual experiments.  
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Figure 3.6 MPL
Y591
 receptor phosphorylation TPO dose response 
Ba/F3 cells stably expressing human WT or mutant MPL were stimulated with rhTPO for 5min, 
lysed and subjected to immunoprecipitation with an anti- MPL antibody. Immunoprecipitates were 
analysed via western blot using a phospho-tyrosine probe to compare total receptor 
phosphorylation of the mutant to the wild-type receptor in response to TPO stimulation; blots were 
stripped and re-probed with an anti- MPL antibody to assess the level of immunoprecipitated 
protein. 
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Figure 3.7 MPL
Y591
 receptor phosphorylation TPO time course 
Ba/F3 cells stably expressing human WT or mutant MPL were stimulated with 10ng/mL rhTPO, 
lysed and subjected to immunoprecipitation with an anti- MPL antibody. Immunoprecipitates were 
analysed via western blot using a phospho-tyrosine probe to compare total receptor 
phosphorylation of the mutant to the wild-type receptor in response to TPO stimulation; blots were 
stripped and re-probed with an anti-MPL antibody to assess the level of immunoprecipitated 
protein.   
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3.3.2 MPL Y591F exhibits hypersensitive, enhanced and prolonged ERK1/2 
activation upon TPO stimulation 
TPO binding to MPL results in receptor activation and subsequent initiation of 
numerous signalling cascades including the JAK/STAT, PI3K/Akt and MAPK 
pathways(106). To determine the role of MPL
Y591
 in TPO-mediated signalling, 
Ba/F3-MPL WT or MPL
Y591F
 cells were cytokine starved and stimulated with 
rhTPO. Consistent with previous reports, cells expressing MPL
Y591F
 exhibited a 
significant increase in the level and duration of ERK1/2 phosphorylation compared 
to MPL
WT
 (Figure 3.8 and Figure 3.9)(1). Cells expressing MPL
Y591F
 stimulated for 
5min with increasing concentrations of rhTPO exhibited a significant hypersensitive 
response in ERK1/2 phosphorylation at low doses (0.1ng/mL) of rhTPO and 
enhanced maximal levels ERK1/2 phosphorylation (Figure 3.8). Akt phosphorylation 
is also increased in the MPL
Y591F
 mutant; however, activation of the JAK/STAT 
signalling was unaffected (Figure 3.8) (1). To study the mechanism behind the 
enhanced and prolonged ERK1/2 phosphorylation in MPL
Y591F
 expressing cells, the 
activation state of a stimulator upstream of the MAPK/ERK pathway, the small 
GTPase Ras was assessed. Ba/F3-MPL
WT
 or MPL
Y591F
 cells were cytokine starved 
for 18hr followed by 10ng/mL rhTPO stimulation. Cells were then analysed for 
active, GTP-bound Ras as described in Section 3.2.3. We observed a two-fold 
increase in the level of Ras-GTP in cells expressing the MPL
Y591F
 mutant receptor 
compared to WT (Figure 3.10). 
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Figure 3.8 MPL
Y591F
 TPO Signalling Dose Response 
(A)Western blot analysis of phosphorylation levels of JAK2, STAT5, AKT and ERK1/2 in Ba/F3-
MPL
WT
and MPL
Y591F
 cells stimulated with 0, 0.1, 1 and 10 ng/mL rhTPO for 5 min. (B) Densitometry 
of phospho-ERK1/2 blot. Error bars represent ± SEM. (n = 3) Densitometry was performed using 
ImageJ (National Institutes of Health, Bethesda, MD).  
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Figure 3.9 MPL
Y591F
 TPO Signalling Time Course 
(A)Western blot analysis of phosphorylation levels of JAK2, STAT5, AKT and ERK1/2 in Ba/F3-
MPL
WT
and MPL
Y591F
 cells stimulated with 10 ng/mL rhTPO for 0, 15, 60, or 120 min. (B) 
Densitometry of phospho-ERK1/2 blot. Error bars represent ± SEM. (n = 3). Densitometry was 
performed using ImageJ (National Institutes of Health, Bethesda, MD).  
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Figure 3.10 Activated Ras in Ba/F3 MPL
Y591F
 cells 
(A) Detection of active, GTP-bound Ras in Ba/F3-MPL
WT
 and MPL
Y591F
 cells by 
immunoprecipitation and western blot. (B) Densitometry of GTP-bound Ras western blot. Error bars 
represent ±SEM. (n = 3). Densitometry was performed using ImageJ (National Institutes of Health, 
Bethesda, MD).  
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3.3.3 SHP-1 and SYK associate with phosphorylated MPLY591 in vitro 
An SH2/phosphotyrosine-binding(PTB) domain microarray performed in 
collaboration with Dr. Alexis Kaushansky (Harvard University) was used to identify 
potential binding partners for pY591. A 5,(6)-TAMRA labeled pY591 sequence peptide 
was diluted to 8 varying concentrations (5μM, 3μM, 2μM, 1μM, 500nM, 200nM, 
100nM and 10nM) and used to probe a protein array comprised of 136 SH2 or PTB 
domains (Table 3.1). Data was analysed using GraphPad Prism Software to 
determine specific binding. Peptides bound at <2μM, with R2 ≥ 0.89 were considered 
viable targets. The phospho-MPL
Y591
 peptide bound with high affinity in a manner 
consistent with saturation binding to domains from B lymphocyte kinase (BLK), 
Bruton agammaglobulinemia tyrosine kinase (BTK), Gardner-Rasheed feline 
sarcoma viral (v-fgr) oncogene homolog (FGR), interleukin-2-inducible T-cell 
kinase (ITK), SH2 domain-containing protein 1A (SH2D1A), SHP-1 (gene: PTPN6), 
spleen tyrosine kinase (SYK) and guanine nucleotide exchange factor VAV2 
(VAV2) (Figure 3.11). mRNA expression of targets was confirmed in bone marrow, 
Ba/F3, CD41
+
 cells and megakaryocytes by reverse transcriptase PCR as described 
in Section 2.4. Primers are listed in Table 3.2. FGR, ITK, SH2D1A, BTK, PTPN6 
and SYK were all expressed in bone marrow cells (Figure 3.12A). To narrow down 
potential targets, expression of these genes was subsequently checked in Ba/F3 cells 
as our initial in vitro findings were performed in these cells, along with CD41
+
 bone 
marrow cells and megakaryocytes. Only BTK, PTPN6 and SYK were expressed in 
these cell types (Figure 3.12B). Peptide pulldowns performed using synthesized 
MPL
Y591
 and phospho-MPL
Y591
 peptides were used to validate potential targets 
identified in the SH2/PTB domain microarray. As the peptides are based on human 
MPL, lysates used for pulldowns are from a human non-lymphoid leukaemia cell 
line, F-36P induced to ectopically express human MPL. A TPO stimulation time 
course was performed to determine the time at which MPL is maximally 
phosphorylated (Figure 3.13). Although maximal phosphorylation of MPL was 
achieved at 30 minutes post-TPO stimulation, lysates used for peptide pulldowns 
were stimulated for only 5 minutes to identify partners involved in receptor 
phosphorylation. MPL
Y591
 peptides were incubated with lysate in the absence of 
TPO stimulation and phospho-MPL
Y591
 peptide was incubated with lysate stimulated 
with 1ng/mL rhTPO for 5 min. Data shows that SHP-1 preferentially binds to 
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phosphorylated MPL
Y591
, SYK binds to only phosphorylated MPL
Y591
 and BTK 
binds equally to phosphorylated and unphosphorylated MPL
Y591
 (Figure 3.14). The 
clathrin-mediated endocytosis adaptor protein, AP2, has been shown previously to 
interact with YXXØ motifs, where Y represents a tyrosine, X represents any amino 
acid and Ø represents an amino acid with a bulky hydrophobic side chain(269). 
There are 2 of these motifs found in MPL, Y591RRL being one of them, thus AP2 
was used as a control for these pulldowns (Figure 3.14). Given these results, we 
continued to study both SHP-1 and SYK and their role in MPL
Y591
 regulation of 
TPO signalling. 
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Table 3.1 SH2/PTB Domain Binding Array Genes 
  
ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase) IRS4 (insulin receptor substrate 4) 
ABL2 (c-abl oncogene 2, non-receptor tyrosine kinase) ITK (interleukin-2-inducible T-cell kinase) 
ANKS1 (ankyrin repeat and SAM domain containing 1) JAK2 (Janus kinase 2) 
APBA1 (Amyloid beta A4 precursor protein-binding family A 
member 1)  
JAK3 (Janus kinase 3)  
APBA3 (Amyloid beta A4 precursor protein-binding family A 
member 3) 
LCK (lymphocyte-specific protein tyrosine kinase) 
APBB1 (Amyloid beta A4 precursor protein-binding family B 
member 1) 
LCP2 (Lymphocyte cytosolic protein 2) 
APBB2 (Amyloid beta A4 precursor protein-binding family B 
member 2) 
LNK (CG17367 gene product from transcript CG17367-RC) 
APBB3 (Amyloid beta A4 precursor protein-binding family B 
member 3) 
LYN (Tyrosine-protein kinase Lyn) 
APPL (adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing 1) 
MATK (Megakaryocyte-associated tyrosine-protein kinase) 
APS (CG6391 gene product from transcript CG6391-RC) NCK1 (non-catalytic region of tyrosine kinase adaptor protein 
1) 
BCAR3 (breast cancer anti-estrogen resistance 3) NCK2 (Cytoplasmic protein NCK2) 
BLK (B lymphocyte kinase) NUMB (numb homolog (Drosophila)) 
BLNK (B-cell linker) NUMBL (numb homolog (Drosophila)-like) 
BMX (BMX non-receptor tyrosine kinase) PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1)  
BRDG1 (Signal transducing adaptor family member 1) PIK3R2 (phosphoinositide-3-kinase, regulatory subunit 2 
(beta)) 
BTK (Bruton agammaglobulinemia tyrosine kinase) PIK3R3 (phosphoinositide-3-kinase, regulatory subunit 3 
(gamma)) 
CBL (Cbl proto-oncogene, E3 ubiquitin protein ligase) PLCG1 (Phospholipase C, gamma 1) 
CCM2 (cyclin-dependent kinase inhibitor 2A) PLCG2 (phospholipase C, gamma 2 (phosphatidylinositol-
specific)) 
CHN2 (chimerin 2) PTK6 (protein tyrosine kinase 6) 
CRK (Proto-oncogene c-Crk) PTPN11 (Tyrosine-protein phosphatase non-receptor type 11) 
CRKL (v-crk avian sarcoma virus CT10 oncogene homolog-
like) 
PTPN6 (protein tyrosine phosphatase, non-receptor type 6) 
CTEN (tensin 4) RASA1 (RAS p21 protein activator (GTPase activating protein) 
1) 
DAB1 (Dab, reelin signal transducer, homolog 1 
(Drosophila)) 
RIN1 (Ras and Rab interactor 1) 
DAB2 (Dab, mitogen-responsive phosphoprotein, homolog 
2 (Drosophila)) 
SH2B (SH2B adaptor protein 1) 
DAPP1 (Dual adapter for phosphotyrosine and 3-
phosphotyrosine and 3-phosphoinositide) 
SH2D1A (SH2 domain-containing protein 1A) 
DOK1 (downstream of tyrosine kinase 1) SH2D2A (SH2 domain containing 2A) 
DOK2 (docking protein 2, 56kDa) SH2D3A (SH2 domain containing 3A) 
DOK4 (docking protein 4) SH2D3C (SH2 domain containing 3C) 
DOK5 (docking protein 5) SH3BP2 (SH3-domain binding protein 2) 
DOK5L (docking protein 6)  SHB (Src homology 2 domain containing adaptor protein B) 
E105251 SHC1 (SHC (Src homology 2 domain containing) transforming 
protein 1) 
E109111 SHC3 (SHC (Src homology 2 domain containing) transforming 
protein 3) 
E129946 SLA2 (Src-like-adaptor 2) 
E138606 SRC (Proto-oncogene tyrosine-protein kinase Src) 
E169291  STAT1 (Signal Transducers and Activators of Transcription 1) 
E18941 STAT2 (Signal Transducers and Activators of Transcription 2) 
EAT2 (SH2 domain containing 1B) STAT3 (Signal Transducers and Activators of Transcription 3) 
EB1 (cytochrome c oxidase subunit VIIa polypeptide 2 like) STAT4 (Signal Transducers and Activators of Transcription 4) 
EPS8L2 (EPS8-like 2) STAT5 (Signal Transducers and Activators of Transcription 5) 
FER (fer (fps/fes related) tyrosine kinase) STAT6 (Signal Transducers and Activators of Transcription 6) 
FES (feline sarcoma oncogene) SYK (Spleen tyrosine kinase) 
FGR (Gardner-Rasheed feline sarcoma viral (v-fgr) 
oncogene homolog) 
TEC (Tyrosine-protein kinase Tec) 
FRS3 (fibroblast growth factor receptor substrate 3)  TENC1 (tensin like C1 domain-containing phosphatase) 
GRAP2 (GRB2-related adapter protein 2) TENS1 (Tensin 3) 
GRB10 (growth factor receptor-bound protein 10) TNS (Tensin 1) 
GRB14 (growth factor receptor-bound protein 14) TRX (trithorax) 
GRB2 (Growth factor receptor-bound protein 2) TXK (TXK tyrosine kinase) 
GRB7 (growth factor receptor-bound protein 7) VAV1 (Proto-oncogene vav) 
GULP1 (GULP, engulfment adaptor PTB domain containing 
1) 
VAV2 (Guanine nucleotide exchange factor VAV2) 
HCK (hemopoietic cell kinase) VAV3 (Guanine nucleotide exchange factor VAV3) 
HSH2D (hematopoietic SH2 domain containing) YES1 (Proto-oncogene tyrosine-protein kinase Yes) 
INPPL1 (inositol polyphosphate phosphatase-like 1) Zap-70 (Zeta-chain-associated protein kinase 70) 
IRS1 (insulin receptor substrate 1)  
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Figure 3.11 Saturation binding curves for MPL
pY591
 SH2 domain microarray 
targets  
Saturation binding curves were generated from data gathered from an SH2 domain microarray probed 
with 8 varying concentrations of 5,6-TAMERA labeled MPL
pY591
 peptide.  Graphs, equilibrium 
constants (KD) and R
2
 were generated using GraphPad Prism 4 software. Plots show normalized 
fluorescence as a function of peptide concentration  
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Table 3.2 Primers to validate expression of SH2 domain array targets 
 
Gene Sequence Tm 
(°C) 
Size 
(bp) 
Accession 
Blk F-5’-AAGATCCGCACCCAGGACAA-3’ 
R-5’-TTGTTCATCGGAGCCAGCAA-3’ 
65.12 
65.08 
353 NM_007549.2 
Btk F-5’-ATGGCGTCTGCACCAAACAA-3’ 
R-5’-CCCCAAAAGCCCAGATGTCA-3’ 
64.87 
65.43 
372 NM_013482.2 
Fgr F-5’-TGCAGCACAAAGGTGGCAGT-3’ 
R-5’-AGGATGTTGGCTGCCCTCAA-3’ 
65.24 
65.29 
317 NM_010208.4 
Itk F-5’-TAAAAGCATCAGCCGCGACA-3’ 
R-5’-TGCCAATCTCCTGCACGAAC-3’ 
65.04 
64.63 
386 NM_001281965.1 
Ptpn6 F-5’-TGCCCAGTTCATCGAAACGA-3’ 
R-5’-TGCAGGGATCAAGGCTGATG-3’ 
64.96 
64.61 
301 NM_013545.3 
Sh2d1a F-5’-GGGCCCATCAAAGAGTTTGC-3’ 
R-5’-ATGCCTTGATCCGGCTTCTG-3’ 
64.03 
64.74 
306 NM_011364.3 
Syk F-5’-TCCCCTTATGAGCCCCGTTT-3’ 
R-5’-AGTGCCGTGAATGGGTGACA-3’ 
64.92 
64.92 
377 NM_011518.2 
Vav2 F-5’-CGAGCCATCGATGTGTCCAT-3’ 
R-5’-TGGCTTCCAGGGCTTCTTTG-3’ 
64.39 
64.82 
331 NM_009500.1 
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Figure 3.12 SH2 domain array target expression verification   
(A) C57Bl/6 bone marrow was harvested, lysed, mRNA was isolated and cDNA was made using 
Invitrogen Superscript II. PCR was performed on cDNA, made with and without reverse transcriptase, 
using primers specific for the listed gene. (B) Ba/F3-MPL cells and CD41
+
 cells and megakaryocytes 
isolated from cultured C57Bl/6 bone marrow cells were lysed, mRNA was isolated and cDNA was 
made. PCR was performed on cDNA using primers specific for genes that yielded PCR product in 
bone marrow cDNA.        
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Figure 3.13 F36-P MPLWT receptor phosphorylation TPO time course 
F36-P cells stably expressing human WT was stimulated with rhTPO, lysed and subjected to 
immunoprecipitation with an anti- MPL antibody. Immunoprecipitates were analysed via western blot 
using a phospho-tyrosine probe to compare total receptor phosphorylation of the mutant to the wild-
type receptor in response to TPO stimulation; blots were stripped and re-probed with an anti--MPL 
antibody to assess the level of immunoprecipitated protein.   
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Figure 3.14 MPL
Y591
 peptide pulldowns    
Biotinylated peptides corresponding to the amino acid sequence surrounding Y591 were synthesized 
(LCSSQAQMD(Y591/pY591)RRLQPSCLGT), conjugated to NeutrAvidin agarose resin and 
incubated with F-36P-MPL
WT
 whole cell lysate from cells treated with or without rhTPO. Proteins 
interacting with peptides were eluted and separated on SDS-PAGE and analysed via western blot. 
SHP-1, SYK and BTK antibodies were used to confirm potential partners and AP2 was used as a 
control.   
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3.3.4 SYK binds phosphorylated MPLY591 to negatively regulate TPO-
mediated ERK1/2 signalling 
We sought to determine if SHP-1 and SYK were responsible for the increased 
ERK1/2 and Akt signalling observed in Ba/F3-MPL
Y591F
 cells. To do so, we used 
siRNAs to either Ptpn6 (the gene encoding SHP-1) or Syk to reduce SHP-1 and SYK 
protein expression, respectively. In MPL
WT
 cells, reduction of SHP-1 protein 
expression resulted in no significant change in TPO induced ERK1/2 (Figure 3.15) 
or Akt phosphorylation (Figure 3.16), relative to treatment with control siRNA. 
Conversely, reducing SYK protein expression in MPL
WT
 cells resulted in 
significantly increased ERK1/2 phosphorylation with TPO stimulation compared to 
the control (Figure 3.17A-B).  SYK siRNA treatment of MPL
WT 
cells was unable to 
induce ERK1/2 phosphorylation to the same extent as observed in MPL
Y591F
 cells; 
however, this is likely the result of incomplete knockdown of SYK (Figure 3.17A). 
We observed no difference in Akt phosphorylation as a result of SYK knockdown 
(Figure 3.18). To further understand the role of SYK in TPO-mediated ERK1/2 
signalling, we assessed the phosphorylation state SYK including SYK
Y317
, SYK
Y346
 
and SYK
Y519/520 
(SYK
Y323
, SYK
Y352
 and SYK
Y525/526
 in human SYK, respectively). 
Phosphorylation of SYK Y317, a negative regulatory residue(270), was unaltered 
between MPL
WT
 and MPL
Y591F
 in response to TPO (Figure 3.19). However, baseline 
phosphorylation of SYK
Y346
 was higher in MPL
WT
 compared to MPL
Y591F
 (Figure 
3.19). We were unable to detect phosphorylation of SYK
Y519/520
. We found no 
difference in the phosphorylation state of SHP-1 (Figure 3.19).   
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Figure 3.15 ERK1/2 phosphorylation following siRNA knockdown of Ptpn6    
(A) Western blot analysis of phosphorylation of ERK1/2 in Ptpn6 siRNA treated Ba/F3-MPL
WT
 and 
MPL
Y591F
 cells stimulated with 10ng/mL rhTPO for 15min. Knockdown efficiency was analysed by 
immunobloting for SHP-1, numbers represent densitometric quantification of protein levels. (B) 
Densitometric quantification of phospho-ERK1/2 blot using ImageJ software (**P < 0.01). Error bars 
represent ±SEM. (n=3). 
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Figure 3.16 Akt phosphorylation following siRNA knockdown of Ptpn6    
(A) Western blot analysis of phosphorylation of Akt in Ptpn6 siRNA treated Ba/F3-MPL
WT
 and 
MPL
Y591F
 cells stimulated with 10ng/mL rhTPO for 15min.  
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Figure 3.17 ERK1/2 phosphorylation following siRNA knockdown of Syk    
(A) Western blot analysis of phosphorylation of ERK1/2 in Syk siRNA treated Ba/F3-MPL
WT
 and 
MPL
Y591F
 cells stimulated with 10ng/mL rhTPO for 15min. Knockdown efficiency was analysed by 
immunobloting for SYK, numbers represent densitometric quantification of protein levels. (B) 
Densitometric quantification of phospho-ERK1/2 blot using ImageJ software. Error bars represent 
±SEM. (n=3). 
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Figure 3.18 Akt phosphorylation following siRNA knockdown of Syk    
(A) Western blot analysis of phosphorylation of Akt in Syk siRNA treated Ba/F3-MPL
WT
 and 
MPL
Y591F
 cells stimulated with 10ng/mL rhTPO for 15min.  
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Figure 3.19 Phosphorylation of SYK and SHP-1    
Western blot analysis of phosphorylation of SYK and SHP-1 from Ba/F3-MPL
WT
 and MPL
Y591F
 cells 
stimulated with 10ng/mL rhTPO for the indicated times.  
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3.4 Discussion 
MPL is critical for the maintenance of haematopoietic stem cells, in addition to being 
the key regulator of megakaryopoiesis(62,103,271). Therefore, its regulation is 
essential to prevent uncontrolled activation of the receptor, which can result in the 
development of MPNs(124,200). In this chapter, we demonstrate for the first time 
that Y591 in wild-type MPL is phosphorylated in response to TPO and that removal 
of Y591 phosphorylation results in decreased total receptor phosphorylation. Y591 
regulates the level of active Ras within the cell following TPO stimulation thus, its 
removal contributes to the higher levels of pERK1/2 observed in Y591F. 
Additionally, we identify SYK and SHP-1 as novel potential binding partners for 
pY591, and moreover, that knockdown of Syk mimics the Y591F phenotype, 
suggesting that SYK contributes to the negative regulatory effects of Y591 in wild-
type cells. These findings suggest a significantly more important role than previously 
thought for Y591 in TPO signalling and receptor function. 
 
In previous studies, using receptor truncations, Y591 was identified as a potential 
negative regulator of TPO-mediated proliferation(3). This has been further supported 
by our work showing that the Y591F point-mutation in MPL confers a proliferative 
advantage to cells in response to TPO(1). To determine whether the observed 
phenotype is the consequence of the removal of a phosphorylation site at Y591, 
within the intracellular domain of MPL, we determined the phosphorylation state of 
Y591 in wild-type MPL after TPO stimulation. Phosphorylation of MPL Y591 has 
been previously reported in the disease state associated with a W515A activating 
mutation of MPL(116) but here we report that MPL Y591 is also phosphorylated in 
response to TPO in the wild-type receptor. As such, we tested whether 
phosphorylation of Y591 provides a docking site for SH2 domain containing 
proteins to bind and act as direct downstream effectors or as a scaffold for additional 
effector proteins in TPO mediated signalling.  
 
It has been known for many years that multiple residues of MPL are phosphorylated 
upon TPO binding. Previous studies have focused on Y625 and Y630(3); our 
demonstration in this study that MPL Y591 is also phosphorylated provides an 
additional potential point of regulation of receptor activity. Moreover, based on our 
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experiments using single tyrosine to phenylalanine mutations of MPL, the decrease 
in total receptor phosphorylation in the Y591F cells is greater than would be 
predicted based on loss of a single tyrosine site. This result also suggests that MPL 
Y625 and Y630 phosphorylation levels are, in part, dependent on the 
phosphorylation state of Y591 and that pY591 is required for maximal 
phosphorylation at Y625 and Y630. If so, these results suggest that Y591 might also 
serve as a docking site of a kinase responsible for phosphorylation of Y625 and 
Y630. To better explore this hypothesis the temporal phosphorylation profile of MPL 
would need to be explored.  
 
Since TPO is the primary megakaryocyte growth factor(272), much has been 
discovered about the positive signals involved in its regulation. However, the 
mechanisms that negatively regulate its signalling are less well understood. The 
YRRL motif appears twice in the cytoplasmic domain of MPL and are important in 
negative regulation of TPO signalling. Y529RRL is required for lysosomal targeting 
and subsequent degradation and Y591RRL is important for MAPK pathway 
activation and suppression of proliferation(1).  Our data suggest that Y591 can 
regulate MAPK pathway activation through modulation of active Ras levels within 
the cells. Active Ras is necessary for megakaryocyte differentiation(271), and 
therefore it is possible that a role of Y591 is to suppress megakaryocytic 
differentiation through downregulation of active Ras. The mechanism by which 
Y591 suppresses Ras activation is an important area for future studies as aberrant 
Ras signalling has been observed in a number of human cancers, including 
haematological malignancies(273). 
 
Although attempts to co-immunoprecipitate MPL and SYK have been unsuccessful, 
which is a likely consequence of the transient nature of SH2 interactions, we found 
using an SH2-domain binding array followed by a peptide pulldown, that SYK may 
potentially binds to Y591 of MPL. SYK typically binds immunoreceptor tyrosine-
based activation motifs (ITAMs), characterized by two YXXL/I sequences 6-9 
amino acids apart(274). The region of MPL around Y591RRL does not contain 
additional YXXL/I motifs but MPL signals as a dimer; therefore, pY591RRL could 
serve as a hemi-ITAM for SYK binding. The role of SYK in immunoreceptor 
signalling has been well characterized and typically results in receptor activation and 
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positive signalling (reviewed in (274)). Surprisingly, however, our preliminary data 
shows that the elimination of this SYK binding site yields an increase in ERK1/2 
signalling, suggesting that in wild-type cells, SYK is somehow downregulateting the 
phosphorylation of ERK1/2 in response to TPO. SYK phosphorylation decreases 
following TPO stimulation of both WT and Y591F MPL supporting its role as a 
negative regulator of TPO signalling. SYK Y346 has been linked to ERK activation 
in immune cells(270) and the decrease in SYK pY346 in MPL Y591F supports a link 
between the two proteins albeit a negative rather than the typical positive 
association. SYK function has been reported to interfere with epidermal growth 
factor (EGF)-mediated cellular responses through epidermal growth factor receptor 
(EGFR), thus in some cases, SYK functions as a negative regulator(275). However, 
the exact mechanisms by which MPL and SYK may interact and how this potential 
interaction affects TPO signalling requires further investigation. It is possible that 
there are a number of signalling intermediates between SYK and ERK including 
other negative regulatory proteins functioning as effectors facilitating negative 
regulation through Y591. However, the mechanisms through which SYK negatively 
regulates ERK signalling and its role in megakaryopoiesis have yet to be elucidated.  
 
In addition to identifying SYK as a potential binding partner for pY591 and a 
regulator of ERK activation, peptide pulldowns identified two additional novel 
binding partners for Y591, SHP-1 and BTK. SHP-1 is a phosphatase that 
preferentially binds pY591, yet is not responsible for the increased ERK1/2 
activation resulting from the Y591F mutation; however, SHP-1 could modulate other 
aspects of TPO signalling outside of ERK1/2 activation. SHP-1 negatively regulates 
signalling of type I cytokine receptors through binding of phosphorylated tyrosine 
residues on activated receptors and subsequent dephosphorylation of 
JAK2(276,277). We observed a slight increase in the level of phosphorylated JAK2 
in the Y591F mutant; therefore, it is possible that in MPL, SHP-1 binding to pY591 
mediates JAK2 activation. Additional experiments are required to further understand 
the role of Y591 in SHP-1 regulation.  
In this report we show that MPL Y591 is phosphorylated in response to TPO, 
providing a novel docking site for SH2-domain containing proteins SHP-1 and SYK. 
Once bound to pY591, SYK negatively regulates ERK1/2 phosphorylation. Tight 
regulation of the cellular response to TPO is essential, as loss of this control seen in 
Chapter 3 
 
96 
 
clinical mutations of MPL (MPL W515L) results in development of haematological 
malignancies. Interestingly, a novel MPL Y591D mutation has been identified in a 
patient with JAK2V617F-positive polycythaemia vera(278). At the time of 
discovery, the function of the mutation was unknown; however, our data suggests 
that loss of Y591 in this patient may be facilitating the disease phenotype due to loss 
of a negative regulator. Thus, an understanding of the molecular details of TPO 
signalling is important for identification of areas for therapeutic intervention. A 
negative regulatory site such as Y591 and its associated effector proteins provide 
potential therapeutic targets for dysregulated cellular responses to thrombopoietin. 
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CHAPTER 4 DISSECTING THE ROLE OF MPL IN IN 
VITRO JAK2
V617F
-POSITIVE SIGNALLING AND 
PROLIFERATION  
2.  
4.1 Experimental Rationale  
Taken together, the functional interdependence of MPL and JAK2 in maintenance of 
haematopoiesis and the ability of both proteins to induce MPNs, suggests that MPL 
may be capable of modulating the effects of JAK2
V617F
. Therefore, in this chapter, 
we sought to determine the relationship between the phosphorylated tyrosine 
residues of MPL and JAK2
V617F
 pathogenesis in vitro.  
4.2 Materials and Methods 
4.2.1 Cloning of MPL and JAK2 containing plasmids  
4.2.1.1 pMX-puro-MPL  
pMX-puro-MPL was generated as described in Section 3.2.1 and mutagenesis was 
performed as described in Section 2.6 to generate MPL mutants. These new mutants 
include MPL
Y625F
 and MPL
Y630F
. Mutagenesis primers annealing temperatures are 
listed in Table 2.3. For these studies, the previously generated MPL
WT
 and MPL
Y591F
 
plasmids from Section 3.2.1 were also used.     
4.2.1.2 pQCXIN-JAK2 
pQCXIN is a retroviral expression vector Figure 4.1. It contains a CMV promotor, 
neomycin resistance gene as a selectable marker following an internal ribosome 
entry site (IRES), ampicillin resistance for bacterial selection. pQCXIN was obtained 
from Clontech and JAK2
WT
 cloned in using in-fusion cloning strategy between the 
BamHI and EcoRI restriction sites within the MCS (Figure 4.2)and subsequently 
mutagenized to JAK2
V617F
 using site-directed mutagenesis  as described in Section 
2.6 by Dr. S. Leah Etheridge to generate pQCXIN-JAK2
WT
 and pQCXIN-JAK2
V617F 
. 
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Figure 4.1 pQCXIN backbone vector  
The  pQCXIN vector contains an ampicillin resistance gene for selection in E.Coli and a neomycin 
resistance gene for selection in mammalian cells.  
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Figure 4.2 pQCXIN-JAK2
WT
 vector 
Human JAK2 cDNA was cloned into the pQCXIN backbone vector between restriction sites for 
BamHI and EcoRI of the MCS.  
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4.2.2 XTT Cell Viability Assay 
Tetrazolium salts are utilized in numerous biochemical assays and their widespread 
application is attributed to their ability to be reduced and form colored formazan 
dyes. Triphenyl tetrazolium chloride (TTC) was the first of these salts to be 
synthesized and since, scientists have been modifying this parent compound to 
produce a number of tetrazolium salts with specific properties for use in a wide range 
of biochemical applications (reviewed in (279)). The most common tetrazolium salt 
used for proliferation assays previously was 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT). However, acidified isopropanol used solubilize the 
MTT was dangerous and volatile leading increased health risk and increased 
likelihood of sample variation. Therefore, as a way to assess the necessity of MPL 
and JAK2
V617F
 for proliferation in cells, we performed 2,3-Bis-(2-Methoxy-4-Nitro-
5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) proliferation assays. XTT is 
similar to MTT as their reduction is dependent on the rate of NAD(P)H production. 
However, XTT is not cell permeable and therefore, reduction occurs at the surface of 
the cell membrane(279). Cells were cultured in triplicate at 2.0x10
5
 cells/well of 96-
well cell culture plates in the absence of 1ng/mL recombinant human TPO (rhTPO). 
At 24, 48 and 72 hours, XTT reagent was added to the cells and any proliferating 
cells would reduce the XTT compound resulting in a colorimetric change directly 
proportional to the number of metabolically active cells when read at 490nm. 
Although these assays do not directly measure the number of viable cells, studies 
have shown that data generated from these assays correlates with proliferation data 
gathered by cell counts and radioisotope assays(280). 
4.3 Results 
4.3.1 Generation of pMX-puro-MPL mutants  
MPL mutants were generated by site directed mutagenesis as described in Section 
4.2.1.1. Mutants were verified by sequencing using primers to full length human 
MPL (Figure 3.3, Figure 4.3 and Figure 4.4). MPL sequencing primers are listed in 
Table 2.4. 
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Figure 4.3 pMX-puro-MPL
Y625F
 Sequencing Results  
Sequence analysis of WT and mutagenized MPL in the pMX-puro-MPL vector. 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
102 
 
 
 
 
 
 
 
 
 
Figure 4.4 pMX-puro-MPL
Y360F
 Sequencing Results  
Sequence analysis of WT and mutagenized MPL in the pMX-puro-MPL vector. 
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4.3.2 Total MPL and JAK2 expression in generated Ba/F3 cell lines  
After cells were generated and selected for plasmid integration, cells were lysed and 
expression of MPL and JAK2 was determined by western blot (Figure 4.5). In lines 
not engineered to express MPL, there was no MPL expression detected (Figure 4.5). 
Total MPL expression varied between different MPL mutants with MPL
WT
 being 
maximally expressed. Total MPL
Y591F
 expression was approximately half that of 
MPL
WT
 (Figure 4.5). In both MPL
WT
 and MPL
Y591F
, expression of JAK2
V617F
 rather 
than JAK2
WT
 did not affect total MPL expression (Figure 4.5). MPL
Y625F
 expression 
was absent when JAK2
WT
 was expressed but rescued with JAK2
V617F
 expression 
(Figure 4.5). The opposite was true for MPL
Y630F
 expression whereby expression 
was higher when co-expressed with JAK2
WT
 rather than JAK2
V617F
 (Figure 4.5). 
Overall, expression of JAK2 was unaltered between cells expressing JAK2
WT
 or 
JAK2
V617F
 (Figure 4.5). β-actin was used as a loading control (Figure 4.5).    
4.3.3 Cell surface expression of MPL in generated Ba/F3 cell lines 
MPL cell surface expression was assayed by flow cytometry. All cell lines express 
MPL at varying levels on their cell surface (Figure 4.6). However, MPL
Y625F
 
exhibited decreased cell surface localization relative to MPL
WT
JAK2
WT
 (Figure 4.6). 
MPL
Y630F
JAK2
WT
 cells exhibited a bimodal distribution of MPL cell surface 
expression despite culture under puromycin selection (Figure 4.6).  
4.3.4 Cell signalling in MPL/JAK2 Ba/F3 cell lines  
Cell signalling was assessed in the MPL/JAK2 Ba/F3 cell lines. Cells were starved in 
RPMI 1640 supplemented with 2% FBS in the absence of IL-3 for 16 hours followed 
by stimulation with or without 10ng/mL rhTPO for 5min. Whole cell lysates were 
harvested and western blot analysis was performed as described in 2.5.  Western 
blots are presented in Figure 4.7 and values determined by densitometry are 
presented in Figure 4.8. In the absence of MPL expression, JAK2 is not significantly 
phosphorylated. Co-expression of MPL
WT
, MPL
Y591F
 and MPL
Y630F
 with JAK2
WT
 
results in TPO induced phosphorylation of JAK2. However, co-expression of 
MPL
Y625F
 and JAK2
WT
 does not result increased JAK2 phosphorylation following 
TPO stimulation. When MPL
WT
 and JAK2
V617F
 are co-expressed, JAK2 
phosphorylation was present despite absence of cytokine. This is consistent with 
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Figure 4.6 MPL cell surface expression  
Flow cytometry analysis of MPL cell surface expression in BaF/3 MPL and JAK2 mutants. Pools of 
BaF/3 cells expressing various human MPL and JAK2 constructs were stained with an antibody 
against the extracellular domain of MPL (Amgen) followed by secondary staining with an anti-mouse 
Qdot 565 antibody.  The open peak corresponds to cells stained with anti-mouse Qdot 565 secondary 
alone.  
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Figure 4.8 Densitometric quantification of pJAK2 and pSTAT3 
Quantification of western blot from Figure 4.7. Values for phosphorylated protein are normalised to 
level of total (A)JAK2 or (B)STAT3 and are relative to MPL
WT
JAK2
WT
.  Analysis was performed 
using ImageJ software.  
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previous reports demonstrating JAK2
V617F
 is able to confer cytokine independent 
signalling in cell lines(181). Similarly, JAK2
V617F
 was able to induce JAK2 
phosphorylation when co-expressed with all MPL mutants (MPL
Y591F
, MPL
Y625F
 and 
MPL
Y630F
). This suggests that JAK2
V617F
 activation occurs independently of and 
precedes MPL receptor phosphorylation. Cells expressing JAK2
V617F
 and MPL are 
still able to respond to TPO as JAK2 phosphorylation increases following 
stimulation with TPO; however, this is potentially a result of the presence of 
endogenous murine JAK2
WT
.  As expected, phosphorylation of downstream target, 
STAT3(281), mirrors the phosphorylation pattern observed for JAK2 in both 
JAK2
WT
 and JAK2
V617F
 expressing cells.  
4.3.5 Analysis of cell viability in MPL/JAK2 Ba/F3 cell lines 
Cell viability was assessed in cells co-expressing WT or mutant MPL and WT or 
mutant JAK2 based on the percentage of cells capable of reducing XTT relative to 
those cultured in IL-3.  XTT assays were performed on cells co-expressing MPL: 
WT, Y591F or Y625 and JAK2: WT or V617F. Y630F proliferative capacity was 
not assessed as cell surface expression was not uniform (Figure 4.6). Cells were 
cultured in the absence or presence of 1ng/mL rhTPO and XTT reduction capacity 
was measured at 24, 48 and 72hrs. Cells expressing JAK2
WT
 or JAK2
V617F
 in the 
absence of MPL were unable to maintain metabolic activity in the presence or 
absence of cytokine (Figure 4.9 and Figure 4.10). Similarly, cells expressing MPL
WT
 
and JAK
WT
 were not viable in the absence of cytokine; however, co-expression of 
MPL
WT
 with JAK2
V617F
 sustained metabolic activity in the absence of cytokine 
(Figure 4.9). As expected from previous studies, when cultured in the presence of 
cytokine both MPL
WT
JAK2
WT
 and MPL
WT
JAK2
V617F
 cells were metabolically active 
although mutant JAK2 was more effective at sustaining activity (Figure 4.10). These 
data support previous works showing that MPL expression is required for 
JAK2
V617F
-mediated proliferation in vitro in the absence of cytokine(264). Analysis 
of MPL point mutants demonstrated that co-expression of MPL
Y591F
 with JAK2
WT
 
was able to sustain metabolic activity in the absence of TPO albeit to a lesser extent 
than MPL
WT
JAK2
V617F
 cells (Figure 4.9). Additionally, there was slightly increased 
metabolic activity in MPL
Y591F
JAK2
V617F
 cells  
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Figure 4.9 XTT assay with MPL point mutants in the absence of cytokine  
Ba/F3-MPL-JAK2 cells were cultured in RPMI + 2%FBS in the absence of rhTPO. The ability of 
metabolically active cells to reduce XTT was measured at 24, 48 and 72 hours post-culture and is 
shown as a percentage relative to maximal activity when cultured in IL-3. Experiments were 
performed in triplicate and data are presented as mean ±s.e.m; n=3.  
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Figure 4.10 XTT assay with MPL point mutants with cytokine 
Ba/F3-MPL-JAK2 cells were cultured in RPMI + 2%FBS and 1ng/mL rhTPO. The ability of 
metabolically active cells to reduce XTT was measured at 24, 48 and 72 hours post-culture and is 
shown as a percentage relative to maximal activity when cultured in IL-3. Experiments were 
performed in triplicate and data are presented as mean ±s.e.m; n=3. 
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compared to MPL
WT
JAK2
V617F 
cells observed at 72hours when cultured in TPO 
(Figure 4.10); however, the difference was not statistically significant. This was not 
surprising as MPL
Y591
 is a negative regulator of TPO-induced signalling and removal 
of this residue has been shown to increase proliferation as measured by MTT(1). 
Interestingly, metabolic activity for MPL
Y591F
JAK2
WT
 cells was almost identical in 
both the presence and absence of cytokine (Figure 4.9 and Figure 4.10). MPL
Y625
 
was shown previously to be necessary for TPO mediated proliferation(3,282). 
Likewise, removal of MPL
Y625
 (MPL
Y625F
) was unable to sustain activity when co-
expressed with JAK2
WT
 in either the presence or absence of cytokine; however, 
when co-expressed with JAK2
V617F
, metabolic activity remained similar to 
maximally active cells cultured in IL-3(Figure 4.9 and Figure 4.10). These data 
suggest that removal of MPL
Y591
 and MPL
Y625
 within MPL is unable to overcome to 
proliferative effects induced by JAK2
V617F
 expression in cells.  
 
4.4 Discussion 
Removal of MPL in vitro prevents cytokine independent signalling despite presence 
of JAK2
V617F
. This is consistent with previous reports(264). Studies in cell lines 
expressing mutant MPL demonstrate the importance of receptor phosphorylation on 
downstream signalling(1,3,283). However, disruption of tyrosine phosphorylation 
sites within the cytoplasmic domain MPL had little effect on regulating JAK2
V617F
-
induced signalling. This is not entirely unexpected as platelets from mice expressing 
the MPL receptor lacking the distal 60 amino acids (Δ60), a region containing all 
three phosphorylated tyrosine residues, was still able to active the JAK/STAT 
pathway(284). In these mice, activation of the MAPK and Akt signalling pathways 
were disrupted; therefore, MPL phosphorylation plays a larger role in activation of 
these pathways and is unable to regulate JAK2
V617F
-mediated signalling as 
demonstrated by our data. The box1/2 regions of MPL are important for association 
with JAK2 and disruption of these regions results in diminished TPO induced 
signalling and proliferation(104). These regions may be able to control JAK2
V617F
-
induced signalling through disruption of MPL/JAK2 association; however, this has 
yet to be examined.  
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Although numerous studies utilize the Ba/F3 cell line to study MPNs, it is important 
to note the limitations of using these cells. Ba/F3 cells are derived from murine pro-
B cells. Being of lymphoid origin, intrinsic differences between these cells and those 
of the myeloid lineage may affect experimental outcomes and result in a number of 
experimental artefacts. For example, JAK2
V617F
 expression in these cell lines results 
in complete cytokine independence; however, in vivo, JAK2
V617F
 confers cytokine 
hypersensitivity(179,285). Nonetheless, studies utilizing cell lines provide 
preliminary evidence and rationale for investigation in a more relevant model. These 
data clearly demonstrate that MPL is required for JAK2
V617F
 signalling prompting 
further investigation into the role of MPL in JAK2
V617F+
 MPN development in vivo.  
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CHAPTER 5 GENERATION OF A HUMAN JAK2
V617F
-
POSITIVE MOUSE MODEL LACKING 
THROMBOPOIETIN OR MPL  
3.  
5.1 Experimental Rationale  
Results from the previous chapter showing that MPL cell surface expression is 
necessary for in vitro JAK2
V617F
-induced transformation suggest that MPL may have 
an essential role in myeloproliferation. To further test the hypothesis that TPO and 
MPL are indeed necessary for MPN development, we generated in vivo models 
utilising crosses of transgenic mice and bone marrow chimeras. This chapter details 
the process of generating these mice.       
5.1.1 Lineage restriction of JAK2V617F expression in murine HSCs  
5.1.1.1 Flip-flop mouse model 
Flip-Flip (FF1) mice were generated by Tiedt et al using a bacterial artificial 
chromosome (BAC) transgene containing the first 12 exons of human JAK2 in a 
forward orientation and exons 13-25 containing the V617F mutation in a reverse 
orientation flanked by antiparallel lox71 and lox66 sites(191). 9 consecutive copies 
of the transgene were integrated into the genome at chromosome 8 band A1, at a 
locus near the centromere where the authors report contains no known genes. In this 
orientation, the gene is not expressed. However, in the presence of Cre-recombinase, 
the antiparallel lox71 and lox66 sites recombined causing inversion of exons 13-25 
into a forward orientation resulting in expression human JAK2
V617F
 under the 
endogenous human JAK2 promoter. Additionally, upon inversion and ligation in the 
forward orientation, mutant lox71 and lox66 are ligated forming a new lox71/66 site 
which is no longer recognized by Cre-recombinase and a normal loxP site(286). 
These loxP sites are important as they allow for excision of extra copies of transgene 
resulting in expression of only one copy of human JAK2
V617F
 (Figure 5.1 and Figure 
5.2).  
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Figure 5.1 Flip-flop human JAK2
V617F
 transgene
 
 
Flip-flop (FF1) mice contain a human JAK2
V617F
 transgene. The first 12 exons are in the correct 
orientation while exons 13-25, which contains the V617F mutation, is in the reverse orientation 
flanked by anti-parallel mutant loxP sites. Presence of Cre recombinase results of ‘flipping’ of exons 
13-25 to the correct orientation resulting in transcription of human JAK2V617F. Transcription is 
under the control of the native human JAK2 promoter.    
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5.1.1.2 Tie2-Cre mouse  
Developed by Kisanuki et al., the Tie2-Cre transgene contains the Tie2 promoter, 
Cre cDNA, MT-1 polyA signal sequence and a Tie2 intron 1 enhancer. The 
transgene was microinjected into C57BL/6 x SJLF1 oocytes and offspring were 
tested for presence of the transgene by PCR. Tie2-Cre mice were crossed with Cre 
mediated lacZ expressing transgenic mice (CAG-CAT-Z or R26R) confirming that 
the Tie2 promoter and enhancer regions were able to drive Cre transgene expression 
in a pan-endothelial fashion. Although they report no detectable lacZ expression in 
hematopoietic cells in E8.5 yolk sacs, they observe a subset of circulating lacZ-
positive cells within the dorsal aorta(287). Tang et al. showed that the Tie2-Cre 
mouse was able to drive Cre transgene expression in 88% of primitive hematopoietic 
progenitor cells of Tie2-Cre;Rosa26R-Enhanced yellow fluorescent protein (EYFP) 
E9.5 embryos(288), suggesting the identity of the lacZ positive dorsal aorta cells 
identified by Kisanuki et al. to be  primitive hematopoietic cells. In adult mice, 85% 
of bone marrow and 84% of splenic cells from Tie2-Cre;Rosa26R-EYFP mice were 
EYFP
+
 indicating Tie2 expression in adult hematopoietic cells from multiple 
lineages. Together these data support that Tie2-Cre
 
induced
 
recombination occurs 
within a primitive stem cell.    
5.1.1.3 Flip-flop/Tie2-Cre mouse 
The FF1/Tie2-Cre mice are generated from a cross between the FF1 and Tie2-Cre 
mouse and was characterized by Etheridge et al. as a JAK2
V617F+
 ET mouse 
model(149). This mouse expresses JAK2
V617F
 in its hematopoietic and endothelial 
cells and develops pronounced thrombocytosis, neutrophilia and splenomegaly by 16 
weeks of age. JAK2
V617F
 was not grossly overexpressed in these mice and ranged 
from 10-50% of endogenous murine Jak2
WT
. Expression of JAK2
V617F
 was present in 
all colony forming cells (CFCs) tested from FF1/Tie2-Cre mice (Figure 5.3). Despite 
severe thrombocytosis, these mice exhibited attenuated thrombosis following injury 
due in part to dysregulated expression of vWF.  
5.1.2 Thpo-/- mouse  
The Thpo
-/-
 mouse used in this study was generated by de Sauvage et. al.(65). To 
generate the Thpo
-/-
 mouse, a targeting vector was engineered to remove 23 amino 
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acids of a fragment responsible for receptor binding and activation(62) and insert a 
neomycin-resistance (neo
r
) gene to disrupt the mouse Thpo gene. The targeting 
vector was linearized and electroporated into a 129/Sv murine embryonic stem (ES) 
cell line(289) and selected for neomycin resistance. Selected cells were subsequently 
microinjected into C57Bl/6J blastocysts. Chimeric males were bred to C57Bl/6J 
females and offspring were checked for germline transmission of the mutant TPO 
allele by PCR and Southern blot analysis. Subsequently, mice positive for the mutant 
allele were interbred to generate homozygous Thpo gene-targeted (Thpo
-/-
) mice. The 
authors reported normal Mendelian distribution of litters and adult Thpo
-/-
 mice 
displayed no overt abnormalities. Northern blot analysis revealed no detectable Thpo 
transcripts in kidneys and livers of Thpo
-/-
 mice and reported a reduction of Thpo 
transcripts in both tissues by half in heterozygotes (Thpo
+/-
) compared to wild-type 
(WT). Tpo
-/-
 mice showed an 88% decrease in the number of peripheral platelets 
accompanied by an increase in mean platelet volume (MPV). Thpo
+/-
 mice however, 
exhibited a 33% reduction in peripheral platelets. There was no observed 
compensatory increase in IL-3, IL-6 or GMCSF resulting from removal of Thpo. 
Additionally, disruption of Thpo resulted in no significant difference in other 
hematopoietic cell lineages.    
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Figure 5.3 JAK2
V617F 
Expression in Individual Bone Marrow CFU-G Colonies  
RT-PCR of individual bone marrow CFU-G colonies to show expression of mouse JAK2 and human 
JAK2
V617F
.  
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5.1.3 Mpl-/- mouse  
The Mpl
-/-
 mouse used in this study was generated by Gurney et al.(78). To generate 
the Mpl
-/-
 mouse, a targeting vector was engineered to contain a neomycin-resistance 
(neo
r
) gene under the mouse phosphoglycerate kinase 1 (pkg) promoter inserted into 
the third exon of Mpl using a synthetic NotI restriction site. This vector was 
electroporated into murine ES cells and ES colonies positive for homologous 
recombination, as detected by a HindIII site from the neo
r
 gene, were subsequently 
microinjected into blastocysts. Once germline transmission was determined, two 
separate lines were interbred to generate homozygous Mpl gene-targeted (Mpl
-/-
) 
mice. The authors reported no detectable Mpl transcripts through RT-PCR in spleens 
of Mpl
-/-
 mice. Mpl
-/-
 mice showed an 85% decrease in the number of peripheral 
platelets and reduced numbers of megakaryocytes in the spleen and bone marrow 
compared to wild-type, despite having increased levels of TPO in their serum. 
Additionally, heterozygous Mpl gene-targeted (Mpl
+/-
) mice showed no significant 
changes in platelet and megakaryocyte numbers or TPO levels in serum. Disruption 
of Mpl resulted in no significant difference in other hematopoietic cell lineages. 
5.1.4 B6.SJL-Ptprca Pep3b/BoyJ mouse 
The B6.SJL-Ptprc
a
 Pep3
b
/BoyJ mouse strain in on a C57BL/6 background and 
carries a differential allele for protein tyrosine phosphatase, receptor type C (Ptprc), 
Ptprc
a
, while WT C57BL/6 strains carry the Ptprc
b
 allele. Ptprc
a
 is also referred to as 
CD45.1 or Ly5.1 whereas Ptprc
b
 is referred to as CD45.2 or Ly5.2. The receptor is 
expressed on all leukocytes and because antibodies can readily distinguish between 
the two isotypes, this strain has become a widely used in transplantation studies 
(http://jaxmice.jax.org/strain/002014.html).  
5.2 Materials and Methods 
5.2.1 Mouse colony organization  
Breeding pairs were set up and receive a non-redundant identifying breeding 
number. Males were considered sexually mature at 6 weeks of age and female mice 
at 8 weeks of age. At 10 days of age, mouse pups were sexed, tagged and catalogued 
using an ear punch method before being placed back into the cage with the mother. 
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Males were tagged and catalogued first followed by females. Each mouse 
identification number was based on the breeding number of the parents followed by 
a mouse number determined by the number of mice a breeding pair has already 
generated. The identification numbers were recorded and listed on cage cards. Pups 
receive ear punches using a 2mm thumb style EP-T 900 small animal ear punch 
(Braintree Scientific, Inc., Braintree, MA, USA) in the following order: single right 
and single left, two right, two left, two right and a single left, two left and a single 
right or two right and two left. The number of pups for each sex of a single litter has 
never surpassed the eight identifiable markings listed. The tissue is saved for 
subsequent genotyping as described in Section 5.2.2.1.  
5.2.2 Genotyping of mice  
5.2.2.1 Genomic DNA (gDNA) isolation for genotyping  
Tissues from ear punches are placed into individually labelled microcentrifuge tubes, 
corresponding to the mouse identification number. Samples are then digested in 
300μL Cell Lysis Buffer (Qiagen) with 0.2μg/mL Proteinase K in 10mM Tris-HCl, 
pH 8.0 at 55°C for 8 hours. Samples are then brought up to room temperature (25°C) 
and 100μL of Protein Precipitation solution is added and the sample vortexed. The 
sample is then centrifuged at 13,000g for 4 minutes to pellet the precipitate and 
supernatant then added to 300μL isopropanol to precipitate out the gDNA. The 
gDNA is then pelleted at 13,000g for 2 minutes and washed with 300μL of 70% 
EtOH and resuspended in 50μL of gDNA hydration solution. This gDNA is then 
used for the genotyping reaction.     
5.2.2.2 Conventional polymerase chain reaction (PCR) of genomic DNA for 
genotyping 
Genomic DNA is isolated as described in Section 5.2.2.1. Genotyping is performed 
using HotStarTaq DNA polymerase Kit (Qiagen). A final concentration of 1X PCR 
buffer, 1X Q-solution, 4.5mM MgCl2, 200μM of each dNTP, 0.2µM of forward and 
reverse primer and 0.625U HotStarTaq DNA polymerase was brought up to 25µL 
with PCR grade H2O in a thin walled 0.2mL PCR tube and run on a Veriti thermal 
cycler (Life technologies), primers and annealing temperatures are listed in Table 
5.1. PCR products were mixed with DNA loading dye (6X: 0.25% bromophenol blue  
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Table 5.1 Primers for Conventional Genotyping 
     
Gene Sequence Size 
(bp) 
Tm
* 
(°C) 
Ref 
FF1 F-5’-GAGCAAGCTTTCTCACAAGC-3’ 
R-5’-AATTCTGCCCACTTTGGTGC-3’ 
~500 54.5 
56.4 
(191) 
Tie2-Cre F-5’-CTGCATTACCGGTCGATGCA-3’ 
R-5’-ACGTTCACCGGCATCAACGT-3’ 
~300 57.8 
59.9 
(290) 
Mpl WT F-5’-GAGGAAGAGGCAGCACCCAGTG-3’ 
R-5’-GGGAATACAGGGGGCATGCACG-3’ 
~350 62.2 
62.8 
 
Mpl neo F-5’-TAGCGGCTGATGTTGAACTG-3’ 
R-5’-ACTATCCCGACCGCCTTACT-3’ 
~200 55.2 
57.6 
 
Tpo WT F-5’-GTCGACCCTTTGTCTATCCCT-3’ 
R-5’-GGTGAATGTAACCTGGGATAA-3’ 
~300 56.1 
51.9 
(65) 
Tpo neo F-5’-AAGTATCCATCATGGCTGATG-3’ 
R-5’-TAGCCAACGCTATGTCCTGATA-3’ 
~350 55.4 
52.3 
 
 
*
in 50mM NaCl 
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(w/v), 0.25% xylene cyanol FF (w/v), 30% glycerol (v/v)) to 1X and resolved using 
1.5% agarose gels in TBE  containing 0.2µg/mL EtBr at 120 volts for 50 minutes. 
5.2.2.3 Quantitative PCR (qPCR) of genomic DNA for genotyping  
Genotyping of transgenic mice to determine allelic copy number was accomplished 
using a TaqMan
®
 Copy Number Assay (Invitrogen) as per manufacturer’s 
instructions. Reaction components include TaqMan
®
 Genotyping Mastermix, 
TaqMan
®
 Copy Number Assay, TaqMan
®
 Copy Number Reference Assay and 20ng 
gDNA. The TaqMan Genotyping Mastermix contains AmpliTaq
®
 Gold DNA 
Polymerase, UP (UltraPure) and dNTPs necessary for target gene amplification. The 
TaqMan
®
 Copy Number Assay contains unlabeled forward and reverse primers for 
the gene of interest in addition to a 6-carboxyfluorescein (FAM
™
) dye-labeled minor 
groove binder (MGB) probe that binds a sequence of the target gene between the 
forward and reverse primers. The TaqMan
®
 Copy Number Reference Assay used is 
similar to the TaqMan
®
 Copy Number Assay but its forward and reverse primers and 
VIC
®
 dye-labeled tetramethylrhodamine (TAMRA
™
) probe recognizes the mouse 
transferrin receptor gene (trfc) and serves as an internal control. The reaction is 
considered a duplex reaction as both sets of primers and probes are assayed in the 
same reaction mixture. Genomic DNA is isolated as described in 4.2.2.1, the 
concentration is then quantified using a NanoDrop spectrophotometer (Thermo 
Scientific) and diluted in H2O to 5ng/µL. When all the components of the reaction 
probes are added to the PCR reaction, there is no detectable signal because the 
proximity of the quencher to the FAM
™
 or VIC
®
 dye-labeled reporter prevents 
detection of the reporter signal. When the reaction proceeds, the gDNA template is 
denatured, the forward and reverse primers and the probes anneal to their target gene 
sequences. During the elongation step, the AmpliTaq
®
 Gold DNA Polymerase 
amplifies both the target and reference sequences. However, because the probes bind 
to a sequence between the forward and reverse primers the AmpliTaq
®
 Gold DNA 
Polymerase uses its 5’ nuclease activity to cleave the probe in order to complete the 
elongation step. As a result, the dye is released and the signal is no longer quenched, 
allowing for detection with each round of amplification. Assays were performed in 
96-well plates with samples assayed in duplicate. Each plate contained the unknown 
samples, a sample of a known copy number (calibrator sample) and a no template 
control sample. The FF1 transgene was assessed with Copy Number Assay 
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Hs02201428_cn for JAK2. The Tie2-Cre transgene was assessed with Copy Number 
Assay Mr00635245_cn for cre. Mouse transferrin receptor (Trfc) was used as an 
internal reference gene (4458366, Invitrogen). The reaction was run on an Applied 
Biosystems 7300 Real-Time PCR System. Data was interpreted using 7300 System 
Software and analysed using CopyCaller™ Software v2.0 (Invitrogen). Tie2-Cre 
homozygosity was determined using Taqman Copy Number assays for cre. 
5.2.3 Hematopoietic cell transplantation  
5.2.3.1 Preparation of donor bone marrow 
Primary murine bone marrow was isolated as described in Section 2.1.2, counted and 
resuspended in DPBS at 5.0 x 10
7
 cells/mL. Prepared cells are kept on ice until 
needed.  
5.2.3.2 Bone marrow transplantation  
48 hours prior to transplantation, 6-8 week old recipient mice are placed on antibiotic 
water containing 400mg/L sulfamethoxazole and 80mg/L trimethoprim. Mice are 
lethally irradiated, receiving a single 1000cGy dose of gamma-irradiation (Stony 
Brook University Division of Laboratory Animal Resources (DLAR) cesium 
source). Following irradiation, mice are anesthetized using isoflurane and 5.0 x 10
6
 
cells, 0.1mL of the prepared cells described in Section 5.2.3.1, are injected retro-
orbitally into each mouse using a 28G½ insulin syringe. Antibiotic water is replaced 
every other day for two weeks post-transplant and every 3-4 days thereafter until 
mice are at least 90% reconstituted.      
5.2.3.3 Submandibular bleeds 
Mice are anesthetized using isoflurane and venesection is performed along the 
submandibular vein using a mouse-bleeding lancet (Goldenrod, MEDIpoint, Inc., 
Mineola, NY). Approximately 100μL of blood is collected into an EDTA containing 
blood collection tube (BD Biosciences) to prevent clot formation. A sterile gauze 
pad is applied to the wound with little pressure and bleeding ceases in under a 
minute if not immediately.    
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5.2.3.4 Determination of bone marrow chimerism  
50μL of peripheral blood collected via submandibular bleed as described in Section 
5.2.3.3 is added to 450μL of DPBS and then RBCs are lysed by addition of 4.5mL of 
a 0.8% NH4Cl, 0.1mM EDTA solution, vortexed and kept on ice for 5 minutes. The 
sample is then centrifuged at 500g and washed 3x with DPBS. Cells were then 
resuspended in 100μL DPBS + 1% BSA and dual stained with PE/Cy7 conjugated 
anti-mouse CD45.1 clone A20 (Biolegend, 110729) and Alexa Fluor 488
® 
conjugated anti-mouse CD45.2 clone 104 (Biolegend, 109815) antibodies at 1:100 in 
the dark at 25°C for 30 minutes. The staining reaction was stopped by addition of 
400μL of DPBS + 1% BSA and cells were then analysed using flow cytometry. 
5.2.4 Mpl cell surface expression on platelets  
Mouse platelets were obtained from blood collected from mice via cardiac puncture 
immediately following CO2 asphyxiation. Blood was drawn into a syringe containing 
acid citrate dextrose (ACD) (BD Biosciences), at a 1:9 ratio and diluted with an 
equal volume of Wash Buffer (150 mM NaCl, 20 mM Pipes, pH 6.5) and centrifuged 
at 60g for 10 min to isolate platelet rich plasma (PRP). To subsequently isolate 
platelets PRP was centrifuged at 240g for 10 min and resuspended in 1% NP-40 lysis 
buffer with inhibitors and subjected to western blot analysis (Section 2.5). 
5.2.5 JAK2V617F Expression  
Bone marrow neutrophils (BMNs) were isolated using a Neutrophil isolation kit 
according to the manufacturer’s protocol (Miltenyi Biotec) and mRNA was obtained 
using an RNeasy mini kit following the manufacturer’s protocol (Qiagen). cDNA 
was prepared as described in 2.3. Human/mouse JAK2 cDNA ratios were calculated 
using Taqman Gene Expression assays Hs01078117_m1 and Mm01208495_m1 
(Applied Biosystems) for human JAK2 and mouse Jak2, respectively. Standard curves 
were generated from linearized pcDNA3.1 plasmids containing either human JAK2 
or mouse Jak2. 
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5.3 Results 
5.3.1 Breeding of FF1+/-Tie2+/- mice 
To generate mice expressing JAK2
V617F
 in their HSCs, FF1
+/-
 mice were mated with 
Tie2-Cre
+/+
 mice. These matings generated desired FF1
+/-
Tie2
+/-
 mice and Tie2
+/-
 
littermate controls. Litters exhibit non-Mendelian patterns of inheritance with a 
prejudice against the FF1
+/-
Tie2
+/-
 genotype. Only 80 of 400 pups from 88 litters 
were FF1
+/-
Tie2
+/-
,
 
20% compared to the expected 50% (P<0.0001, two-tailed 
bionomial test) (Figure 5.4). Mean litter size was 4.8 with 54.75% females. This 
mouse has been previously characterized(149).  
 
5.3.2 Breeding of FF1+/-Tie2+/-Mpl-/- and FF1+/-Tie2+/-Mpl+/- mice 
Mice expressing JAK2
V617F
 in their HSCs in the absence of Mpl were generated as 
depicted in Figure 5.5. FF1 and Tie2-Cre mice were crossed with Mpl
-/-
 mice to 
generate FF1
+/-
Mpl
+/-
 and Tie2
+/-
Mpl
+/-
 mice. These mice were then bred to Mpl
-/-
 
mice to generate FF1
+/-
Mpl
-/-
 and Tie2
+/-
Mpl
-/-
 mice. To maximize the number of 
usable mice and to overcome the partial embryonic lethality of FF1
+/-
Tie2
+/-
 mice 
mentioned in 5.3.1, Tie2
+/-
Mpl
-/-
 mice were crossed to generate Tie2
+/+
Mpl
-/-
. 
Homozygosity for Tie2-Cre was determined using qPCR as described in 5.2.2.3. 
Finally, Tie2
+/+
Mpl
-/-
 mice were crossed with FF1
+/-
Mpl
-/-
 mice to generate FF1
+/-
Tie2
+/-
Mpl
-/-
 experimental mice along with Tie2
+/-
Mpl
-/-
 littermate controls as 
depicted in Figure 5.5. Litters exhibited non-Mendelian patterns of inheritance with 
only 14 pups born of 301 pups in 64 litters being FF1
+/-
Tie2
+/-
Mpl
-/-
, only 4.65%  
compared to the expected 50% (P<0.0001, two-tailed binomial test) (Figure 5.4). 
Mean litter size was 4.625 with 49.44% females.  Additionally, to generate FF1
+/-
Tie2
+/-
Mpl
+/-
 mice, FF1
+/-
Mpl
-/-
 mice were crossed with Tie2
+/+
 mice or FF1
+/-
 were 
crossed with Tie2
+/+
Mpl
-/-
 mice to generate FF1
+/-
Tie2
+/-
Mpl
+/-
 experimental mice and 
Tie2
+/-
Mpl
+/-
 littermate controls as depicted in Figure 5.6. Litters exhibited non-
Mendelian patterns of inheritance with only 8 pups born of 43 pups in 9 litters being 
FF1
+/-
Tie2
+/-
Mpl
+/-
, only 18.60%  compared to the expected 50% (P=0.0013, two-
tailed binomial test) (Figure 5.4). Mean litter size was 5 with 54.17% females. 
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Figure 5.4 Proportion of experimental mice born 
Proportion of (A) FF1
+/-
Tie2-Cre
+/-
 (B) FF1
+/-
Tie2-Cre
+/-
Mpl
+/-
 (C) FF1
+/-
Tie2-Cre
+/-
Mpl
-/-
 and (D) 
FF1
+/-
Tie2-Cre
+/-
Tpo
-/-
 mice born are shown in blue. Based on the experimental design, experimental 
mice are expected to consist of 50% of the litter.  
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Figure 5.6 Schematic Depicting Breeding Strategy to Generate JAK2
V617F+
Mpl
+/-
 
mice  
Mice generated during breeding of FF1
+/-
Tie2-Cre
+/-
Mpl
-/-
 mice were bred to generate FF1
+/-
Tie2-
Cre
+/-
Mpl
+/-
 mice and Tie2-Cre
+/-
Mpl
+/- 
littermate controls 
 
 
 
 
 
 
 
x 
 
 
 
 
 
 
Chapter 5 
 
129 
 
5.3.3 Mpl expression in FF1+/-Tie2+/-Mpl-/- and FF1+/-Tie2+/-Mpl+/- mice 
To confirm the phenotype of Mpl
-/- 
and Mpl
+/- 
mice, Mpl expression was analysed by 
western blot (Section 2.5) in platelets isolated from congenital FF1
+/-
Tie2
+/-
Mpl
-/-
, 
FF1
+/-
Tie2
+/-
Mpl
+/-
 and control mice. Platelet Mpl expression was halved in Mpl 
heterozygous (Mpl
+/-
) mice compared to WT mice and Mpl
-/-
 mice had undetectable 
levels of Mpl (Figure 5.7). Additionally, JAK2
V617F
 expression resulted in increased 
Mpl expression on both a WT and Mpl
+/-
 background (Figure 5.7). 
 
5.3.4 Breeding of FF1+/-Tie2+/-Thpo-/- mice 
Mice expressing JAK2
V617F
 in their HSCs in the absence of TPO were generated as 
depicted in Figure 5.8. The strategy for generating FF1
+/-
Tie2
+/-
Thpo
-/-
 mice is the 
same as discussed for FF1
+/-
Tie2
+/-
Mpl
-/-
 in 5.3.2 but in place of Mpl
-/-
 mice, here 
Thpo
-/-
 mice were used for breeding. Litters exhibit non-Mendelian patterns of 
inheritance with only 7 pups born of 76 pups in 22 litters being FF1
+/-
Tie2
+/-
Tpo
-/-
, 
only 9.21%  compared to the expected 50% (P<0.0001, two-tailed binomial test) 
(Figure 5.4). Mean litter size was 3.45 with 46.57% females. 
 
5.3.5 Plasma TPO levels in FF1+/-Tie2+/-Thpo-/- mice 
To confirm the phenotype of Thpo
-/-
 mice, plasma TPO levels were measured by 
ELISA as described in Section 2.8.  TPO levels in FF1
+/-
Tie2
+/-
Thpo
-/-
 mice were 
below the limit of detection confirming the absence of circulating TPO in mice on a 
Thpo
-/-
 background (Figure 5.9). TPO levels in FF1
+/-
Tie2
+/-
 mice were reduced 
compared to WT (Figure 5.9).  
 
5.3.6 JAK2V617F expression in neutrophils isolated from congenital FF1+/-
Tie2
+/-
Mpl
-/-
, FF1
+/-
Tie2
+/-
Mpl
+/-
 and FF1
+/-
Tie2
+/-
Thpo
-/-
 mice 
Levels of JAK2
V617F
 expression in the FF1
+/-
Tie2
+/-
 MPN mouse model has been 
previously reported(149). To ensure that manipulation of either Mpl or Thpo 
expression does not alter the level of JAK2
V617F
 expression, JAK2 expression in the 
generated models was tested as detailed in Section 5.2.5 by Dr. S. Leah Etheridge. 
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JAK2
V617F
 expression was comparable to endogenous Jak2. There was no significant 
difference in levels of hJAK2 expression between FF1
+/-
Tie2
+/-
, FF1
+/-
Tie2
+/-
Mpl
-/-
, 
FF1
+/-
Tie2
+/-
Mpl
+/-
 and FF1
+/-
Tie2
+/-
Thpo
-/-
 mice (Figure 5.10). 
5.3.7 Generation of FF1+/-Tie2+/-Mpl-/- mice through bone marrow 
transplantation 
To generate JAK2
V617F+
Mpl
-/-
 transplant mice, FF1
+/-
Tie2
+/-
Mpl
-/-
 donor marrow was 
transplanted into Mpl
-/-
 recipients. Due to its critical role in hematopoiesis, Mpl
-/-
 
marrow has severely decreased repopulating activity(96). Therefore, to ensure 
engraftment of donor marrow and rather than recovery of recipient marrow, donor 
cells lacking Mpl were transplanted into Mpl
-/-
 recipients rather than WTs. Control 
transplants were also performed and include WT into WT, FF1
+/-
Tie2
+/- 
into WT, and 
Mpl
-/- 
into Mpl
-/-
 as summarized in Figure 5.11. Chimerism was checked by flow 
cytometry and control mice were at least 90% reconstituted by 8 weeks post-
transplant (Figure 5.12). Despite successful colonization of Mpl
-/-
 or JAK2
V617F+
Mpl
-
/-
 donor marrow in irradiated WT recipients, there was a significantly increased death 
rate when Mpl
-/-
 or JAK2
V617F+
Mpl
-/-
 donor marrow was transplanted into Mpl
-/-
 
recipients compared to other transplant groups (Figure 5.13).  
5.3.8 Generation of FF1+/-Tie2+/-Thpo-/- mice through bone marrow 
transplantation 
To generate JAK2
V617F+
Thpo
-/-
 transplant model, FF1
+/-
Tie2
+/-
Thpo
+/+
 bone marrow 
was transplanted into Thpo
-/-
 recipients. As TPO is synthesized primarily in the liver, 
transplantation into a Thpo
-/-
 background results in a functionally Thpo
-/-
 mouse. 
Control transplants were also performed and include WT into WT, FF1
+/-
Tie2
+/- 
into 
WT and WT into Thpo
-/-
 as summarized in Figure 5.11. Chimerism was checked by 
flow cytometry and control mice were at least 90% reconstituted by 8 weeks post-
transplant (Figure 5.12). 
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Figure 5.7 Murine platelet Mpl expression  
Western blot analysis of MPL on platelets from WT, JAK2V617F
+
 (VF
+
), Mpl
+/-
, JAK2V617F
+
Mpl
+/-
 
(VF
+
Mpl
+/-
), Mpl
-/-
 and JAK2V617F
+
Mpl
-/-
 (VF
+
Mpl
-/-
) mice at 16 weeks of age. Numbers represent 
densitometric quantification of protein levels normalized to WT.   
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Figure 5.9 Plasma TPO levels  
Plasma TPO levels in Tpo transgenic mice. Plasma was collected from 16-week old WT, JAK2
V617F+
 
(VF
+
), Tpo
-/-
 and JAK2
V617F+
Tpo
-/-
 mice and TPO levels were quantified by ELISA. Each data point 
represents a single mouse and bars are presented as mean ±s.e.m; asterisks indicate significance 
compared to WT. 
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Figure 5.10 Human JAK2
V617F+
 expression relative to endogenous mouse JAK2
WT  
qPCR quantification of human JAK2V617F expression relative to endogenous mouse Jak2 expression 
in neutrophils from WT, JAK2V617F
+
 (VF
+
), JAK2V617F
+
Mpl
+/-
 (VF
+
Mpl
+/-
), JAK2V617F
+
Mpl
-/-
 
(VF
+
Mpl
-/-
) and JAK2V617F
+
Tpo
-/-
 mice. Data is normalized to VF
+
 and presented as mean ±s.e.m.   
This work was performed by Dr. S Leah Etheridge. 
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Figure 5.11 Generation of JAK2
V617F+
Mpl
-/-
 and JAK2
V617F+
Tpo
-/-
 mice by 
transplantation. 
Bone marrow transplants were utilized to generate JAK2
V617F+
Mpl
-/-
 and JAK2
V617F+
Tpo
-/-
 mice to 
better simulate acquisition of the JAK2
V617F
 mutation.  
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Figure 5.12 Representative chimerism plots for JAK2
V617F+
Mpl
-/-
 and 
JAK2
V617F+
Tpo
-/- 
transplant models 
Peripheral blood was analysed by flow cytometry for CD45.1 vs CD45.2 expression in transplant 
models where possible. (A) Control samples. (B) Transplants for generation JAK2
V617F+
Mpl
-/-
 and 
JAK2
V617F+
Tpo
-/-
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Figure 5.13 Survival proportions for JAK2
V617F+
Mpl
-/-
 and JAK2
V617F+
Tpo
-/-
 
transplant mice. 
Survival of transplant mice was monitored for 16 weeks post-transplant (112 days) and subjected to 
Kaplan-Meier survival analysis. Overlapping curves have been nudged for ease of viewing. 
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5.4 Discussion   
5.4.1 FF1+/-Tie2+/-, FF1+/-Tie2+/-Mpl-/-, FF1+/-Tie2+/-Mpl+/- and                    
FF1
+/-
Tie2
+/-
Tpo
-/- 
mice exhibit non-Mendelian patterns of inheritance  
Although generation of FF1
+/-
Tie2
+/-
, FF1
+/-
Tie2
+/-
Mpl
-/-
, FF1
+/-
Tie2
+/-
Mpl
+/-
 and                    
FF1
+/-
Tie2
+/-
Tpo
-/- 
mice was successful, the number of viable experimental mice 
generated was vastly disproportionate from that expected based on the breeding 
scheme. There was no report of non-Mendelian inheritance patterns when the FF1 
mouse was originally generated or subsequently mated with Vav-Cre or Mx-Cre to 
generate FF1/Vav-Cre and FF1/Mx-Cre mice, respectively(191). Genetic analysis of 
FF1
+/-
Tie2
+/-
 mice reveals non-Mendelian inheritance. The average litter size 
reported for C57BL/6J mice by Jackson Laboratories is 4.9 
(http://ko.cwru.edu/info/breeding_strategies_manual.pdf), which is similar to the 
average litter sizes observed from mating pairs generating FF1
+/-
Tie2
+/-
,  FF1
+/-
Tie2
+/-
Mpl
-/-
 and FF1
+/-
Tie2
+/-
Mpl
+/-
 mice. Therefore, the non-Mendelian pattern of 
inheritance exhibited for these matings may not be a result of embryos being 
prematurely resorbed in utero. In contrast, average litter size is reduced in matings 
generating FF1
+/-
Tie2
+/-
Tpo
-/-
 mice. Thus, it is possible that a small amount of 
embryonic lethality is occurring. However, this average is similar to the average 
litter size for generation of Tpo
-/-
 mice, which is 3.8 for our colony, suggesting that 
the decreased litter size is not due to embryonic lethality resulting from expression of 
JAK2
V617F
. The decreased litter size for Tpo
-/-
 compared to Mpl
-/-
 mice is not 
unexpected as there are a number of clinical mutations that have been described in 
MPL(56,98) causing CAMT eventually resulting in complete bone marrow failure, 
yet there is only one report of a mutation in TPO able to recapitulate the disease(76).  
As TPO and MPL comprise of the same signalling axis, this suggests that although 
MPL mutations are detrimental, it is possible that mutations in TPO are lethal. 
Although it seems that introduction of the JAK2
V617F
 mutation is not causing 
abortion and resorption of embryos, it cannot be ruled out. The Tie2 promotor is 
active in the haemangioblast(287), a precursor to HSCs and endothelial 
cells(Reviewed in (30)), and inducing JAK2
V617F
 expression so early on in our mouse 
model could be developmentally detrimental. Studies of angiogenesis in MPNs 
revealed increased microvessel density (MVD) in MPN patients(245). Additionally, 
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CD105
+
-MVD, which are indicative of newly formed vessels, correlates with 
JAK2
V617F
 allele burden(291). It is possible that because JAK2
V617F
 is being 
expressed during early development in our congenital models, it results in 
dysregulated angiogenesis resulting in loss of embryos. Introduction of JAK2
V617F
 
during adulthood, as modelled via our transplant models, does not result in death 
resulting from introduction of the mutant JAK2. Although this suggests a defect 
resulting from early expression of JAK2
V617F
; the actual effects on embryonic 
development have not been assessed.  
 
It is notable that platelet counts for FF1
+/-
Tie2
+/- 
at 4 weeks are indistinguishable to 
counts from WT mice suggesting the possibility that FF1
+/-
Tie2
+/-
 mice having a 
more severe phenotype are naturally aborted prior to birth. Additional genetic 
experiments would need to be performed to determine the cause of the non-
Mendelian inheritance pattern observed in FF1
+/-
Tie2
+/-
, FF1
+/-
Tie2
+/-
Mpl
-/-
, FF1
+/-
Tie2
+/-
Mpl
+/-
 and FF1
+/-
Tie2
+/-
Tpo
-/- 
mice.   
 
5.4.2 Mpl expression is increased when JAK2V617F is co-expressed 
In FF1
+/-
Tie2
 +/-
 mice, Mpl expression is increased when JAK2
V617F 
is co-expressed. 
This is in contrast to a report that Mpl can be downregulated specifically by 
JAK2
V617F
(292). Additionally, reduced MPL expression has been reported in platelets 
and megakaryocytes of MPN patients(238-241). However, MPL expression in these 
patients was assessed after development of the disease; therefore, it is difficult to 
distinguish if reduced MPL expression is a contributing factor or consequence of 
MPN development. Later studies reported heterogeneity of MPL expression within 
patients(243-247). Thus, the correlation between MPL expression in MPNs remains 
weak. It is possible that in our mice, the expression of human JAK2
V617F
 in addition 
to expression of endogenous mouse Jak2 results in the observed increase in MPL as 
JAK2 acts to stabilize the receptor(255). Another possibility is that Mpl expression 
decreases with disease progression. We have only examined expression at a single 
time point; however, monitoring MPL over time in our model or in patients will 
provide important information about the relationship between MPL and disease 
progression. Although this has not been performed in this study, it is currently under 
investigation.  
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5.4.3 JAK2V617F expression levels in FF1+/-Tie2+/- mice is physiological and is 
unaltered upon modulation of Mpl or Tpo expression  
Since the identification of JAK2
V617F
 in 2005, a number of mouse models have been 
developed in an effort to better understand the underlying mechanisms associated 
with disease development and progression (Reviewed in (293)). The earliest models 
utilized BM transplantation of retrovirally transduced BM cells. Although these 
studies were able to show that JAK2
V617F
 expression is sufficient for MPN 
development in mice, expression levels were varied and sometimes super-
physiological(186-189). However, in the FF1 mouse generated by Tiedt et al, 
expression of JAK2
V617F
 remains under the control of the minimal JAK2 promotor. 
Therefore, when the FF1 mouse was crossed with either VavCre or MxCre mice, 
mutant JAK2 expression was less than half of or equal to endogenous Jak2, 
respectively. This is in stark contrast to the three-fold higher expression of mutant 
JAK2 reported in retrovirally transduced BM(191). JAK2
V617F
 expression in FF1
+/-
Tie2
+/- 
mice was comparable to endogenous Jak2, mirroring the ratio of JAK2
V617F
 to 
JAK2
WT
 reported in granulocytes of ET patients(191). This level of expression  
supports the ET-like phenotype observed in FF1
+/-
Tie2-Cre
+/-
 mice(149).  
 
In approximately 30% of PV patients, a mitotic recombination event results in 
duplication event resulting in homozygosity for JAK2
V617F
(179-181,285).  Although 
these patients have progenitor cells that are homozygous for JAK2
V617F
, overall they 
exhibit a combination of homozygous, heterozygous and WT progenitors(294). 
Based on the breeding strategy to generate JAK2
V617F
 (FF1
+/-
Tie2-Cre
+/-
) mice in this 
study, it is expected that the mice are heterozygous for the mutant allele. 
Homozygosity resulting from a gene duplication event was not analysed. The 
JAK2
V617F
 mutation however, was present in all granulocyte-macrophage progenitors 
tested. Although this is not common in MPN patients, it is conceivable that in a truly 
clonal disorder, expression of mutant JAK2 is present in the majority of cells. 
Additionally, because there is a selective advantage for mutant progenitors(294), 
with time, the proportion of JAK2
V617F
-positive cells predominates(183). In fact, 
there are clinical reports of JAK2
V617F
 expression in 100% of tested 
progenitors(183,295,296).  
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5.4.4 Transplantation models of JAK2V617FMpl-/- mice exhibit decreased 
survival  
To mimic the conditions of an acquired mutation, BM transplants were performed to 
introduce JAK2
V617F
 in the bone marrow of adult WT, Mpl
-/-
 or Tpo
-/-
 mice. WT and 
Tpo
-/-
 recipient mice were largely unaffected by irradiation and transplantation. In 
contrast, Mpl
-/- 
mice exhibited decreased survival post-transplantation despite 
achieving at least 90% chimerism. It is likely that this is due to stem cell exhaustion. 
Although Mpl
-/-
 mice are able to survive to adulthood without overt complications, 
humans lacking expression of functional MPL develop CAMT and suffer from stem 
cell exhaustion in childhood, necessitating a bone marrow transplant(98). When  
Mpl
-/-
 bone marrow is transplanted into irradiated recipients, it must repopulate the 
BM compartment. As a high percentage of chimerism is achieved, these cells are 
capable of differentiation to fulfil this role. However, because MPL is necessary for 
maintenance of HSCs(94), it is possible that the capacity of the original pool of 
HSCs from the Mpl
-/-
 mice to maintain normal haematopoiesis is diminished 
resulting in bone marrow failure and subsequent death.  
 
Despite the unexpected non-Mendelian inheritance patterns observed for JAK2
V617F+
 
mice, in this chapter, we have generated viable JAK2
V617F+
Mpl
+/-
, JAK2
V617F+
Mpl
-/- 
and JAK2
V617F+
Tpo
-/-
 mice by genetic crossings. Additionally, we have generated 
JAK2
V617F+
Mpl
-/- 
and JAK2
V617F+
Mpl
-/- 
mice by transplantation to recapitulate 
acquisition of the mutation as with the human disease. These mouse models will 
allow us to study the roles of MPL and TPO in MPNs in vivo.
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CHAPTER 6 THE ROLE OF THROMBOPOIETIN 
AND MPL IN MYELOPROLIFERATIVE NEOPLASM 
DEVELOPMENT IN VIVO 
4.  
6.1 Experimental Rationale  
Results from the previous chapter demonstrate that MPL expression is necessary for 
JAK2
V617F
-mediated signalling and proliferation in cell lines, the in vitro correlate of 
myeloproliferation in vivo. However, its role in MPN development in vivo has yet to 
be demonstrated.  Therefore, in this chapter, we sought to determine the role of MPL 
in MPN development utilizing a JAK2
V617F
-positive MPN mouse model. 
Additionally, since TPO was able to induce a higher level of JAK/STAT signalling 
in the presence of JAK2
V617F
, the role of TPO was also determined.  
6.2 Materials and Methods 
6.2.1 Complete blood counts  
Whole blood was collected by submandibular bleeds, as described in 4.2.3.3, were 
used to perform complete blood counts. Counts were performed on a Hemavet
®
950 
(Drew Scientific, Inc., Miami Lakes, FL, USA), which draws 20μL of whole blood 
for each count directly from the blood collection tube. To ensure accurate and 
consistent results, prior to each round of counts, a background read was taken 
followed by a count using a fixed mouse blood control from the manufacturer, which 
was then compared to known values. Complete counts include white blood cells 
(WBC), neutrophil (NE) count and percentage, lymphocyte (LY) count and 
percentage, monocyte (MO) count and percentage, eosinophil (EO) count and 
percentage, basophil (BA) count and percentage, red blood cells (RBC), 
haemoglobin (Hb), haematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration 
(MCHC), red blood cell distribution width (RDW),  platelet count (PLT) and mean 
platelet volume (MPV).  
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6.2.2 Colony Forming Cell Assay 
Myeloid colony forming assays were performed in methylcellulose-based medium 
containing 15% FBS, 2% BSA, 2mM L-glutamine, 5 x 10
-5
M β-ME, 10µg/mL rh-
insulin and 200µg/mL human transferrin in the presence or absence of 50ng/mL 
recombinant murine rmSCF, 10ng/mL rmIL-3, 10ng/mL rmIL-6 and 5IU/mL rhEpo 
(R&D Systems). Bone marrow cells were harvested as described in Section 2.1.2 and 
plated at 1 x 10
4
 per dish in triplicate. Plates were incubated at 37ºC with 5% CO2 
for 7 days at which point colonies were scored by morphology. Single colonies were 
harvested from plates and lysed for mRNA analysis as previously described(149). 
Megakaryocyte colony forming assays were performed in collagen-containing 
medium containing 1% BSA, 10µg/mL rh insulin, 200µg/mL iron saturated human 
transferrin, 4% lipid solution, 1 x 10
-4
M β-ME, 2mM L-glutamine (MegaCult™-C 
Collagen and Medium with Lipids; Stem Cell Technologies) in the presence or 
absence of 50ng/mL rhTPO and 10ng/mL rmIL-3. Bone marrow cells were plated at 
1 x 10
5
 per well of a double chamber slide (Stem Cell Technologies) in duplicate and  
incubated at 37ºC with 5% CO2 for 7 days. Colonies were dehydrated, fixed in 
acetone and stained for 6 hours in acetylthiocholine iodide (Sigma-Aldrich) 
following the manufacturer’s suggested protocol prior to scoring.  
6.2.3 Flow Cytometry  
E-SLAM HSC enumeration: Murine BM cells were harvested as described in 
Section 2.1.2. Red blood cells were lysed at 4ºC for 10min using a 1:10 
DPBS:ammonium chloride solution (15.5mM NH4Cl, 1.2mM NaHCO3, 0.1mM 
EDTA) followed by 3 washes with DPBS. 5 x 10
6
 cells were stained using CD45 
(Clone 104) (Biolegend, San Diego, CA, USA), EPCR(CD201) (Clone eBio1560), 
CD48 (Clone HM48-1) and CD150 (Clone mShad150) (eBioscience, San Diego, 
CA, USA) antibodies. CD45
+
EPCR(CD201)
+
CD48
-
CD150
+
 cells were considered 
E-SLAM
+
. Spleen erythroblast determination: Murine spleens were obtained and 
homogenized. Single cell suspensions were obtained by syringe filter through a 
100µm filter basket. A red cell lysis was performed and cells were stained with 
antibodies to murine TER119 and CD71 (Clone RI7217) (Biolegend).  Flow 
cytometric analysis was performed on a BD Accuri C6 Flow Cytometer (BD 
Biosciences) using FCS express software (De Novo Software, Glendale, CA, USA). 
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6.2.4 Histology 
For histological analysis of bone marrow, femurs were collected and epiphyses were 
removed, bones were then fixed in 4% paraformaldehyde for 24 hours and 
decalcified using Richard-Allan Scientific™ Decalcifying Solution (Thermo 
Scientific) following manufacturer’s instructions. Paraffin sections (5-μm thickness) 
were stained with haematoxylin and eosin (H&E). For analysis of spleens, spleens 
were harvested and weighed. To control for differences resulting from intrinsic 
differences in size between males and females, spleens weights are represented as 
percent total body weight.   
6.3 Results 
6.3.1 Mpl and Tpo are necessary for development of JAK2V617F-positive 
MPNs 
Transgenic mice expressing human JAK2
V617F
(149) were studied in an Mpl 
homozygous null (JAK2
V617F+
Mpl
-/-
), Mpl heterozygous (JAK2
V617F+
Mpl
+/-
) or Tpo 
homozygous null (JAK2
V617F+
Tpo
-/-
) background. Platelet MPL expression was 
halved in Mpl heterozygous (Mpl
+/-
) mice compared to Mpl homozygous WT mice 
(WT) (Figure 5.7). Additionally, JAK2
V617F
 expression resulted in increased Mpl 
expression (Figure 5.7).  Levels of JAK2
V617F 
cDNA ranged from 10% to 50% that of 
the endogenous murine JAK2(149), close to that expected in blood cells of patients 
with MPNs expressing a single copy of the mutant kinase.  
 
JAK2
V617F
 expression in HSCs resulted in MPN development by 12 weeks of age 
with a significant increase in platelet (Figure 6.1A) and neutrophil count (Figure 
6.1B) but no change in haematocrit or red blood cell count (Figure 6.1C and Figure 
6.2) compared to WT.  
 
Despite JAK2
V617F
 expression, in the complete absence of Mpl (JAK2
V617F+
Mpl
-/-
) the 
mice remained thrombocytopenic, with platelet levels similar to that of Mpl
-/-
 
controls (Figure 6.1A). When Mpl expression was halved (JAK2
V617F+
Mpl
+/-
), 
platelet counts were significantly decreased compared to JAK2
V617F+
 controls, to 
levels comparable with WT mice (Figure 6.1A). Neutrophil counts were also reduced  
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Figure 6.1 Platelets, neutrophils and haematocrit of congenital JAK2
V617F
Mpl 
and JAK2
V617F
Tpo mice 
(A) Platelet (B) neutrophil counts and (C) haematocrit were monitored for 16 weeks after birth in WT, 
JAK2V617F
+
 (VF
+
), JAK2V617F
+
Mpl
+/- 
(VF
+
Mpl
+/-
), JAK2V617F
+
Mpl
-/-
 (VF
+
Mpl
-/-
) and JAK2V617F
+
Tpo
-
/-
 (VF
+
Tpo
-/-
) mice. Data are presented as mean ±s.e.m; n = 3-9 mice per time point. 
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in JAK2
V617F+
Mpl
+/-
 compared to JAK2
V617F+
 mice, but were significantly higher than 
WT controls at 16 weeks (Figure 6.1B). Tpo ablation (JAK2
V617F+
Tpo
-/-
) also 
significantly decreased platelet number compared to JAK2
V617F+
 controls. However, 
expression of JAK2
V617F
 was able to increase platelet counts over time to levels 
comparable to WT levels (Figure 6.1A). Neutrophil counts, haematocrit and red 
blood cell counts in JAK2
V617F+
Tpo
-/- 
mice were not significantly different from WT 
(Figure 6.1B-C and Figure 6.2).  
 
The uptake and destruction of TPO by platelet MPL is a major regulator of 
circulating TPO blood levels(297). As expected, the thrombocythaemia observed in 
JAK2
V617F+
 mice resulted in reduced TPO plasma levels, whereas Mpl
-/- 
and
 
JAK2
V617F+
Mpl
-/-
 mice showed significantly increased plasma TPO levels (Figure 
6.4). Mpl
+/-
 and JAK2
V617F+
Mpl
+/-
 mice show a slight increase compared to WT and 
JAK2
V617F+
 mice and Tpo
-/-
 mice are completely TPO deficient (Figure 6.4). 
Increased bioavailability of TPO may provide a potential explanation as to why the 
JAK2
V617F+
Mpl
+/-
 mice display a moderate increase in platelet and neutrophil counts 
at 16 weeks (Figure 6.1A-B) and is also demonstrated by the increased baseline 
platelet count in Mpl
+/-
 mice, compared to Mpl
-/- 
mice.  
 
We previously reported that this JAK2
V617F+
 mouse model develops splenomegaly 
with abnormal splenic architecture, elevated number of megakaryocytes and 
significant expansion of primitive (TER-119
+
 CD71
+
) and more mature (TER-119
+
 
CD71
-
) erythroblasts in the spleen(149). In the absence of, or with reduced 
expression of Mpl, splenomegaly was significantly reduced (P = 0.0166 and P = 
0.0181, respectively compared to JAK2
V617F+
 by one-way ANOVA; Figure 6.5E-F). 
Removal of Mpl (JAK2
V617F+
Mpl
-/-
) significantly decreased the number of splenic 
megakaryocytes (Figure 6.6A-B) and splenic erythrocyte expansion was reduced in 
JAK2
V617F+
Mpl
-/-
 and JAK2
V617F+
Mpl
+/-
 mice (Figure 6.7). Conversely, removal of 
Tpo was not effective in reducing spleen size and weight as evidenced in our 
JAK2
V617F+
Tpo
-/- 
mice (Figure 6.5). Splenic megakaryocytes were more prevalent in 
JAK2
V617F+
Tpo
-/-
 compared to JAK2
V617F+
 mice although average megakaryocyte size 
was reduced (Figure 6.6A-C). We also observed an expansion of splenic TER-119
+
 
CD71
+
 erythroid progenitors in these mice (Figure 6.7). 
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Figure 6.2 Blood counts for JAK2
V617F+
Mpl
+/-
 and JAK2
V617F+
Mpl
-/-
 mouse 
models. 
Blood counts were monitored in WT, JAK2
V617F+
 (VF
+
), Mpl
+/-
, JAK2
V617F+
Mpl
+/-
 (VF
+
Mpl
+/-
), Mpl
-/-
 
and JAK2
V617F+
Mpl
-/-
 (VF
+
Mpl
-/-
) mice over a 16-week period. Data are presented as mean ±s.e.m; n = 
3-9 mice per time point. 
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Figure 6.3 Blood counts for a JAK2V617F+Tpo-/- MPN mouse model. 
Blood counts were monitored over a 16-week period in WT, JAK2
V617F+
 (VF
+
), Tpo
-/-
 and 
JAK2
V617F+
Tpo
-/-
 mice. WT and VF
+
 counts are the same in Supplemental Figure 2 for comparison 
purposes. Data are presented as mean ±s.e.m; n = 3-7 mice per time point. 
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Figure 6.4 Plasma TPO levels in congenital JAK2
V617F
Mpl and JAK2
V617F
Tpo 
mice 
Plasma TPO levels in Mpl and Tpo transgenic mice. Plasma was collected from 16-week old WT, 
JAK2
V617F+
 (VF
+
), Mpl
+/-
, JAK2
V617F+
Mpl
+/-
 (VF
+
Mpl
+/-
), Mpl
-/-
, JAK2V617F
+
Mpl
-/-
 (VF
+
Mpl
-/-
), Tpo
-/-
 
and JAK2
V617F+
Tpo
-/-
 mice and TPO levels were quantified by ELISA. Each data point represents a 
single mouse and bars are presented as mean ±s.e.m; asterisks indicate significance compared to WT. 
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Figure 6.5 Spleens of congenital JAK2
V617F
Mpl and JAK2
V617F
Tpo mice 
Representative spleens and weights of spleens harvested from 16 week old mice. Data are presented 
as mean ±s.e.m; n = 3-9 mice per time point. Scale bar, 3mm. 
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Figure 6.6 Spleen megakaryocyte analysis  
(A) Representative H&E and vWF stained spleen sections from JAK2
V617F+
 mouse models with 
megakaryocyte (B) count and (C) size. Scale bar, 50µm. Bars are presented as mean ±s.e.m ; asterisks 
indicate significance compared to WT, ***P ≤ 0.001, **P ≤ 0.01 and *P ≤ 0.05 by one-way ANOVA. 
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Figure 6.7 Analysis of mouse spleen erythroid progenitors 
TER119 and CD71 antibody labeling and flow cytometric analysis revealed significant differences in 
the proportion of TER119
+
CD71
+
 cells in spleens of transgenic MPN mouse models at 16 weeks. An 
increase in expression of TER119
+
CD71
+
 cells indicates an increase in more primitive erythroblasts 
compared to TER119
+
CD71
-
 cells. 
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Bone marrow progenitor cells were analysed by colony forming unit (CFU) assays in 
the presence or absence of cytokine. In WT mice, the expression of JAK2
V617F
 
significantly increased the number of cytokine-dependent (Figure 6.8A) and 
cytokine-independent (Figure 6.8B) marrow progenitor cells. However, removal of 
Mpl (JAK2
V617F+
Mpl
-/-
) resulted in CFU numbers being dramatically reduced both in 
the presence or absence of cytokine to levels not significantly different to those 
found in WT marrow (Figure 6.8A-B). Consistent with the observed 
thrombocytopenia, JAK2
V617F+
Mpl
-/-
 mice exhibited an almost complete ablation of 
megakaryocyte progenitors, CFU-MK (Figure 6.8C). A similar phenotype was 
observed in factor-dependent colony formation in marrow from JAK2
V617F+
Mpl
+/-
 
mice (Figure 6.8A), although in the absence of cytokine, CFU numbers were similar 
to JAK2
V617F+
 controls (Figure 6.8B), potentially accounting for the neutrophilia 
observed in these mice at 16 weeks (Figure 6.1B). CFU-MK in JAK2
V617F+
Mpl
+/- 
mice
 
and Mpl
+/-
 controls were not significantly different to WT (Figure 6.8C). In the 
absence of cytokine, CFU numbers for Tpo
-/-
 and JAK2
V617F+
Tpo
-/-
 mice were 
significantly reduced compared to JAK2
V617F+
 controls (P < 0.0001 and P = 0.0014, 
respectively compared to JAK2
V617F+
 by one-way ANOVA; Figure 6.8B). 
Megakaryocyte progenitors of JAK2
V617F+
Tpo
-/-
 mice were significantly increased 
compared to WT; however, there were still significantly less CFU-MK compared to 
JAK2
V617F+ 
mice (P = 0.0013 compared to JAK2
V617F+
 by one-way ANOVA; Figure 
6.8C). Of note, the observed reduction/elimination of JAK2
V617F
-induced pathology 
was achieved despite expression of comparable levels of mutant JAK2 in all of the 
JAK2
V617F+
 mouse lines (Figure 5.10).  
 
Histological analysis of bone marrow sections showed a dramatic increase in the 
number of megakaryocytes in JAK2
V617F+
 mice compared to WT, an effect that was 
completely ablated in JAK2
V617F+
Mpl
+/-
 and JAK2
V617F+
Mpl
-/-
 mice (Figure 6.9A-B). 
Similar to our previous results, JAK2
V617F+
Mpl
+/-
 and JAK2
V617F+
Mpl
-/-
 appeared 
analogous to WT and Mpl
-/-
, respectively.  JAK2
V617F+
Tpo
-/-
 mice showed an increase 
in the number of megakaryocytes compared to WT, which is consistent with the 
increase in CFU-MK. However, mature marrow megakaryocyte number was still 
significantly less than in JAK2
V617F+
 marrow (P < 0.001 compared to JAK2
V617F+
 by 
one-way ANOVA; Figure 6.9A-B). In the absence or reduction of Mpl and absence 
of Tpo, megakaryocyte size was significantly reduced (Figure 6.9C), consistent with  
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Figure 6.8 Progenitor cell analysis in congenital JAK2
V617F
Mpl and 
JAK2
V617F
Tpo mice 
Data was collected from 16 week old WT , JAK2
V617F+
, Mpl
+/-
, JAK2
V617F+
Mpl
+/-
, Mpl
-/-
, 
JAK2
V617F+
Mpl
-/-
, Tpo
-/-
 and JAK2
V617F+
Tpo
-/-
 mice. (A) Number of progenitor cells present per 2 x 10
4
 
marrow cells as determined by CFU assays in the presence and (B) absence of cytokine. Data are 
presented as mean ±s.e.m; n = 3-5. (C) CFU-MK per 1 x 10
5
 marrow cells as determined by Megacult 
assays in the presence of cytokine. Data are presented as mean ±s.e.m. n = 3-5. 
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Figure 6.9 Bone marrow histology in congenital JAK2
V617F
Mpl and 
JAK2
V617F
Tpo mice 
Data was collected from 16 week old WT , JAK2
V617F+
, Mpl
+/-
, JAK2
V617F+
Mpl
+/-
, Mpl
-/-
, 
JAK2
V617F+
Mpl
-/-
, Tpo
-/-
 and JAK2
V617F+
Tpo
-/-
 mice. (A) Representative H&E stained sections of bone 
marrow with (B) megakaryocyte count and (C) size. Scale bar, 50μm.  
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previous reports(298). This effect was overcome by presence of JAK2
V617F
 (Figure 
6.9C). Despite increases in megakaryocyte number in bone marrow of these mice, 
there was no detectable fibrosis of the marrow (Figure 6.10).   
 
Taken together, these data clearly demonstrate that MPL is essential in MPN 
progression. Specifically, the JAK2
V617F
-mediated MPN in this murine model fails to 
develop in the absence of Mpl; however, the disease was only nominally attenuated 
in the absence of Tpo. Importantly, we also demonstrate that reducing Mpl 
expression significantly attenuates MPN progression in JAK2
V617F+
 mice, indicating 
that Mpl is a limiting factor for JAK2
V617F
-driven MPNs.  
6.3.2 Attenuation of JAK2V617F-positive MPNs through removal of Tpo or 
Mpl is not a result of dysfunctional primitive haematopoiesis. 
Mpl is expressed in primitive HSCs during embryogenesis and is also critical in the 
establishment of normal adult haematopoiesis(299). To ensure that the effects we 
observed in the JAK2
V617F+
Mpl
-/-
 mice were not a result of dysfunctional primitive 
haematopoiesis, we performed a series of BM transplantation experiments using 
JAK2
V617F+
 and JAK2
V617F+
Mpl
-/-
 adult donor marrow cells. This allowed us to 
specifically determine the consequences of introducing the JAK2
V617F
 mutation 
during adulthood, therefore better reflecting the development of the human disease 
through acquisition of a somatic mutation in JAK2.  
 
Due to its critical role in haematopoiesis, Mpl
-/-
 marrow has severely decreased 
repopulating activity(96). Therefore, to ensure that the observed effects were due to 
engrafted donor marrow and not due to recovery of recipient marrow, donor cells 
lacking Mpl were transplanted into Mpl
-/-
 recipients rather than WT recipients. To 
generate a JAK2
V617F+
Tpo
-/- 
transplant model, JAK2
V617F+
Tpo
+/+
 marrow cells were 
transplanted into Tpo
-/-
 recipients. As TPO is synthesized primarily in the liver, 
transplantation into a Tpo
-/-
 background results in a functionally Tpo
-/-
 mouse, 
although it is theoretically possible that engraftment of stromal cells from the 
JAK2
V617F+
Tpo
+/+
 marrow could supply a very low level of TPO in our mouse 
model(300). In control mice, chimerism was confirmed at 4 weeks and periodic 
monitoring verified it was maintained at an average of 95%±SD. Similar to the 
congenital JAK2
V617F+
 mutants, WT recipient mice transplanted with JAK2
V617F+
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marrow developed a MPN by 12 weeks post-transplant, shown by increased platelet 
(Figure 6.11A) and neutrophil counts (Figure 6.11B). However, transplantation of 
JAK2
V617F+
Mpl
-/-
 donor marrow (VF
+
Mpl
-/-
 into Mpl
-/-
) failed to drive the 
development of a MPN (Figure 6.11A-B). Such transplant mice remained severely 
thrombocytopenic while neutrophil, haematocrit and red blood cells counts were not 
significantly different to WT (Figure 6.11A-C and Figure 6.12). In a Tpo
-/-
 
background, introduction of JAK2
V617F
 by transplantation (VF
+
 into Tpo
-/-
) was 
unable to generate a severe MPN, but did drive platelet production to levels 
comparable with WT (Figure 6.11A-C and Figure 6.13). The increased platelet count 
was accompanied by an increase in neutrophil count at 16 weeks post-transplant 
(Figure 6.11B).    
 
Splenomegaly present in the JAK2
V617F+
 into WT transplant mice was not observed in 
the JAK2
V617F+
Mpl
-/-
 into Mpl
-/-
 mice or JAK2
V617F+
 into Tpo
-/-
 transplants (Figure 
6.14). Additionally, consistent with the blood counts, colony assays in the presence 
of cytokines demonstrated a significant increase in JAK2
V617F+
 into WT bone marrow 
progenitors compared to WT into WT, JAK2
V617F+
Mpl
-/-
 into Mpl
-/-
 and JAK2
V617F+
 
into Tpo
-/-
 mice (Figure 6.15A). The effect on the development of progenitor cells 
was even more apparent when cells were cultured in the absence of cytokine, with an 
approximate 10-fold decrease in the number of colonies developing from marrow 
derived from JAK2
V617F+
Mpl
-/-
 into Mpl
-/-
 transplant mice compared to marrow from 
JAK2
V617F+ 
into WT controls (Figure 6.15B). In the absence of cytokine, JAK2
V617F+
 
into Tpo
-/-
 mice show a significant decrease in the number of colonies that developed 
compared to JAK2
V617F+
 into WT animals (P = 0.0068; Figure 6.15B).  
 
In JAK2
V617F+
Mpl
-/-
 into Mpl
-/-
mice, CFU-MK were depleted compared to JAK2
V617F+
 
into WT controls (Figure 6.15C), again demonstrating the importance of Mpl in 
JAK2
V617F+
 MPNs. In WT into Tpo
-/-
 mice, CFU-MK were similarly depleted; 
however, in JAK2
V617F+
 into Tpo
-/-
 mice, counts were comparable with WT into WT 
controls (Figure 6.15C). Consistent with the high platelet count, histological 
examination of JAK2
V617F
 into WT showed greatly elevated numbers of 
megakaryocytes present in the bone marrow (Figure 6.16A-B). However, this effect 
was absent in JAK2
V617F+
Mpl
-/-
 into Mpl
-/-
 and JAK2
V617F+
 into Tpo
-/-
 transplants 
(Figure 6.16 A-B). Megakaryocytes from JAK2
V617F+
 mice were larger than WT,  
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Figure 6.11 Platelets, neutrophils and haematocrit of transplant models of 
JAK2
V617F
Mpl
-/-
 and JAK2
V617F
Tpo
-/- 
mice 
(A) Platelet (B) neutrophil counts and (C) haematocrit from WT into WT, JAK2
V617F+
 into WT (VF
+
 
into WT), Mpl
-/-
 into Mpl
-/-
, JAK2
V617F+
 Mpl
-/-
 into Mpl
-/-
 (VF
+
 into Mpl
-/-
), WT into Tpo
-/-
 and 
JAK2
V617F+
 into Tpo
-/-
 transplant mice were monitored for 16 weeks post-transplant. Data are 
presented as mean ±s.e.m; n = 2-10 mice per time point. 
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Figure 6.12 Blood counts for JAK2
V617F+
Mpl
-/-
 transplant models 
Blood counts were monitored in WT into WT, JAK2
V617F+
 into WT (VF
+
 into WT), Mpl
-/-
 into Mpl
-/-
 
and JAK2
V617F+
 Mpl
-/-
 into Mpl
-/-
 (VF
+
 into Mpl
-/-
) mice for 16-weeks post-transplant. Data are 
presented as mean ±s.e.m; n=2-10 mice per time point. 
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Figure 6.13 Blood counts for JAK2
V617F+
Tpo
-/-
 transplant models 
Blood counts were monitored in WT into WT, JAK2
V617F+
 into WT (VF
+
 into WT), WT into Tpo
-/-
 and 
JAK2
V617F+
Tpo
-/-
 mice for 16-weeks post-transplant. Data are presented as mean ±s.e.m; n=3-9 mice 
per time point. WT into WT and JAK2
V617F+
 into WT (VF
+
 into WT) counts are the same in 
Supplemental Figure 9 for comparison purposes. 
 
 
 
 
 
 
Chapter 6 
 
162 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14 Spleens from JAK2
V617F
Mpl
-/-
 and JAK2
V617F
Tpo
-/- 
transplant models 
Representative spleens and weights of spleens harvested 16 weeks post-transplant. Data are presented 
as mean ±s.e.m; n = 2-10 mice per time point. Scale bar, 3mm. 
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Figure 6.15 Progenitor cell analysis in JAK2
V617F
Mpl
-/-
 and JAK2
V617F
Tpo
-/- 
transplant models 
Data was collected from WT into WT, JAK2
V617F+
 into WT (VF
+
 into WT), Mpl
-/-
 into Mpl
-/-
, 
JAK2
V617F+
 Mpl
-/-
 into Mpl
-/-
 (VF
+
 into Mpl
-/-
), WT into Tpo
-/-
 and JAK2
V617F+
 into Tpo
-/-
 mice 16 weeks 
post-transplant. (A) Number of progenitor cells present per 2 x 10
4
 marrow cells as determined by 
CFU assays in the presence and (B) absence of cytokine. Data are presented as mean ±s.e.m; n = 2-12. 
(C) CFU-MK per 1 x 10
5
 marrow cells as determined by Megacult assays in the presence of cytokine. 
Data are presented as mean ±s.e.m. n = 2-12. 
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Figure 6.16 Bone marrow histology of JAK2
V617F
Mpl
-/-
 and JAK2
V617F
Tpo
-/- 
transplant models 
Data was collected from WT into WT, JAK2
V617F+
 into WT (VF
+
 into WT), Mpl
-/-
 into Mpl
-/-
, 
JAK2
V617F+
 Mpl
-/- 
into Mpl
-/-
 (VF
+
 into Mpl
-/-
), WT into Tpo
-/-
 and JAK2
V617F+ 
into Tpo
-/-
 mice 16 weeks 
post-transplant. (A) Representative H&E stained sections of bone marrow with (B) megakaryocyte 
count, where data are presented as mean ±s.e.m. n = 2-12 and (C) size where each data point 
represents a single megakaryocyte. Scale bar, 50μm. 
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consistent with the higher platelet count in these mice (Figure 6.16C). However, 
despite reduced numbers of megakaryocytes in JAK2
V617F+
Tpo
-/- 
mice, their 
megakaryocytes were also larger compared to WT which may explain the gradual 
increase in platelet count (Figure 6.16C).  Similar to results from our congenital 
mouse models, plasma TPO levels were high in mice with an Mpl
-/-
 background and 
absent in Tpo
-/-
 mice (Figure 6.17). Together, these data demonstrate that Tpo plays a 
less significant role in JAK2
V617F+
 MPN development, while Mpl expression in HSCs 
is absolutely required for JAK2
V617F
-mediated transformation. Additionally, 
introduction of JAK2
V617F
 during adulthood is sufficient for development of an MPN, 
but in this setting too, the disease is partially dependent on Tpo expression and 
entirely dependent on expression of Mpl. 
6.3.3 JAK2V617F promotion of HSC expansion is dependent on Mpl 
expression. 
Given that the JAK2
V617F
 mutation is acquired in HSCs and the importance of both 
Tpo and Mpl in HSC maintenance, we determined whether the observed differences 
in pathology in our mouse models were due to a change in the number of primitive 
HSCs. Therefore, E-SLAM
+
 (CD45
+
EPCR(CD201)
+
CD48
-
CD150
+
)  cells, a highly 
purified population of long-term repopulating (LTR) HSCs(39), were enumerated in 
marrow (Figure 6.18 and Figure 6.19).  In our congenital models of MPNs we found 
that JAK2
V617F
 expression significantly increased the number of E-SLAM
+
 HSCs 
compared to WT (Figure 6.19A). Mpl ablation resulted in greatly decreased E-
SLAM
+
 population, both in the presence and absence of JAK2V617F (Figure 6.19A). 
However, JAK2
V617F+ 
Mpl
+/-
 mice showed reduced numbers of E-SLAM
+
 cells 
compared to JAK2
V617F+ 
controls to a level similar to WT, demonstrating that both 
JAK2
V617F
 and Mpl expression are important for the pathologic increase of HSCs 
observed in MPNs (Figure 6.19A). Conversely, E-SLAM
+
 numbers in 
JAK2
V617F+
Tpo
-/-
 mice are comparable to JAK2
V617F+
 controls, thus Tpo is not 
necessary for JAK2
V617F
 to promote HSC expansion (Figure 6.19A). Mpl expression 
was also found to be critical in expanding the marrow E-SLAM
+
 populations in our 
transplant models of MPNs whereas removal of Tpo had little or no effect (Figure 
6.19B). Our data indicate that JAK2
V617F
 significantly increases the pool of 
E-SLAM
+
 HSCs, likely promoting MPN development. This data shows that the 
proliferative effect of JAK2
V617F
 on HSCs is partially dependent on Tpo expression 
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and entirely dependent on Mpl expression. The decreased number of HSCs 
associated with Mpl reduction or ablation may provide a potential mechanism 
through which the absence of Mpl prevents MPN development. 
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Figure 6.17 Plasma TPO levels in JAK2
V617F
Mpl
-/-
 and JAK2
V617F
Tpo
-/- 
transplant 
models 
Plasma was collected 16 weeks post-transplant from WT into WT, JAK2
V617F+
 into WT (VF
+
 into WT), 
Mpl
-/-
 into Mpl
-/-
, JAK2
V617F+
 Mpl
-/-
 into Mpl
-/-
 (VF
+
 into Mpl
-/-
), WT into Tpo
-/-
 and JAK2
V617F+
Tpo
-/-
 
mice and TPO levels were quantified by ELISA. Each data point represents a single mouse and bars 
are presented as mean ±s.e.m; asterisks indicate significance compared to WT into WT.   
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Figure 6.18 E-SLAM
+
 (CD45
+
EPCR(CD201)
+
CD48
-
CD150
+
) cell identification. 
Representative flow cytometry plots for the identification of E-SLAM
+
 cells. 1 x 10
6
 bone marrow 
cells from (A) 16 week old mice and (B) mice 16 weeks post-transplant were stained using CD45-
AF488 (Clone 104), EPCR(CD201)-PE, CD48-PE/Cy7 (Clone HM48-1) and CD150-APC (Clone 
mShad150) antibodies and analysed. Live cells were first gated for CD48
-
CD150
+
 (green) then 
subsequently gated for CD45
+
CD201
+ 
(red). 
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Figure 6.19 E-SLAM enumeration  
(A) Bone marrow cells harvested from 16-week old congenital or (B) transplant mice 16-weeks post-
transplant were analysed for number of E-SLAM
+
 HSCs by flow cytometry. Data are presented as 
mean ±s.e.m; n = 2-9 mice per group. 
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6.4 Discussion 
TPO and MPL are well known for their role in HSC maintenance and the regulation 
of platelet production(94,97,301). Like many type I cytokine receptors, MPL lacks 
intrinsic kinase activity and relies on JAK2 for signal transduction.  Activating 
mutations in MPL cause ET and recent experimental data shows that JAK2 is 
required for this process(302), further highlighting the interdependency of MPL and 
JAK2. As MPNs are a stem cell disorder and given the role of MPL and TPO in HSC 
homeostasis and the dependency of MPL on JAK2, here we investigated the role of 
TPO and MPL in JAK2
V617F+
 MPNs.  
 
In addition to MPL, JAK2 is also responsible for signal transduction of the EPOR, 
G-CSFR, interleukin-3 receptor (IL-3R) and stem cell factor receptor (c-KIT)(303-
305). Thus, it was possible that removal of Mpl could result in differential receptor 
interaction of JAK2. However, modulation of Mpl or Tpo expression resulted in 
changes to the severity of the MPN compared to our JAK2
V617F+
 control model, but 
did not affect the type of MPN developed. For example, the drop in platelet and 
neutrophil counts resulting from modulation of Mpl or Tpo expression was not 
accompanied by an increase in haemoglobin, red cell count or haematocrit which 
would be indicative of PV. This finding would suggest that MPL is critical in the 
oncogenic transformation of HSCs in JAK2
V617F
-positive MPNs. As the effect of 
MPL modulation is observed at the HSC level, we postulate that reduction or 
removal of MPL in a PV mouse model will also ameliorate the disease. However, as 
our mouse model recreates a disease similar to ET, future investigations are required 
to see if MPL is necessary for the development of other JAK2
V617F+
 MPNs such as 
PV and PMF. 
 
Although complete Mpl ablation in our model prevented MPN development, it 
resulted in thrombocytopenia. This is recapitulated in humans that lack functional 
MPL, resulting in defective responses to TPO causing CAMT(98). However, in 
CAMT patients, unlike our mouse models, thrombocytopenia progresses to 
pancytopenia and these patients require a bone marrow transplant, making complete 
removal of MPL an implausible means for therapeutic intervention. Nevertheless, 
our studies highlight the critical importance of Mpl in JAK2
V617F+ 
MPN development 
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in vivo. Indeed the necessity of MPL is highlighted in our JAK2
V617F+
Mpl
+/-
model, as 
reducing Mpl expression resulted in severely attenuated MPN progression, with 
platelet levels comparable to WT. Additionally, whereas HSCs were dramatically 
reduced in JAK2
V617F+
Mpl
-/- 
mice, expression of half the amount of Mpl in 
conjunction with JAK2
V617F
 decreases the neoplastic HSC pool.  
 
Recent reports have provided new insights into the roles of TPO/MPL/JAK2 in 
megakaryopoiesis. Ng and colleagues have shown that knocking out Mpl specifically 
in megakaryocytes and platelets caused myeloproliferation as a result of increased 
TPO availability(306). In addition, Meyer et al demonstrated that ablation of Jak2 
specifically in megakaryocytes resulted in stem and progenitor cell expansion and 
thrombocytosis, presumably due to reduced internalization and degradation of the 
TPO/MPL complex in the absence of JAK2(307). Similarly, using UT7-MPL cell 
lines, Besancenot et al. showed that low levels of MPL expression increased TPO-
stimulated proliferation, while low doses of JAK2 chemical inhibitors caused 
increased platelet production in mice(308). It would appear that some of these data 
contradict our findings that reduced Mpl expression prevents JAK2
V617F
-mediated 
myeloproliferation. However, there are a number of differences between the studies 
which may explain the varying results. In our study, we reduced or ablated Mpl 
expression throughout haematopoiesis, not just in megakaryocytes or platelets as in 
the studies above. Therefore, in our system, the increases in circulating TPO caused 
by reduced platelet MPL expression, fails to stimulate myeloproliferation due to the 
reduction or absence of MPL in haematopoietic stem and progenitor cells. It would 
also appear that there are significant differences between the roles of TPO/MPL in 
megakaryopoiesis and their roles in haematopoietic progenitor expansion. Whereas 
the data presented by Meyer et al. and Besancenot et al. specifically investigate the 
function of MPL in megakaryopoiesis in vivo or megakaryocytic cell lines in vitro, 
we have focused more on the roles of MPL/JAK2
V617F
 in neoplastic progenitor cell 
expansion. Taken together, these data suggest that our understanding of 
TPO/MPL/JAK2 in haematopoiesis is still evolving and the biphasic roles of MPL 
should be taken into account when targeting MPL therapeutically.   
     
Several groups have shown that expression of MPL or EPOR in conjunction with 
JAK2
V617F
 in cell lines was sufficient to stimulate proliferation in the absence of 
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cytokines(264,309,310), suggesting that the presence of JAK2
V617F
 and a receptor 
scaffold is sufficient for disease development. Although reducing Mpl had a far more 
significant effect on disease progression, it was surprising, and contradictory to 
previous in vitro findings, that Tpo ablation attenuated several aspects of MPN 
development. Despite demonstrating that JAK2
V617F
 and Mpl are sufficient for MPN 
development, our data also suggests that in the presence of TPO, the disease 
progression, specifically thrombocythaemia and neutrophilia, is greatly accelerated.  
However, although at 16 weeks JAK2
V617F+
Tpo
-/-
 mice have platelet counts similar to 
WT, it is possible that these mice will eventually develop thrombocythaemia as 
platelet counts are conceivably still rising. Additionally, JAK2
V617F
 mediated 
splenomegaly and expansion of the HSC pool was not affected by the removal of 
TPO. We postulate that the unresolved splenomegaly in our JAK2
V617F+
Tpo
-/-
 mice is 
a consequence of extramedullary erythrocytosis and megakaryocyte hyperplasia. The 
number of neoplastic HSCs in JAK2
V617F+
Tpo
-/-
 mice is similar to JAK2
V617F+
 
suggesting that in the absence of TPO, JAK2
V617F
 is still able to exert a proliferative 
effect on HSCs. This demonstrates that MPL serves as a scaffold for JAK2
V617F
 and 
is sufficient for initiation of JAK2/STAT signalling in vivo.  
 
Interestingly, we found that MPL protein expression was increased in platelets from 
JAK2
V617F+
 and JAK2
V617F+
Mpl
+/-
 mice. These results are contradictory to previous 
findings with an alternative JAK2
V617F
 knock-in mouse model(116).  It is not clear 
why the mouse models express different levels of MPL, but it should be noted that 
they exhibit significantly different phenotypes. While our FF1/Tie2-Cre mice 
present with thrombocytosis, neutrophilia and splenomegaly, the mice used by 
Pecquet et al, (which were originally generated by Marty and colleagues(311)), also 
develop high red blood cell counts, leukocytosis and myelofibrosis. Whether 
different disease phenotypes alter MPL expression is not currently known, but given 
our data demonstrating the significance of MPL levels in disease progression, this is 
an important subject for future investigations.  
 
JAK2
V617F
 expression increases the number of E-SLAM
+
 HSCs, an effect which is 
severely attenuated by Mpl ablation. Increases in the HSC pool in JAK2
V617F+
Tpo
-/-
 
and JAK2
V617F+
Mpl
+/- 
mice compared to WT could explain the delayed increase in 
neutrophils at 16 weeks. Whether or not JAK2
V617F
 gives HSCs a selective advantage 
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remains controversial(312). Our data supports previous reports that the JAK2
V617F
 
mutation expands the HSC pool(313) possibly through increased cell cycling 
coupled with low apoptosis(314). However, other reports suggest that JAK2
V617F
 
causes an HSC defect, reducing self-renewal thereby resulting in lowered HSC 
numbers(315). However, these discrepancies may be due to significant differences 
between mouse models, which develop various disease phenotypes over different 
periods of time(293).  
 
In this report, we not only demonstrate that MPL is necessary for the development of 
a JAK2
V617F
-mediated MPN in transgenic mouse models, but that the level of 
receptor expression directly affects disease severity and progression. We show that 
the JAK2
V617F
 oncogene requires the MPL transmembrane receptor to initiate the 
haematological malignancy in HSCs and that TPO contributes to disease progression 
but is not necessary for MPN development. The use of JAK2 inhibitors, such as 
ruxolitinib, has now been approved by the FDA to treat splenomegaly associated 
with myelofibrosis. However, clinical response to the drug has been mixed, 
warranting the exploration of other drug targets. Complete ablation of TPO only 
exerted a minor effect on MPN development; therefore, targeting of TPO in MPNs 
would likely require complete inhibition, making TPO a difficult target for clinical 
drug development. Instead, the data presented here highlight MPL as an excellent 
therapeutic target for the treatment of MPNs. Small molecule MPL agonists 
(eltrombopag) and TPO peptidomimetics (romiplostim) are now in clinical use for 
the treatment of idiopathic thrombocytopenic pupura (ITP), clearly demonstrating 
the feasibility of targeting drugs to modulate MPL activity.  Therefore it is possible 
that modifying MPL levels through use of antibodies, small molecule inhibitors or 
peptide mimetics, or preventing its association with TPO in the presence of 
JAK2
V617F
, may alter the clinical and pathological manifestations of MPNs.
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CHAPTER 7 GENERAL DISCUSSION 
 
Haematopoiesis is responsible for production of all the mature blood cells in the 
body which are essential for normal function. It is a tightly regulated process 
governed by a large network of cytokines and their receptors. Dysregulation at any 
point can result in a number of haematological disorders. Most of these disorders are 
the result of deregulation at the HSC level or within early progenitors. TPO and its 
receptor MPL are key regulators of megakaryopoiesis and maintenance of HSCs. 
Mutations resulting in non-functional MPL or TPO typically result in diseases 
characterised by pancytopaenias including CAMT. Survival rates associated with 
these diseases are low and often necessitate a bone marrow transplant. Conversely, 
activating mutations of MPL and mutations resulting in overproduction of TPO 
result in diseases characterised by overproduction of myeloid cells, most commonly 
of platelets resulting in thromocythaemia. Although the prognosis for these diseases 
is better than for those associated with inactivating mutations, myeloproliferation 
significantly increases thrombotic risk which can result in death. These diseases 
highlight the importance of MPL in maintenance of normal haemostasis. Therefore, 
a comprehensive understanding of the biology and regulation of TPO and MPL are 
biologically important. Although a number of studies have been undertaken to 
develop a better understanding of TPO biology, many of these studies occurred soon 
after the cloning of TPO in 1994. Over two-decades later, our understanding of TPO 
and MPL biology has increased yet remains incomplete.  
 
The primary aim of this work was to determine additional negative regulatory 
mechanisms governing TPO signalling in addition to determining the role of MPL 
and TPO in MPN pathogenesis. 
7.1 Negative regulation of TPO signalling  
Activation of TPO signalling is important for HSC maintenance and haematopoiesis. 
However, unsolicited activation of the signalling cascade results in disease thus a 
thorough understanding of the mechanisms in place to prevent deregulation is of 
scientific importance. Although MPL
Y591
 was previously postulated as a negative 
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regulator of TPO signalling, the mechanism by which this occurred had not been 
investigated. In this body of work, novel binding partners of MPL were identified 
including BTK, SHP1 and SYK. SYK was shown to preferentially bind to 
phosphorylated Y591 of MPL to negatively regulate ERK1/2 signalling(Figure 7.1). 
Additionally, SHP1 also preferentially binds to MPL
pY591
 yet it did not exert an 
effect on ERK1/2 signalling. However, it has previously been shown to negatively 
regulate MPL signalling thus it is possible that SHP1 binds to MPL
pY591
 to regulate 
other pathways associated with TPO signalling. A number of negative regulatory 
mechanisms of TPO and MPL are known, such as involvement of negative 
regulators including SOCS proteins, LYN and LNK and pathways such as 
ubiquitination by CBL which results in receptor internalization and degradation. 
However, the mechanism of action, specifically the components of the receptor 
necessary in some of these pathways is less understood. In this work, not only was a 
negative regulatory pathway identified, the specific residue on the receptor, its 
phosphorylation state and an associated protein were all identified. This could prove 
important for development of therapeutics as many proteins involved in signal 
transduction are common between multiple pathways. Targeting of downstream 
effectors could result in undesired off target effects whereas targeting of specific 
components of a pathway such as a receptor would be more specific. Although this 
work has identified an additional element in the understanding of TPO signalling, 
much investigation is still required for a complete understanding of the biological 
roles of TPO and MPL.    
7.2 JAK2V617F and its effects on TPO signalling  
A number of studies have shown that expression of JAK2
V617F
 is sufficient for 
cytokine independent signalling in vitro but only when a homodimeric type I 
cytokine receptor is also expressed. However, these studies were only performed 
with WT cytokine receptors including EPOR and MPL. In this work we sought to 
determine the role of phosphorylated tyrosine resides of the receptor, MPL, as they 
could possibly modulate JAK2
V617F
-induced signalling. We found that removal of 
these resides, namely Y591, Y625 and Y630 had little effect on JAK2
V617F
-induced 
signalling and proliferation. Therefore, phosphorylated tyrosine residues of MPL are 
unable to overcome cellular activation resulting from JAK2
V617F
 expression.  
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Figure 7.1 Summary of identified negative regulatory pathway  
Thrombopoietin binding to MPL results in activation of the TPO signalling cascade. This work 
identifies a novel signalling pathway whereby TPO binding to MPL results in phosphorylation of 
Tyr591 resulting in recruitment and association of SYK to pTry591 which negatively regulates TPO-
induced ERK1/2 signalling.  
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However, as others have shown, removal of the receptor completely prevents 
JAK2
V617F
 from inducing cytokine independent signalling and proliferation. 
Therefore, the specific tyrosine residues may not play a large role in inhibiting 
mutant kinase signalling but the receptor is still necessary, warranting further 
investigation. This work therefore also examines the role of MPL and TPO in an in 
vivo system.    
7.3 Implications of MPL in JAK2V617F-positive MPNs 
Since its identification in 2005, much of the research focus has been on studying the 
role of JAK2
V617F
 in MPN development. JAK2
V617F
 is considered an oncogene; 
however, this work provides evidence that although JAK2
V617F
 is important for MPN 
development in vivo, in the absence of MPL the disease fails to develop. This work 
suggests that JAK2
V617F
 is in fact only one part of a 2 part oncogene, as disease 
development necessitates the expression of MPL(Figure 7.2). TPO plays a role in 
MPN development as disease progression is slowed in its absence. However, the data 
demonstrates that the disease can still develop in the absence of TPO; therefore, the 
role of TPO in MPN development is less significant than MPL. Due to its necessity 
for disease development, this work identifies MPL as a novel target for development 
of novel therapeutics for the treatment of MPNs. Specifically, because its function is 
at the HSC level, targeting of MPL could treat the disease rather than the symptoms. 
Importantly, our data suggests that targeting only a portion of MPL is necessary to 
prevent MPN development. 
7.4 Therapeutic implications 
Current treatments of MPNs include imatinib, allogenic stem cell transplantation, 
aspirin regimen, cytoreductive therapies, splenectomy and the JAK inhibitor 
ruxolitinib. Imatinib is a highly successful drug in the treatment of CML; however, 
treatment of Ph-negative MPNs (ET, PV and PMF) is less straight forward. 
Identification of mutations leading to different Ph-negative MPN pathologies such as 
mutations in JAK2, MPL and CALR has vastly improved our understanding of these 
disorders and development of more specific drug targets, namely JAK inhibitors 
such as ruxolitinib. During its development, there was much hope that ruxolitnib 
would be as successful in treating Ph-negative MPNs as imatinib was for CML.  
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Figure 7.2 Summary of the role of MPL in MPN development  
MPL is necessary for development of a myeloproliferative neoplasm (top panel), in the absence of 
MPL the disease fails to develop but thrombocytopenia also develops (middle panel); however the 
reduction of MPL completely prevents disease development without thrombocytopenia.  
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Patients report improvements following ruxolitinib therapy however, it is believed 
that much of the improvements are related to the ability of ruxolitinib to reduce 
inflammation. JAK2 is involved in numerous signalling pathways so targeting JAK2 
results in off target effects; additionally, it has been shown that ruxolitinib also 
inhibits JAK1, which could be causing the reduction in inflammation. JAK2
V617F
 
positive clones display selective advantage in patients, thus successful treatment with 
JAK2 inhibitors likely requires inhibition of all mutant kinases necessitating higher 
doses which are not tolerable. Our data demonstrates that reducing MPL levels is 
sufficient to prevent development of the disease. This would prove important 
therapeutically as doses of inhibitor sufficient to target only a portion of MPL could 
be successful in treating the disease. Additionally, as reduction of MPL exerts an 
effect at the HSC level by reducing the neoplastic stem cell pool, it is possible that 
targeting of MPL results in treatment of the disease itself rather than the symptoms. 
However, there are currently no available antagonists to MPL which would allow 
this to be tested experimentally. Therefore, the next step in understanding the role of 
MPL in MPN development and determining its feasibility as a novel therapeutic 
target for MPNs is development of an MPL antagonist.  
7.5 Future research  
Although this work identifies MPL at a potential and novel therapeutic target for the 
treatment of MPNs, there is still much work to be done to determine if targeting of 
MPL will be of clinical value.  
 
We found MPL expression to be increased when JAK2
V617F
 was expressed which is 
in disagreement with some reports of MPL expression in patients(238-241). 
However, just as the homozygous JAK2
V617F
 clone increases with time, it is possible 
that MPL expression decreases as the disease progresses or as additional mutations 
are acquired. Previous studies analysing MPL expression in MPN patients reported 
an overall decrease in expression associated with disease. However, these studies 
were performed prior to identification of JAK2
V617F
 and they measure expression 
after disease development thus it is not clear whether MPL expression levels are a 
contributing factor or a result of the disease. Additionally, with the identification of 
additional mutation in MPNs such as JAK2 exon 12, MPL and CALR, MPNs can 
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now be grouped based on mutational profiles thereby allowing for analysis to occur 
in clusters. With the help of HMDS, we are looking to analyse MPL expression in 
MPN patients and compare to mutations and prognostic outcome. Additionally, it 
would be of interest to monitor MPL expression over time to understand how the 
disease modulates expression.  
 
Additionally, in these studies we show that expression of JAK2
V617F
 and half the 
amount of MPL in vivo was able to prevent disease development in an ET-like 
mouse model. It was shown that the reduction in MPL was able to reduce the 
neoplastic stem cell pool. However, the mechanism remains unknown and needs to 
be investigated. It is possible that pathological signalling is diminished due to a 
reduction in MPL expression. Additionally, analysis of differences between gene 
expression in JAK2
V617F+
 compared to JAK2
V167F+
Mpl
+/-
 mice could also provide 
mechanistic insights; however, this remains to be investigated. Furthermore, the in 
vivo data presented in this work is based on a JAK2
V617F+
 ET-like mouse model(149). 
If the effect of MPL reduction is being exerted at the HSC level, this could mean that 
MPL antagonists could be used to treat all subsets of JAK2
V617F+ 
MPNs. To validate 
this possibility it is necessary to perform similar studies in mouse models of PV and 
PMF. If indeed, modulation of MPL expression is able to prevent disease 
development, this would provide additional support for the development and use of 
MPL antagonists in treatment of MPNs.  
 
This work identifies MPL as a novel therapeutic target for the treatment of MPNs; 
however, no antagonists are currently available thus future research includes 
development of an MPL antagonist. Promisingly, there are currently MPL agonists 
that are currently approved for treatment of IPT which have been successful with 
little to no off target effects (Reviewed in (316)); therefore showing that MPL is a 
viable therapeutic target. Unfortunately, there is currently no structural data for MPL 
making drug development difficult. However, a potential strategy for drug design is 
to modify the current MPL agonists and subsequently testing them for antagonistic 
ability.  
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7.6 Concluding remarks  
TPO and MPL were discovered over 20 years ago and soon after were shown to be 
essential in megakaryopoiesis and HSC biology. Study of TPO/MPL biology is not 
only important for the understanding of normal haematopoiesis but also important in 
understanding of haematological disorders. The relationship between MPL and 
MPNs has been postulated previously and this was later confirmed when mutations 
in MPL resulted in development of MPNs. However, in this work it was shown that 
MPL is also important in JAK2
V617F+
 MPNs and that it may be a useful therapeutic 
target. Future work will likely involve additional studies to determine the mechanism 
by which MPL prevents the disease from developing. Additionally, development of 
MPL antagonists is necessary for further examination of the potential of MPL as a 
therapeutic target. However, to do so structural studies of MPL would provide a 
better means for drug development and would provide an invaluable resource for 
further study of TPO/MPL biology. The results of this thesis identify a novel 
negative regulatory pathway in biological TPO signalling in addition to identifying 
MPL as an essential component for Ph-negative MPN pathogenesis; thereby paving 
the way for future studies of TPO and MPL in both a pathological and biological 
setting.   
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